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PART 1: INTRODUCTION 
 
 
CHAPTER 1 
 
DNA Microarray in Cancer Research 
 
Having  the  essentially  complete  sequence  of  the  human  genome  is  similar  to 
having all the pages of a manual needed to make the human body. The challenge to 
researchers and scientists in current post-genomic era is to find those missing definitions, 
to use genomic structural information to display and analyze biological processes on a 
genome-wide  scale,  and  to  explore  gene  functions.  Although  traditional  molecular 
biology  often  takes  a  reductionist  approach  to  biological  questions,  it  has  long  been 
recognized that genes act in concert with other partners, often in separate dimensions of 
time and space. To fully understand the underlying biology, these molecular interactions 
may have to be studied from the conceptual framework of the entire genome. With the 
advent of high throughput technologies, the logistical challenge of which approach is 
being  overcome.  DNA  microarray,  as  one  of  high-throughput  technology,  offers  the 
ability  to  measure  the  expression  of  thousands  of  genes  simultaneously,  providing 
genome-wide views of gene expression from the yeast cells to human cancer cells. By 
supplying quantitative information on cell transcriptomes, this technology has become a 
powerful tool in biomedical research, especially in cancer research and has led to an 
explosion in global gene expression profiling studies. In theory, for human cancer, this   2 
knowledge has the potential to lead to optimized, individualized management of patients. 
The goal of this survey is to summarize the basic principles, the different steps involved 
in  DNA  microarray  technology  and,  more  importantly,  the  proper  data  analysis 
methodologies and applications in cancer biology.  
 
In  general,  DNA  microarrays  are  of  two  kinds,  depending  on  the  materials 
arrayed:  cDNA  microarrays (1) and  oligonucleotide arrays (2) and.  cDNA arrays are 
generated with a robotic arrayer, printing a double-stranded cDNA onto a solid surface 
such as glass, charged nylon membranes, or nitrocellulose filters.  For oligonucleotide 
arrays,  in  situ  synthesis  usually  produces  short  20-25  mers  by  photolithography 
(Affymetrix)  or  lengths  of  up  to  60  nt  by  inkjet  technology  (Agilent  Technologies). 
Another  type  of  oligonucleotide  array  is  made  by  spotting  longer  presynthesized 
oligonucleotides  (~70  nt)  on  glass  slides  (3).  While  cDNA  is  easily  customizable, 
oligonucleotides generally offer greater specificity as they can be specifically tailored to 
minimize  chances  of  cross-hybridization.  Other  advantages  of  oligonucleotide  arrays 
include uniformity of probe length and the ability to distinguish specific variants (4).  
 
The hybridization of a test sample to an array can be detected in one of two ways 
(Figure 1.1). cDNA arrays are commonly designed with 2-dye (also known as 2-channel) 
representing cDNAs from experimental and reference RNA samples experiments. Each 
cDNA  sample  is  labeled  with  its  own  specific  fluorophore.  Expression  values  are 
reported as ratios between two fluorescent values, representing the quantitative difference 
between two cDNA sources. Alternatively, the Affymetrix-like oligonucleotide arrays 
use a single channel system to detect absolute level of gene expression. In addition,   3 
Affymetrix designs “perfect match” (PM) and “mismatch” (MM) probes for each probe 
set, where the “mismatch” probe is one nucleotide different from the “match” probe and 
is intended to indicate the level of non-specific binding. However, whether or not to use 
“mismatch” probes is still an open question. For example, MAS5, the default Affymetrix 
probe  set  algorithm,  utilizes  both  PM  and  MM  probe  information,  while  RMA,  an 
algorithm developed by UC Berkeley ignores MM probes.  
 
Pat  Brown  and  his  colleagues  at  Stanford  University  published  the  first 
microarray paper using cDNA arrays in 1995 (1).  In general, a typical cDNA microarray 
experiment  proceeds  as  follows:  (1)  sample  preparation  and  RNA  isolation,  (2) 
preparation of fluorescently labeled cDNA, (3) hybridization, (4) slide scanning, image 
and data analysis (Figure 1.1). During the experiment, multiple sources of variation may 
be  introduced  including:  mixed  cellular  composition  in  tissue,  genetic  heterogeneity 
within tissue cells, difference in sample preparation, non-specific cross-hybridization of 
spots, different  detection efficiencies for the fluorescent  labels as well as differences 
between individual slides  (4). Thus care must be taken in each step. Once slides are 
scanned, image analysis is first carried out to determine image quality, identify spots and 
output background adjusted fluorescent intensities. A good image shall have a low level, 
uniform  background  and  high  signal-to-noise  ratio.  For  spot  identification,  most 
commercial  scanners  provide  software  to  transform  the  colored  spots  into  numerical 
intensities. During  spot  identification,  background  signal  is  also  estimated.  The  most 
common method is to calculate the background signal locally in the vicinity of each spot 
and then subtract it. The ratios of measured background-subtracted Cy5 to Cy3 intensities   4 
are further subjected to normalization that is intended to remove systematic errors arising 
from the above variations. 
 
Two major normalization steps are commonly used in the literature: (1) within-
array normalization, (2) between-array normalization. For within-array normalization, a 
simple approach is global mean-centered or median-centered based on the assumption 
that the total integrated intensity across all spots in the microarray should be equal for 
both channels because of the equal amount of RNA used for labeling from each sample.  
Other often used methods include normalization against a subset of housekeeping genes, 
global loess, print-tip loess, robust spline or even 2D-loess to address more profound 
spatial  biases  (5,6).  To  adjust  differences  between  arrays,  further  between-array 
normalization may be required. Common methods include global scale normalization, 
quantile normalization or variance stabilizing normalization (vsn) (5,7,8). As Affymetrix 
oligonucleotide arrays use a single-channel system, the normalization steps are slightly 
different. The first step for affymetrix oligonucleotide arrays is to estimate the absolute 
intensity of individual probe sets which represent primarily annotated transcripts. Each 
probe  set  is  typically  represented  by  a  set  of  11–20  PM  and  MM  probe  pairs.  This 
multiple  probe  feature  allows  for  more  robust  background  assessments  and  gene 
expression measures, and has facilitated the development of computational or statistical 
methods to translate image data into a single normalized "signal" for mRNA transcript 
abundance. To date, there are many probe set algorithms that have been developed, with 
a gradual movement away from chip-by-chip methods (MAS5), to project-based model-
fitting methods (dCHIP, RMA, GC-RMA etc.). However, it is debating that which one is   5 
the rational best method (9,10). The best probe set algorithm may vary from project to 
project  (9).  After  calculating  summary  probe  set  intensity,  further  between-array 
normalization may be needed for some probe set algorithms, for example, MAS5. 
 
The normalized microarray expression values are typically log2-transformed, and 
stored as a two-dimensional table, with genes in the rows and profiles in the columns. As 
thousands of data points may be observed per array, microarray data is often grouped and 
visualized as a heatmap.  Each data point can be presented as a color that quantitatively 
and  qualitatively  reflects  its  relative  expression  within  the  data.    For  example,  high 
expression  is  presented  as  red  while  low  expression  is  presented  by  green;  and  the 
intensity of the color represents the degree to which the gene is expressed.  To better 
present such heatmaps, an unsupervised hierarchical clustering is typically adopted along 
with visualization (11). It orders genes or samples based on their similarity of expression. 
For example, one could cluster the samples in a collection of cancer patient cohort into 
subgroups based on the similarity of their aggregate expression profiles. On the other 
hand, genes that share similar patterns of expression in a biological context could be also 
clustered together. As such a method does not require any priori assumption, it has the 
advantage  of  being  unbiased.  More  importantly,  it  allows  one  to  detect  the  inherent 
patterns hidden in a complex dataset. A success example is given in a breast cancer 
profiling reported by David Botstein and Patrick Brown at Stanford University (12) . By 
employing a two-way hierarchical clustering, they grouped both genes and samples based 
on the similar patterns of gene expression profile, leading to the discovery of molecular 
subtypes of breast cancer. Clustering of the tumors based on overall expression profiles 
firstly  divided  the  samples  into  two  distinct  clusters.  One  cluster  of  tumors  shared   6 
relatively high expression of a set of genes expressed in ER+ tumors or breast luminal 
cells, thus being defined as ER+/luminal subtype. The other group of tumor samples 
having relatively low expression of these genes, were further sub-categorized into basal 
cell-like,  Erb-B2+,  and  normal-like  subtype,  each  subtype  with  a  characteristic  gene 
expression  signature.  A  follow-up  study  showed  that  the  ER+/luminal  type  could  be 
further divided into at least two subgroups with different clinical outcome (13).  
 
In  addition  to  unsupervised  learning,  one  common  analysis  is  to  perform 
supervised learning analysis, incorporating the prior knowledge of sample information. A 
typical schema for microarray data analysis is to select a subset of genes that can best 
distinguish two classes of training samples such as disease vs. healthy controls and build 
a computation or statistical model that is able to classify training samples as well as 
predict independent, blinded test samples into these classes. Such supervised analyses are 
particularly  useful  for  cancer  diagnosis  and  prognosis.  However,  they  are  relying  on 
accurate sample information, which may be an issue in cancer given the limitations of 
current histopathologic accuracy. 
 
  A significant effort has been put forth to apply microarray technique to the study 
of cancer (12,14-17), both due to the complexity and heterogeneity of the disease and the 
lack of efficient clinical diagnostic tools and treatments. Cancer can be considered a 
genetic  disease,  occurring  as  a  result  of  the  progressive  accumulation  of  genetic 
alterations in somatic cells. Because hundreds of genes may be simultaneously involved 
in the mechanisms of tumor formation, high-throughput DNA microarray is in particular   7 
useful to screen a large number of genes and thus identify potential interesting marker 
genes. Presently, microarrays have been extensively used in cancer research for several 
applications, including (but not limited to) the following: (1) discovery of novel cancer 
diagnostic  and  prognostic  biomarkers;  (2)  identification  of  novel  target  genes  for 
oncogenes or tumor suppresser genes; (3) molecular class discovery, classification and 
prediction; (4) identification of genes associated with drug resistance and prediction of 
clinical response to drug. In the next section, we will review the main strategies thus far 
employed  in  microarray  gene  expression  profiling  studies,  as  well  as  the  significant 
results obtained from them.  
 
A common goal for cancer microarray profiling is to identify genes differentially 
expressed between two groups of samples, e.g. benign and tumor tissue. Many statistical 
tests can be used to determine the significance of difference of gene expression between 
two  groups.  Some  common  tests  include  student’s  t-test,  signal  to  noise  ratio, 
permutation test and significance of microarray analysis (SAM). However, as thousands 
of genes are being tested simultaneously, the chance of false positive rate is increased. 
Thus,  there  is a  need  to  adjust  for  multiple  hypothesis  testing.  The most  often  used 
procedures  to  control  false  positive  rate  are  estimation  of  family-wise  error  rate 
developed by Westfall and Young (18), and false discovery rate introduced by Benjamini 
and Hochberg (19,20). More details of feature gene selection are discussed in Chapter 2.  
 
There have been many successes in using gene expression profiling to identify 
markers of diagnostic and prognostic value. Our previous study in prostate cancer is a   8 
good example (15). Prostate cancer is the most frequently diagnosed cancer in American 
men. Screening for prostate-specific antigen (PSA) has led to earlier detection of prostate 
cancer, but elevated serum PSA levels are present in non-malignant conditions such as 
benign prostatic hyperlasia (BPH). cDNA microarrays have been used to examine gene-
expression profiles of more than 50 normal and neoplastic prostate specimens and three 
common  prostate-cancer  cell  lines.  Statistical  testing  was  used  to  sort  differentially 
expressed  genes  between  the  sample  groups.  The  highest  scoring  genes  were  then 
subjected to independent tissue microarrays for validation at the protein level. Hepsin, a 
transmembrane serine protease, was found to be highly expressed at the mRNA level and 
protein level in nearly all of the cancer samples, but not in the benign samples, suggesting 
its  role  as  a  novel  biomarker  for  prostate  cancer.  Another  paradigm  in  biomarker 
discovery is alpha-methylacyl CoA racemase (AMACR) (21-24). Luo et al. (2002) and 
our group reported simultaneously that AMACR is a novel tissue biomarker for prostate 
cancer  by  cDNA  microarrays  and  independent  tissue  microarrays.  Our  group  further 
demonstrated that the humoral immune response against AMACR was more sensitive 
and specific than PSA (a clinical prostate cancer marker) in distinguishing sera from 
prostate cancer patients to control subjects (24).   
 
Several groups have used DNA microarrays for classifying tumors from benign 
tissues or distinguishing tumor subtypes on the basis of certain discriminant function. 
Chapter 2 interrogated a wide range of molecular classification methods in detail. The 
first proof-of-principle for microarray-based histological classification was reported by 
Golub et al (16) in 1999. This study demonstrated the feasibility of using expression   9 
profiling  for  cancer  diagnosis.  Using  unsupervised  learning  on  oligonucleotide 
microarrays,  leukemia  samples  are  neatly  clustered  into  known  acute  myelogenous 
leukemia  (AML)  and  acute  lymphocytic  leukemia  (ALL)  solely  based  on  gene 
expression. Supervised learning demonstrated that a set of 40 genes that are differentially 
expressed in AML and ALL could accurately predict a group of unknown samples into 
correct  categories,  again  solely  based  on  gene  expression  profile.  Although  this 
distinction can be detected using modern histopathology and cell surface phenotypes, this 
study has established a paradigm that tumor expression profiling can be used for cancer 
classification. More recently, Armstrong et al.  (25) identified mixed-lineage leukemia 
(MLL), a new molecular subtype of leukemia with a decidedly unfavorable prognosis. 
MLL  arises  from  a  chromosomal  translocation  involving  the  mixed-lineage  leukemia 
gene and has typically been classified with ALL. This study showed that MLL has a 
unique  gene  expression  profile  distinct  from  AML  and  ALL,  demonstrating  that  the 
differences in gene expression are robust enough to classify disease subtypes. 
   
  One of major obstacles to cancer therapy is the development of drug resistance. 
Cancers may be either primarily resistant to the treatment or develop resistance during 
the process of treatment. Multiple mechanisms of drug resistance have been reported and 
drug resistance is likely to involve a diversity group of genetic factors such as tumor 
suppresser genes, growth factor receptors, DNA repair factors and cell death regulators. 
Presently, it is difficult to predict whether chemotherapy will be effective for individual 
patients.  By  using  cDNA  microarrays,  Kudoh  et  al.  (26)  monitored  the  expression 
profiles of Doxorubicin-induced and Doxorubicin resistant cancer cells. A subset of the   10 
Doxorubicin-induced  genes  was  found  to  be  constitutively  over-expressed  in  cells 
selected  for  resistance  to  doxorubicin  and  may  represent  the  signature  profile  of 
doxorubicin resistance phenotype. This study demonstrated the feasibility of obtaining 
potential molecular profile or fingerprint of anticancer drugs in cancer cells by DNA 
microarray, which might yield further insights into the mechanisms of drug resistance 
and suggest alternative methods of treatment. 
 
Gene expression profiling of tumors has been also used for outcome prediction. 
Investigators  have  demonstrated  the  utility  of  using  pretreatment  gene  expression 
profiling to determine prognosis. In a retrospective study of 38 patients with diffuse large 
B-cell lymphoma (DLBCL), Alizadeh et al. (14) firstly demonstrated expression-based 
correlates  of  outcome.  They  clustered  cDNA  microarray  data  and  defined  two 
molecularly distinct forms of DLBCL. By examining patient survival, they found that the 
defined germinal center B-like (GCB) DLBCL had a significantly better overall survival 
than those with activated B-like (AB) DLBCL. Van’t Veer et al. (27) have also reported 
the use of gene expression profiling to develop an outcome predictor for breast cancer 
metastasis. Primary breast tumors from patients who developed distant metastases within 
5 years were compared with tumors from patients who continued to be disease-free after 
a period of at least 5 years.  Supervised classification was used to identify a set of 70 
genes strongly predictive of a short interval to distant metastases. In a follow-up study 
(28),  by  using  the  previously  established  70-gene  prognosis  profile,  they  classified a 
series of 295 primary breast carcinomas as having a gene-expression signature associated 
with either a poor prognosis or a good prognosis. Among the 295 patients, 180 had a   11 
poor-prognosis  signature  and  115  had  a  good-prognosis  signature.  These  two  groups 
showed markedly different outcome (10-year distant metastasis-free survival, 50.6% vs. 
85.2%). They also demonstrated that the prognosis profile could add value to existing 
clinical and histological criteria. 
   
To date, hundreds of mRNA expression profile studies of various cancers have 
been reported in the literature and a large number of datasets have been made available 
(Figure  1.2).  This  tremendous  resource  would  speed  up  the  identification  of  robust 
cancer markers as well as facilitate the development of improved molecular signatures if 
it  could  be  properly  and  fully  utilized.  However,  due  to  the  lack  of  a  unifying 
bioinformatic resource, the majority of these data sit stagnant and disjointed following 
publication, massively underutilized by the cancer research community. While standards 
and repositories have begun to be established, the full potential of cancer microarray data 
will only be reached when it is unified, logically analyzed, and easily accessible. To this 
end, our lab initiated an effort to systematically curate, analyze and make available all 
public  cancer  microarray  data  via  a  web-based  database  and  data-mining  platform, 
designated ‘ONCOMINE’ (http://www.oncomine.org) (29). Besides data collection, our 
effort also includes centralizing gene annotation data from various genome resources to 
facilitate rapid interpretation of a gene’s potential role in cancer. Furthermore, we have 
integrated  microarray  data  analysis  with  other  resources  including  gene  ontology 
annotations and a therapeutic target database so that clinically interesting subsets of genes 
can be focused on. Currently the ONCOMINE database houses 310 independent datasets 
comprising  over  500  million  gene  expression  measurements  from  nearly  22,000   12 
microarray experiments. By making these resources easily accessible to public, we hope 
that this work could benefit the identification of potential cancer markers, maximize the 
utility of data, promote an increase in validation performance, and ultimately lead to the 
improved  understanding  of  cancer  and  the  development  of  novel  diagnostic  and 
therapeutic strategies. 
 
As noise is known significant in DNA microarrays due to genomic variations, 
experimental artifacts, sampling bias, and cross-hybridization so on, there is high demand 
to validate potential cancer markers or gene signatures in independent datasets or through 
independent experimental techniques. While it is common to use the microarray as a 
screening tool and then to validate a few promising candidates using such as reverse 
transcriptase polymerase chain reaction (RT-PCR), or tissue microarrays, it may under-
utilize the microarray dataset and overlook other potential markers. With the increasing 
number  of  publicly  available  gene  expression  datasets,  meta-analysis  in  combining 
multiple  studies  to  determine  the  repeatability  of  one  microarray  result  becomes  a 
promising  method  for  in  silico  validation.  For  example,  our  previous  study  (22) 
demonstrates a statistical model for performing meta-analysis of independent microarray 
datasets. Instead of using the actual expression measurements which may be complicated 
due to distinct microarray technologies, the model utilizes statistic p-values derived from 
individual studies. Differential expression was first assessed independently for each gene 
in each dataset based on a p-value. Then individual study p-values were combined using 
a result that -2log(p-value) has a chi-squared distribution under the null hypothesis of no 
differential  expression.  The  model  was  first  implemented  on  four  publicly  available   13 
prostate cancer gene expression data sets that compared the gene expression profiles of 
clinically  localized  prostate  cancer  to  that  of  benign  prostate  tissue  with  the  goal  of 
identifying genes differentially expressed between the two groups. The analysis revealed 
that four prostate cancer gene expression datasets shared significantly  similar results, 
independent of hybridization platforms, demonstrating that combining p-values is useful 
to obtain more precise estimates of significances. Based on this statistical framework for 
inter-study validation, our lab has extended the approach to a large compendium of public 
cancer  microarray  datasets  in  a  follow-up  study  (30).  We  characterized  a  common 
transcriptional profile that is universally activated in most cancer types relative to the 
normal tissues from which they arose, likely reflecting essential transcriptional features 
of  neoplastic  transformation  (Figure  1.3).  In  addition,  a  meta-signature  of 
undifferentiated  cancer  was  also  uncovered,  consisting  of  69  genes  that  were  over-
expressed  in  undifferentiated  cancer  relative  to  well  differentiated  cancer,  suggesting 
common molecular mechanisms by which cancer cells progress and dedifferentiate. 
 
While the above studies highlight the use of expression profiling for addressing 
important  questions  in  clinical  oncology  and  demonstrate  the  potential  of  DNA 
microarrays in  clinic, many challenges remain.  The first challenge lies in  microarray 
assay  development  and  standardization.  Microarray  technology  is  known  to  be 
susceptible to measurement error due to a long and convoluted chain of decisions on 
sampling, preprocessing, hybridization, calibration, and analysis. Errors and biases may 
involve  the  sampling  of  the  specimens,  their  quality,  the  amount  of  tissue  obtained, 
storage, fixation, plating, and readout of microchips (31). The analytical calibration and 
informatics analysis plan can also be very convoluted. Major decisions need to be made   14 
for  transformation,  normalization,  data  filtering,  removal  of  technical  artifacts,  and 
background correction. For each decision node, there are numerous possibilities, and so 
far there is no standard informatics platform available. Another challenge lies in gene 
annotation. For a given probe, there is some uncertainty to map to the correct target gene 
due to non-specific probe design, cross-hybridization or transcript splice variants of same 
gene; some probes may actually represent a different gene than advertised. In addition, 
DNA microarrays  measure gene expression at  the mRNA level,  while gene products 
function at the protein level.  Some inconsistence may exist between mRNA and protein 
level  expression.  An  mRNA  can  be  alternatively  spliced  prior  to  translation  and 
eventually yield different proteins. Additionally, various post-translational modifications 
may occur in proteins. Another important challenge lies in the availability of sufficient 
numbers of samples. Until now, gene expression profiling has depended mostly on small 
numbers of clinical specimens. Validation of claims has been uncommon, fragmented, 
and  incomplete  (31).  A  final  challenge  relates  to  the  integration  of  data  sets  from 
different laboratories using different profiling technologies. While it is surely best to use 
these  multiple  datasets  to  validate  one  another  so  that  the  most  promising  candidate 
biomarkers can be identified, this task is challenging because microarray data exists on a 
variety of scales depending on the specific technological platform utilized as well as the 
experimental procedure. Although there are some successes to integrate different datasets 
to  date,  more  sophisticated  methods  are  required  for  efficient  data  comparison  and 
integration. 
   15 
In  conclusion,  DNA  microarray  is  an  invaluable  and  promising  technology. 
Developing molecular diagnostic tools by tumor gene expression profiling is conceivable. 
Although  many  challenges  remain  ahead,  identifying  novel  molecular  targets  and 
classifying novel molecular subtypes of cancer on the basis of DNA microarray data may 
facilitate  the  development  of  new  cancer  drug,  the  design  of  clinical  trials,  and  the 
planning of cancer therapy. 
    16 
 
Figure 1.1. Experimental workflow of a typical microarray using either oligonucletide or 
cDNA spotted array technique. [Adapted from Ramaswamy et al., Journal of Clinical 
Oncology. 2002. 20(7):1932-1941]   17 
 
 
Figure 1.2. Number of expression profiling studies carried out for individual cancer type 
as of early 2007 in ONCOMINE database (http://www.oncomine.org).   18 
 
 
Figure  1.3.  Meta-signature  of  neoplastic  transformation.  (A)  Sixty-seven  genes 
overexpressed in cancer relative to normal tissue counterpart in at least a dozen ‘‘cancer 
vs. normal’’ signatures from independent microarray studies. White boxes signify either 
not present or not significant. Red boxes signify significant overexpression in cancer 
relative to normal tissue, the shade of red indicating the percentage of cancer samples that 
had an expression value greater than the 90th percentile of normal samples. (B) The 
signature  was  able  to  significantly  predict  ‘‘cancer  vs.  normal’’  status  in  32  of  39 
analyses. The two bars above each heat map represent the predicted class (P) and the true 
class (T): red signifies cancer and blue signifies normal tissue. In the color maps, black 
signifies data not available, white signifies less than or equal to the normal class mean 
expression level, and red signifies the degree of over-expression relative to the mean 
normal class expression level.   19 
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CHAPTER 2 
 
Towards Cancer Classification Using Gene Expression Data 
 
One  challenge  of  cancer  treatment  is  to  develop  specific  therapies  for 
pathogenetically  distinct  tumor  types,  to  maximize  efficacy  and  minimize  toxicity. 
Cancer classification and class discovery have thus been central to advances in cancer 
treatment  (1).  Previously,  cancer  classification  has  primarily  been  on  the  basis  of 
morphological  and  clinical  characteristics  of  the  tumor.  However,  these  traditional 
methods  have  been  reported  to  have  serious  limitations  (1).  Tumors  with  similar 
histopathological appearance can be molecularly heterogeneous, differently responsive to 
particular therapy, and thus may require different clinical courses (1). To gain a better 
insight into this issue, demand on developing more systematic approaches to examine 
global gene expression has been on the rise. The recent advent of microarray technology 
has  made  it  straightforward  to  simultaneously  monitor  the  expression  patterns  of 
thousands of genes. Although still in its early stage of development, current successes 
have indicated its promising future. 
 
To date, various statistical or machine learning techniques have been proposed for 
molecular  cancer  classification.  In  this  survey  report,  a  comprehensive  overview  of 
current  cancer  classification  methods  will  be  presented.  Due  to  the  high-dimensional 
nature  of  gene  expression  data,  we  will  also  summary  the  prevailing  feature  gene   22 
selection methods as it is an integrated part for molecular classification. Finally, we will 
discuss several challenges related to cancer classification and present solutions. A typical 
workflow of molecular cancer classification can be seen in Figure 2.1. 
 
Gene Selection 
Different from traditional data used for classification, gene expression data has 
several unique characteristics as follows: high dimensionality, small sample size and a 
large  number  of  redundant  and  irrelevant  genes.  Gene  expression  data  sets  usually 
contain thousands to tens of thousands of genes. However, a majority of genes do not 
have expression change between cancer classes. In addition, many genes are redundant 
and highly correlated. Further, current gene expression data sets in the literature have 
relative small set of samples (often less than 100). With such a huge dimension space, it 
appears  easy  for  classic  statistical  or  computational  methods  to  over-fit  the  data. 
Moreover,  inclusion  of  a  large  number  of  irrelevant  genes  not  only  increases  the 
computation time, but also introduces noise and confuses the classifiers. A common way 
to deal with this issue is to perform gene selection prior to classification in the literature 
in order to improve the performance of classifiers, reduce computational running time, 
and facilitate post-classification analysis for biological insights of genes involved in the 
classification.  
 
The  most  commonly  used  gene selection  approach  is  individual  gene  ranking 
based on some correlation measuring criteria. Each gene is ranked by its correlation with 
the  class  labels  and  the  top  ones  are  selected.  Conventional  statistical  methods  for   23 
individual  gene  selection  include  student’s  t-test,  Wilcox  rank  sum  test,  logistic 
regression, and Pearson correlation so on. Golub et al. (1) proposed a correlation metric 
measuring the relative correlation between the expression values of a gene and the class 
labels, termed signal-to-noise (S2N). For a gene with two classes (e.g., Class 1 vs. Class 
2), the signal-to-noise statistic is (µ Class1-µ Class2)/(σClass1+σClass2) where µ and σ are the 
mean and standard deviation of the expression for the gene. This method favors genes 
that  have  large  between-class  mean  difference  and  small  within-class  variation. 
Comparing to t statistic, this method penalizes genes that have higher variance in each 
class more than those genes that have a high variance in one class and a low variance in 
another. Similarly, in order to penalize genes with small standard errors, several attempts 
have been made based on an ad hoc fix by simply adding a constant to the observed 
standard error: 
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 , where s0 is a fudge factor. 
Efron et al. (2) simply computed s0 as the 90th percentile of the sei's. In the SAM method 
developed  by  Tibshirani  group  at  Stanford  University  (3),  s0  is  determined  based  on 
minimizing the coefficient of variation of  i t ~ as a function sei. 
 
Alternatively, Smyth (4) developed a hierarchical model and derived an empirical 
Bayes estimate for the gene-wise variance. This empirical Bayes approach is equivalent 
to shrinkage of the estimated sample variances towards a pooled estimate, resulting in far 
more stable inference when the sample size is small. Similarly, Baldi et al. (5) developed 
a  regularized  t-test  that  uses  a  Bayesian  estimate  of  the  variance  among  gene   24 
measurements  within  an  experiment  for  the  identification  of  statistically  significantly 
differential genes. 
  
While genes selected by the above methods are highly correlated with the class 
individually, combining them together may not give the best discrimination power as 
these methods lack the capability of exploiting correlation and interaction among genes. 
In addition, these methods may include redundant genes. For example, genes regulated in 
the same pathway may be included as they contain similar high correlation information 
with the class labels.  Moreover, these methods may not be able to detect genes that are 
complement to each together and contribute to the classification while individual of them 
does  not  exhibit  high  correlation  with  class  labels.  This  is  common  as  tumor 
heterogeneity has been observed in many cancers and some genes may be dys-regulated 
only in a subtype of cancer. One approach to overcome these barriers is to find a group of 
genes that serve together to maximize the classification accuracy. One can monitor the 
change on the expected value of error when one gene is removed. The expected value of 
error  is  the  error  rate  computed  on  an  infinite  number  of  examples,  which  can  be 
approximated by a cost function computed on the training samples given a training set. 
Guyon et al. (6) proposed a recursive feature elimination (RFE) approach to perform gene 
selection using support vector machine. The basic idea is to apply the SVM classification 
algorithm on the training data, compute the change in cost function for the removal of 
each gene, find the gene that minimizes the cost function change after its removal, and 
then remove that gene and repeat the entire procedure. Finally, a ranked feature list is 
generated. The subset of genes that are top ranked (eliminated last) together yields the   25 
optimal classification performance, but those genes are not necessarily the ones that are 
individually most relevant (6) as the method has no effect on correlation metrics. The 
authors found that the SVM-RFE method worked better for cancer classification than the 
individual gene ranking approach and was able to select genes that are directly related 
with cancer, whereas the other method tends to pick up genes that are differential because 
of the different cell compositions in two classes of tissues. 
 
Cancer Classification Method 
While we believe that a fair amount of attention should be paid to gene selection 
as an integral preprocessing step, the central role of cancer classification is to develop 
classification methods to accurately classify cancer classes. One promising use of DNA 
microarray data in cancer classification is to accurately determine individual patient’s 
diagnostic and prognostic status based on his/her individual genomic profile, eventually 
leading  to  personalized  cancer  therapy  for  individual  patients.  Typically,  a  classifier, 
which consists of a set of discriminant functions, will be built on a “training” set, and 
then  evaluated  on  an  independent  “test”  dataset  that  does  not  participate  in  the 
development of the classifier. To date, a wide range of supervised classification methods 
have  been  developed  for  gene  expression  data  sets.  Golub  and  his  co-workers  have 
pioneered  a  molecular  classification  approach  for  gene  expression-based  histological 
classification (1). They selected 50 “informative” genes based on signal-to-noise ratio 
and proposed a weighted voting method to classify acute myeloid leukemia (AML) and 
acute lymphoid leukemia (ALL). They have demonstrated that AML and ALL can be   26 
accurately distinguished solely based gene expression values without previous knowledge 
of these classes.  
 
Khan et al. (2001) (7) first attempted to classify four types of the small, round 
blue-cell tumors (SRBCTs) that share similar histopathological characteristics to specific 
diagnostic  categories  based  on  their  gene  expression  signatures.  They  performed 
dimension  reduction  on  the  full  set  of  gene  expression  data  by  using  Principle 
Component  Analysis.  The  first  ten  components  were  then  trained  in  artificial  neural 
networks (ANNs). The ANNs correctly classified all samples and identified the genes 
most relevant to the classification based on measuring the sensitivity of the classification 
to a change in the expression level of each gene. To test the ability of the trained ANN 
models  to  recognize  SRBCTs,  the  authors  analyzed  additional  blinded  samples,  and 
correctly  classified  them  in  all  cases.  The  study  have  successfully  demonstrated  the 
potential  applications  of  gene  expression-based  classification  methods  to  classify 
histopathologically similar cancers. 
 
Decision tree, also known as classification trees, is a widely used classification 
method. The construction of the decision tree involves two phases: the growing phase and 
the pruning phase. In the growing phase, a decision tree is built from the training data. 
The purity-based entropy function selects the best gene at each internal node to split the 
data set into subsets that minimizes the misclassification error. In the pruning phase, the 
tree  is  pruned  using  some  heuristics  to  avoid  overfitting  of  data  and  increase  the 
generality of the classifier. Using a public colon cancer data set, Zhang et al. (2001) (8)   27 
introduced a recursive partitioning classification method based on classification tree and 
demonstrated its high accuracy for discriminating among distinct colon cancer tissues 
with a cross validation misclassification rate of 6-8%. In an extended study (9), in order 
to improve classification and prediction accuracy, the authors proposed a deterministic 
procedure to form forests of classification trees. When two published and commonly used 
data sets are used, they found that the deterministic forests performed far better than the 
single trees.  
 
Some  similarity-based  classification  methods  have  been  also  applied  for 
molecular cancer classification. One simple yet common method is Nearest Neighbor 
(NN) or its variant, K-Nearest Neighbor (KNN). Briefly, for each testing sample s, its 
class  label  is  determined  by  the  training  sample  whose  expression  profiling  is  most 
similar to s, according to certain distance measure. The distance measure can  be any 
similarity/dissimilarity matrix such as Pearson correlation, Euclidean distance, Manhattan 
distance etc. If using KNN (K>1), the class label of s is assigned using majority vote from 
K  training  samples  with  highest  similarity  to  s.  Utilizing  three  public  cancer  gene 
expression  data  sets,  Dudoit  et  al.  (10)  compared  the  performance  of  different 
classification methods including KNN, linear discriminant analysis, classification trees 
and more recent aggregating classifiers. They found that the nearest-neighbor, diagonal 
linear discriminant analysis (DLDA) in general had the smallest misclassification rates, 
whereas fisher linear discriminant analysis (FLDA) had the highest.  
   28 
From  a  different  point  of  view,  one  may  consider  the  training  process  of  a 
classifier as a process to find a hyperplane that best separates the training samples into 
different groups according to their classes. The best hyperplane could be the one with 
maximum margin, where margin is defined as the distance from a hyperplane to the sets 
of data points that are closest to it. Such a hyperplane is more robust and may less prone 
to change when given a slightly different training set. One of max-margin classification 
algorithms  is  Support  Vector  Machine  (SVM),  which  has  been  widely  used  in  data 
mining applications including molecular classification based on gene expression data (11-
14). Mukherjee et al. (11) first demonstrated that SVM yielded superior performance for 
gene  expression-based  classification  tasks.  Ramaswamy  et  al.  (12)  extended  SVM 
method to solve multiclass problems by employing a simple one-versus-all technique. 
Guyon et al. (6) proposed a SVM-RFE method to perform gene-selection, and recent 
study (13) extended it to be MSVM-RFE for multiclass gene selection. The ability of 
SVM for producing hyperplane with maximized margin and for tuning the amount of 
training  errors  has  made  SVM  especially  suitable  for  the  gene  expression  data 
classification (15). 
 
Another  popular  similarity-based  classification  method  in  molecular  cancer 
classification is nearest shrunken centroid method (PAM) developed by Tibshirani et al. 
(16).  One  major  modification  to  standard  nearest  centroid  classification  is  that  it 
"shrinks" each of the class centroids toward the overall centroid for all classes by an 
amount  termed  as  the  threshold.  This  shrinkage  has  led  to  two  advantages:  1)  more 
accuracy  on  classification  by  reducing  the  effect  of  noisy  genes,  2)  automatic  gene   29 
selection. In a comparison of PAM to six other classification algorithms including SVM, 
KNN, DLDA, and RandomForest, the authors have observed that PAM in overall has the 
lowest average error rate and is just slightly behind SVM in average rank. In a recent 
extended study (17), the authors introduced a modified version of linear discriminant 
analysis, termed the "shrunken centroids regularized discriminant analysis" (SCRDA). 
They have claimed that this method often outperforms the PAM method and can be as 
competitive as the support vector machines classifiers.  
 
Recently, one class of machine learning technique, Evolutionary Algorithm (EA) 
has also been introduced to cancer classification on gene expression data (18-23). For 
example,  researchers  including  our  lab  have  demonstrated  one  EA  approach,  genetic 
programming (GP) could be a promising approach for discovering comprehensible rule-
based classifiers from gene expression profiling data (19,20,22,24). Our lab applied GP to 
cancer gene expression data to select feature genes and develop molecular classifiers 
(24). By examining GP on  one Small Round Blue Cell Tumors (SRBCTs), one lung 
adenocarcinoma and five prostate cancer datasets,  we have found that GP classifiers, 
which often comprise five or less genes, successfully predicted cancer classes. Further, 
we  have  demonstrated  that  GP  classifiers  remain  predictive  ability  on  independent 
datasets across microarray platforms. 
 
Gene  expression  profiles  have  been  also  used  to  predict  disease  or  treatment 
outcome of patients. Van 't Veer et al. (25) compared primary breast tumors from patients 
who developed distant metastases within 5 years to tumors from patients who continued   30 
to  be  disease-free  after  a  period  of  at  least  5  years.    Correlation-based  supervised 
classification  successfully  identified  a  set  of  70  genes  with  an  expression  signature 
strongly predictive of a short interval to distant metastases. Beer et al. (26) developed a 
compound covariate predictor and generated a risk index based on the top 50 genes which 
identified  low-risk  and  high-risk  stage  I  lung  adenocarcinomas  with  significantly 
different  outcome.  Other  common  methods  include  semi-supervised  principle 
components (27), penalized Cox regression (28), and threshold gradient descent method 
(29) etc.  
 
Challenges in Cancer Classification 
Although results of molecular classification obtained thus far seem promising, 
there are still considerable challenges. In this section, we discuss some important issues 
in cancer classification and review current solutions thus far. However, these questions 
are still open. Further research is needed to fully address these issues.  
 
The first challenge lies in the unique characteristic of high-throughput data: the 
huge  dimensionality  and  high  co-linearity.  High-throughput  data  such  as  DNA 
microarray usually contain a large number of genes yet relatively small sample size. Such 
data disable application of standard discrimination methods. For example multivariate 
logistic regression, can not be directly applied to obtain the parameter estimates on gene 
expression data. Presently, the prevailing strategies include pre-filtering by gene selection 
as  described  in  the  previous  section,  performing  dimension  deduction,  or  using 
regularized statistical models. One way to achieve dimension reduction is to transform   31 
the large number of genes to a new set of variables which are uncorrelated and ordered 
such that the first few account for most of the variation in the data. Principle component 
analysis (PCA) is one of well known methods. It transforms the original variables (genes) 
to  a  new  set  of  predictor  variables,  which  are  linear  combinations  of  the  original 
variables.  In  mathematical  terms,  PCA  sequentially  maximizes  the  variance  of  the 
original data. Khan et al (7) applied PCA to SRBCT gene expression data and used the 
first  10  principle  components  to  train  a  neural  network.  Other  dimension  deduction 
methods include singular value decomposition (SVD), the partial least squares (PLS) and 
sliced  inverse  regression  (SIR)  so  on.  One  major  disadvantage  of  these  dimension 
deduction methods is the loss of gene information as the followed classification algorithm 
is developed solely upon the new variables. Interestingly, some researchers utilized these 
dimension-reduction  methods  to  remove  highly  correlated  genes  in  a  gene  predictor 
where individual gene selection may be carried out first to form the predictor (27,30). A 
large portion of genes selected by individual gene ranking are often redundant or highly 
correlated. In term of classification accuracy, it is thus necessary to remove such genes as 
they do not contribute much towards the performance of a classifier although they may be 
important  in  biological relevance. For example, such groups of genes may reflect an 
essential de-regulated pathway for the cancer progression. 
 
In addition to dimension deduction, the other approach is to use the regularized 
estimation  methods.  A  common  regularization  is  to  add  a  penalty  function  to  a 
multivariate partial likelihood in order to stabilize the parameter estimates.  Commonly 
employed penalty functions include L2 and L1 penalizations. For example, classical linear   32 
regression with L2 penalty is known as “ridge regression”(31).  Li et al. (32) was the first 
to investigate L2 penalized estimation of the Cox model in the high-dimension and low-
sample size settings and applied their method to gene expression profile for censored 
patient outcome. One limitation of L2 penalization is that it uses all the genes in the 
prediction and does not provide a way of select relevant genes. An alternative is to use L1 
penalized estimation, which was proposed by Tibshirani et al. (33) and was called the 
least  absolute shrinkage  and selection  operator  (Lasso).  Using  newly  developed  least 
angle regression (LARS) by Efron et al. (34), Gui et al. (28) proposed an efficient way to 
estimate L1 penalized Cox regression model , termed LARS-Lasso. Friedman et al. (35) 
have  recently  proposed  a  step-wise  optimization  method  termed  threshold  gradient 
descent (TGD) and demonstrated its application in classification problems. Interestingly, 
they showed that with different threshold value, TGD can approximate the estimates of 
partial least square, ridge regression, Lasso and LARS. Gui et al. (29) further extended 
the TGD method to the Cox regression model for selecting genes that are associated with 
patient survival and building a predictive model to predict the risk of a future patient.  
 
It has to be anticipated that in situations where the number of genes exceeds by 
far  the  number  of  samples  in  the  data,  the  overfitting  of  naively  applied  statistical 
strategies and resulting over-optimism of the prediction error may be overwhelming. This 
leads to another challenge in molecular classification about how to estimate unbiased 
prediction error rate. The standard practice for performance validation is to use a set of 
samples  as  a  training  set  for  the  development  of  the  prediction  model  and  use  a 
completely independent set of samples for estimating the prediction error. However, it is   33 
rare to obtain readily available sufficiently large numbers of specimens that are amenable 
to microarray analysis and accompanied by the necessary clinical information. Thus the 
sample size of a typical microarray study is usually less than 100. To maximize the utility 
of samples, gene expression profile studies generally estimate prediction accuracy using 
the same data by proper application of resampling methods such as cross-validation or 
bootstrapping. These methods use the data efficiently and are almost unbiased when used 
correctly. However, it does have significant variance when used with small sample size 
and can be subject to bias if used naively. For example, an inappropriate usage of cross-
validation  may  lead  to  two  types  of  biases:  selection  bias  and  optimization  bias 
(parameter selection bias). A proper cross-validation leaves out a single ‘test fold’ of the 
data, selects the model, variables and parameters solely based on the remaining ‘training 
folds’ and then evaluates the misclassification rate on the test fold. When averaged over 
folds, this should provide a nearly unbiased estimate of the true misclassification rate of 
the classifier. A ‘selection’ bias’ can occur when a subset of variables are selected based 
on all the available data and then the error rate is estimated by cross-validation using this 
fixed set  of variables. On the other hand, an ‘optimization bias’ may  occur if cross-
validation is used to estimate the error rate for multiple sets of free parameters, and then 
the set of parameter values with the lowest estimated error rate is chosen for the final 
classifier  (36).  This  happens  because  the  same  data  is  used  to  both  select  a  set  of 
parameters and to estimate the error rate. To deal with this issue, a separate two-level 
cross-validation is needed to estimate its error rate. As suggested by Wood et al (36), 
two-level cross-validation should be used as follows. Assumed K fold cross validation is 
used, at the top level, one of K1 folds of data is left out for the purpose of assessing the   34 
error rate of the finished classifier. At the lower level, K2-fold cross-validation is then 
performed on the remaining data to select the optimal value of any free parameters. When 
all parameters are selected, the classifier can be tested on the left-out fold at the top level. 
By repeating this for all K1 folds at the top level, one can generate a cross-validated 
assessment of the cross-validated choice. To simplify the procedure, one may select K2 = 
K1-1, so that the same fold structure can be used for both levels.  
 
Even perfect and complete cross-validation may suffer from unknown external 
validity, making molecular classifiers difficult to move towards clinical practice. One 
challenge lies in the limited sample size of the data. The profiled set of samples may not 
represent the general populations in clinic. Thus, in order to truly assess the classifier 
performance, one may perform a completely independent validation which may include 
but  not  limited  to  different  data  samples  from  independent  disease  centers,  same 
protocols  and  same  definition  of  analytical  end  point,  and  independent  testing  by 
independent research investigators so on. Another challenge is the fact that the genes 
selected for each proposed profile may be not stable. Different splits of the training and 
validation data may result in very different sets of genes being selected. Some genes may 
be valid only in the reported dataset. Ein-Dor et al. (37) have reported that thousands of 
samples are needed to generate a robust gene list for predicting outcome in cancer. This is 
about  100-fold  larger  than  the  sample  sizes  currently  being  used  to  date.  Thus  new 
methods may be needed in selecting the robust genes relevant to cancer classification.  
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One may question why not to estimate prediction accuracy using existing external 
datasets  as  there  are  numerous  gene  expression  profiles  reported  in  the  literature.  In 
theory, this is a most rigorous validation. However, one challenge lies in the lack of a 
unified microarray platform and standardized procedure to integrate public datasets. The 
challenge is two-folds. First, there is no unified microarray platform thus far. For an 
instance,  Affymetrix  platforms  measure  the  absolute  mRNA  expression  levels  of 
individual genes of individual samples while cDNA microarrays measure the relative 
mRNA expression change between two samples. Different reference samples may be 
used for cDNA arrays on different studies. In addition, datasets from different platforms 
may contain different sets of genes. To address these issues, efficient methods for data 
transformation and gene annotation need to be developed. Second, even when a unified 
platform is used for gene expression profiling, systematic biases may still exist between 
datasets from different laboratories. Non-standardization of data may introduce noise and 
error  into  the  classification  accuracy.  Special  care  must  be  taken  to  inter-study 
classification.  A  simple  approach  to  normalize  inter-study  datasets  is  to  standardize 
individual genes within each dataset with zero mean and unit variance after between-
array  normalization.  This  procedure  transforms  and  makes  same  genes  of  different 
datasets at the same location and scale. In practice, this is similar to calculate relative 
gene expression levels of individual sample to a reference sample where each gene’s 
expression  level  equals mean  expression  value of  the  gene across  all  samples  in  the 
dataset.  This  method  was  used  in  Chapter  3  to  validate  a  breast  cancer  outcome 
signature developed from a training set on multiple independent datasets. The signature 
successfully dichotomized the patients in individual datasets into high-risk and low-risk   36 
groups with strongly different outcome. However, this method may not work well on 
datasets with small sample sizes. Warnat et al. (38) used median rank scores and quantile 
discretization  to  derive  numerically  comparable  measures  of  gene  expression  from 
different platforms. The basic idea of this method is to transform gene expression values 
of different microarray platforms to a common numerical range by replacing numerical 
values of one study by numerical values from the other study, with respect to the relative 
ranks of expression values within each study. Our lab also developed a data integration 
method based on poe (probability of expression) transformation (39). The poe model 
transformed  the  raw  gene  expression  data  into  signed  probability  of  differential 
expression for each gene in each sample, thus providing a unified measure across studies. 
The  platform-free  scaleless  property  of  this  model  is  particularly  useful  for  data 
integration  in  the  domain  of  gene  expression  profiling.  Further,  the  transformation 
improved  contrast  in  each  data set  by  removing  the  influence  of  extreme  expression 
values. Following this poe model, we combined multiple breast cancer studies (n = 305 
samples) and developed a 90-gene meta-signature, which demonstrated strong association 
with  survival  in  breast  cancer  patients.    A  more  advanced  method  was  proposed  by 
Benito et al. (40) for the identification and adjustment of systematic biases present within 
microarray  data  sets.  They  presented  a  new  approach,  called  'Distance  Weighted 
Discrimination (DWD)', to adjust system biases in microarray datasets. The new method 
was shown to be very effective in removing systematic biases present in published breast 
tumor cDNA microarray data sets and could be used to merge multiple breast tumor data 
sets completed on different microarray platforms. 
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Taken  together,  in  this  chapter,  we  provided  a  comprehensive  survey  on  the 
existing cancer  classification  methods.  As  an  important  step  of  classification,  feature 
gene selection was presented in detail as well. Molecular classification based on gene 
expression profiling has been rapidly evolving from an interesting scientific concept to a 
clinical tool in the last decade. It provides a more systematical and unbiased way for 
cancer diagnosis and prognosis. Through this survey,  we conclude that, although the 
progress of molecular classification varies for different cancers and there are still a great 
amount  of  work  that  needs  to  be  further  addressed,  the  results  obtained  so  far  is 
promising and the future is possibly fascinating.    38 
 
 
Figure 2.1.A typical workflow of molecular cancer classification and prediction model.   39 
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PART 2: GENE EXPRESSION-BASED CANCER DIAGNOSIS AND 
PROGNOSIS  
 
 
CHAPTER 3 
 
A Transcriptional Fingerprint of Estrogen in Human Breast Cancer Predicts 
Patient Survival  
 
Estrogen  signaling  plays  an  essential  role  in  breast  cancer  progression,  and 
Estrogen  Receptor  (ER)  status  has  long  been  a  marker  of  hormone  responsiveness. 
However, ER status alone has been an incomplete predictor of endocrine therapy, as 
some ER+ tumors, nevertheless, have poor prognosis. Here we sought to use expression 
profiling  of  ER+  breast  cancer  cells  to  screen  for  a  robust  estrogen-regulated  gene 
signature  that  may  serve  as  a  better  indicator  of  cancer  outcome.  We  identified  532 
estrogen-induced genes and further developed a 73-gene signature that best separated a 
training  set  of  286  primary  breast  carcinomas  into  prognostic  subtypes  by  step-wise 
cross-validation.  Notably,  this  signature  predicts  clinical  outcome  in  over  ten  patient 
cohorts  as  well  as  their  respective  ER+ sub-cohorts.  Further,  this signature separates 
patients who have received endocrine therapy into 2 prognostic subgroups, suggesting its 
specificity as a measure of estrogen signaling, and thus hormone sensitivity. The 73-gene 
signature also provides additional predictive value for patient survival, independent of 
other clinical parameters, and outperforms other previously reported molecular outcome   43 
signatures.  Taken  together,  these  data  demonstrate  the  power  of  using  cell  culture 
systems to screen for robust gene signatures of clinical relevance. 
   
Breast  cancer  is  the  most  common  type  of  cancer  among  women  in  the 
industrialized world, accounting for nearly 1 of every 3 cancers diagnosed. Estrogen is 
essential for the normal growth and differentiation of the mammary gland, and plays a 
critical role in the pathogenesis and progression of breast cancer (1). Increased lifetime 
exposure to estrogen  is a well-known factor for increased breast cancer risk (1), and 
drugs that block the effects of estrogen has been used to inhibit the growth of hormone-
dependent  breast  cancers  (2).  In  the  last  few  decades,  systemic  adjuvant  therapy  to 
patients with predicted poor prognosis has significantly increased breast cancer survival 
(3). Current prognostic markers for breast cancer include tumor stage, size, histological 
grade,  and  estrogen  receptor  status.  However,  approximately  1  out  of  4  patients 
diagnosed  with  breast  cancer  nevertheless  die  from  the  disease  (4),  indicating  the 
insufficiency of current prognostic biomarkers. In addition, a large number of patients 
with ER-positive tumors failed on endocrine therapy, suggesting the need of more precise 
biomarkers of therapy prediction.  
 
Taking advantage of global expression profiling, molecular predictors have been 
developed to classify and predict patient prognosis (5-10). This prognostication of breast 
cancer outcome may be used for the selection of high-risk patient for adjuvant therapy. 
Transcriptional changes of these predictor genes are presumed to reflect the activity of 
essential signaling pathways in tumors and thus greatly increase the prediction power.   44 
For example, the expression of prostate-specific-antigen (PSA) indicates the activation of 
androgen  receptor  and  serves  as  a  much  better  diagnostic/prognostic  biomarker  of 
prostate cancer than androgen receptor itself. Similarly, for several decades ER status has 
been used as a marker of hormone responsiveness to guide adjuvant therapy, with ER+ 
tumors having significantly better clinical outcome (11). Some ER+ tumors, nevertheless, 
incur disease recurrence, indicating that ER status alone is an incomplete assessor and 
additional biomarkers are required. A transcriptional fingerprint of estrogen may better 
reflect the activity of estrogen signaling, thus being a more definitive predictor of breast 
cancer recurrence and patients’ response to hormonal therapy. 
 
In this study, we attempted to delineate downstream effector genes of estrogen 
signaling. We hypothesized that these genes may indicate an activated state of estrogen 
receptor,  and  thus  predict  cancer  outcome  and  hormone  responsiveness.  To  identify 
robust  estrogen-regulated  genes,  we  employed  three  ER+,  estrogen-responsive  breast 
cancer  cell  lines,  MCF-7,  T47D  and  BT-474.  We  stimulated  these  cells  with  17β-
estradiol to emulate the transcriptional events induced by estrogen signaling in vivo. To 
ensure that we capture the transcriptional changes due to direct regulation by estrogen, 
rather than downstream effects, we focused primarily on early time-points (0, 1, 2, 4, 8, 
12  and  24hrs)  following  estrogen  stimulation  (12).  By  a  time-course  analysis  on 
expression profiling of these cell lines, we identified 532 estrogen-induced probe sets, 
representing 446 unique genes (FDR<0.01, see Methods and Figure 3.1a).  
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Several  lines  of  evidence  support  that  the  genes  we  selected  represent  a  true 
downstream  transcriptional  network  of  estrogen  signaling.  Firstly,  a  subset  of  these 
genes, including PGR, PDZK1, CTSD, MYC, MYB, MYBL1, MYBL2, STK6, Ki-67 
and  GREB1,  have  been  previously  confirmed  to  be  induced  by  estrogen  (13-15). 
Secondly,  Molecular  Concept  Map  (MCM)  analysis  (16),  which  allows  for  the 
identification of molecular correlates of our gene set, revealed significant enrichment of 
‘up-regulated by estrogen treatment’ signatures (P-values<=0.001, Odds ratios >=4.35) 
previously identified by several independent groups (17-19) (Figure 3.1b). To evaluate 
the  biological  relevance  of  our  gene  set  in  vivo¸   MCM  analysis  of  cancer  profiling 
concepts found strong enrichment  of ‘over-expressed in  ER+ breast cancer’ concepts 
derived from a number of human breast cancer profiling studies executed by independent 
investigators  (5,8,10,20).  Therefore,  our  estrogen-regulated  gene  set  is  relevant  to 
previously identified gene sets of estrogen regulation reported from both in vitro cell line 
experiments and in vivo tumor profiling. Interestingly, integrative analysis with a public 
genome-wide  location  data  of  ER  occupancy  (21)  showed  that  a  highly  significant 
portion (P <0.00001) of our estrogen-induced genes are direct targets of ER, suggesting 
that our gene set may represent the direct transcriptional network evoked by activated 
ER. 
 
To obtain an overall annotation of our estrogen-regulated genes, we performed 
MCM analysis on Gene Ontology (GO) concepts. Significantly enriched gene ontology 
(GO) categories include “DNA replication”, “regulation of cell cycle”, “protein folding”, 
“tRNA processing”, “cytokinesis”, “DNA replication”, and “DNA repair” (Figure 3.1c).   46 
This result is consistent with previously reported functions of estrogen-regulated genes 
(13,22). 
 
Intriguingly,  another  distinct  interaction  network  revealed  by  MCM  analysis 
enriched  in  the  ‘over-expressed  in  high  grade  breast  cancer’  signatures  from  various 
datasets such as the Miller et al.  (5), Sotirious et al (20), and van de Veer et al. (9) 
datasets (Figure 3.1d). Notably, this enrichment network also includes several concepts 
of  ‘over-expressed  in  metastasis,  dead  or  recurrent  breast  cancers’, suggesting a  link 
between  our  gene  signature  and  breast  cancer  outcome.  Thus,  we  next  attempted  to 
confirm this survival association using breast cancer expression profiling datasets. We 
performed  k-mean  clustering  (k=2)  with  Pearson  correlation  distance  of  286  node-
negative primary breast carcinomas (10). Kaplan-Meier (KM) survival analysis revealed 
that the resulted two clusters differed significantly in patient outcome (P = 0.002). The 
“high-risk”  group  with  poorer  outcome  has  higher  expression  of  several  known  ER 
targets  (13,15),  such as  MYBL1, MYBL2, MKI67,  and MCM2. By  contrast,  “good-
outcome” genes that are over-expressed in the “low-risk” group include PGR, CD44, 
ADD1, and PTGER3.  
 
To develop an optimal outcome predictor using top survival-related genes, we 
ranked the 532 estrogen-regulated genes by their corresponding survival significance and 
performed step-wise cross-validation. Our results demonstrated a set of top-ranked 73 
genes (Table 3.1) that yielded optimal survival association with the least cross-validation 
error (Figure 3.2a). This 73-gene signature successfully dichotomized the 286 training   47 
samples into high-risk and low-risk groups  with significantly different outcome  (P  < 
0.00001, Figure 3.2b). Importantly, by performing 1000 Monte Carlo simulations we 
found that the probability for a randomly selected subset of 73 genes to cluster the same 
samples with equivalent or better significance was less than 0.001, re-affirming that the 
performance of our 73-gene signature could not be achieved by chance.  
 
To validate the prediction power of our 73-gene signature, we collected all public 
breast  carcinoma  datasets  (n=11)  with  available  patient  survival  information  from 
ONCOMINE (23) database. The 73-gene signature was then applied to predict individual 
samples within  each dataset  into either “high-risk” or “low-risk” group using  nearest 
centroid classification. Strikingly, in 10 out of these 11 datasets KM survival analysis 
revealed a remarkable outcome difference between the predicted “high-risk” and “low-
risk” groups (Figure 3.3a-j). For the only dataset wherein our outcome signature failed to 
predict, it revealed a marginally significant (log-rank P = 0.15, Figure 3.3k) association 
with distance metastasis within 5 years. To the best of our knowledge, this is the first 
study  thus  far  that  reports  a  breast  cancer  outcome  predictor  which  is  validated 
extensively in such many independent patient cohorts.  
 
We observed that our gene signature correctly predicted most ER- breast tumors 
within individual datasets as “high-risk”. As a subset of ER+ tumors relapses regardless 
of standard anti-hormone therapy, they may as well have poor prognosis. It is therefore 
important  to  identify  these  patients  for  more  effective  adjuvant  therapies.  We  thus 
examined  the  ability  of  our  predictor  in  stratifying  the  ER+  tumors  into  prognostic   48 
subgroups.  We  have  taken  the  ER+  samples  from  each  dataset  and  carried  out  KM 
survival  analysis  for  the  predicted  “high-risk”  and  “low-risk”  groups  by  the  73-gene 
signature. Notably, KM survival analysis demonstrated a strong discriminative power of 
our 73-gene signature in distinguishing ER+ patients with different prognoses (Figure 
3.4). 
 
Prognostication of breast cancer outcome may guide the respective selection of 
patients at high risk for systemic adjuvant therapy. However, there is no guarantee that 
these selected patients will actually benefit from the therapy. It is therefore of important 
clinical  value  to  predict  therapy  responsiveness  and  to  spare  some  patients  from 
unnecessary adjuvant therapies which have side effects that may cause more harm than 
good. For example, endocrine therapy may be sufficient for some node-positive and ER-
positive patients, and more aggressive adjuvant therapy may not additionally help these 
patients. Out  of  the  11 datasets  we  analyzed  above,  four  contained  patient  treatment 
information.  We  extracted  hormone-treated  samples  from  each  dataset  and  assessed 
whether our gene predictor was able to predict patient response to hormonal therapies. 
Again, we predicted the hormone-treated samples into “high-risk” and “low-risk” groups. 
Importantly,  in  each  cohort  we  observed  significantly  different  outcome  for  the  two 
predicted groups, suggesting an ability of our signature in therapy prediction (Figure 
3.3j, Figure 3.5a-c).  
 
To further confirm the association of our gene signature with estrogen sensitivity, 
we determined whether the 73-gene signature is able to classify ER+/ER- cell lines in   49 
vitro. We performed hierarchical clustering based on the expression pattern of the 73 
genes in 5 ER- and 3 ER+ cell lines. Interestingly, we found that the 73 genes perfectly 
separated the 8 cell lines into their respective ER+ and ER-clusters, demonstrating that 
our signature genes are specific to estrogen signaling. Furthermore, as we selected our 
estrogen-induced genes based on expression induction at relative early time points (no 
later than 24hrs) following 17β-estradiol treatment, we hypothesized that this subset of 73 
genes is also enriched for direct targets of ER. Concordantly, comparative analysis with 
ER-occupied genes described in a previous study  (21) identified a significant overlap 
(P=0.0001), re-confirming the specificity of our signature to estrogen activity.  
 
As estrogen may also play an important role in the development of glioma (24) 
and  lung  cancer, especially  lung  adenocarcinoma  (25,26),  we  examined  our  outcome 
signature in 3 glioma and 1 lung adenocarcinoma datasets. Notably, our gene signature 
successfully predicted patient outcome, with P=0.0006 for the Freije et al. Glioma (27), 
P=0.008 for the Phillips et al. Glioma (28), P=0.11 for the Nutt et al. Glioma (29) and 
P=0.006 for the Bhattacharjee et al. lung adenocarcinoms (30) dataset (Figure 3.5d-j). 
 
Global  gene  expression  profiling  of  breast  cancer  has  yielded  a  number  of 
prognostic signatures in the last decade. To properly evaluate the predictive power of our 
signature,  we  compared  it  with  established  clinical  parameters  as  well  as  previously 
reported gene predictors. We first compared our signature with an 822-gene estrogen-
regulated signature (termed as “estrogen-SAM”) developed by Oh and the co-workers 
(14) based on SAM analysis that classified the ER+ cases of the Rosetta data set (n=225)    50 
into prognostic subtypes (8). We selected the Rosetta data as the test dataset since it has 
been  routinely  used  as  a  validation  dataset  for  breast  cancer  outcome  signatures. 
Multivariate Cox proportional-hazards regression analysis of these patients showed that 
both  our  signature  and  the  estrogen-SAM  signature  were  significant  predictors  for 
relapse-free survival (RFS), independent of standard clinical factors (RFS P=0.002 and 
P=0.004 respectively,  Table 3.2). Importantly, our  outcome signature was by far the 
strongest predictor for both relapse-free and overall survival (OS) (RFS P=0.002, Hazard 
ratio [HR]: 2.24, 95% Confidence Interval [CI]: 1.35-3.70; and OS P=0.001, HR: 3.27, 
95% CI: 1.62-6.62). Thus, our outcome signature achieved better predictive power while 
using substantially fewer genes. In addition, our signature comprised solely of estrogen-
regulated genes, thus  representing the biological significance of estrogen activity. By 
contrast,  the  estrogen-SAM  signature  genes  were  selected  based  on  their  differential 
expression  between  two  tumor  subtypes  predefined  by  estrogen-regulated  genes,  and 
hence may or may not themselves be regulated by estrogen. 
 
We  next  extended  the  comparison  of  our  signature  and  the  estrogen-SAM 
signature to the Rosetta 70-gene signature as well using the Rosetta data set. As the 
Rosetta  signature  utilized  a  subset  of  44  samples  during  its  development,  to  avoid 
potential bias these samples were excluded from our analysis. Importantly, our signature 
and  the  Rosetta  70-gene  signature  were  both  significant  predictors  of  relapse-free 
survival (P=0.026 and P=0.021 respectively, Table 3.3) in this dataset. Surprisingly, our 
signature was the only significant predictor of overall survival (P=0.008), independent of 
other  clinical  parameters  and  signatures.  To  further  compare  the  performance  of  our   51 
signature  to  previously  reported  breast  cancer  gene  signatures,  we  examined  their 
respective  predictive  abilities  on  multiple  datasets.  As  shown  in  the  Table  3.4,    the 
Rosetta  70-gene  signature,  Oncotype  DX  gene  predictor,  and  our  gene  signature 
demonstrated  superior  performance  over  other  signatures  while  our  gene  signature 
showed overall best performance. 
 
To investigate the molecular difference between our signature and other breast 
cancer gene predictors of similar size, we examined the number of overlapping genes. 
Interestingly, only two (PRC1 and CENPA), one (CD44) and three (BRRN1, CDCA8, 
and MYBL2) genes overlapped between our 73-gene signature and the Rosetta 70-gene 
signature (9), the Wang et al (10) 76-gene signature, and the Miller et al (5) 32-gene 
signature, respectively. This lack of overlap suggests that our signature is comprised of 
genes  distinct  from  previously  reported  gene  predictors.  Nevertheless,  two-way 
contingency  table  analysis  revealed  strong  associations  between  prediction  results  of 
individual samples made by our outcome signature and the Rosetta 70-gene signature, the 
wound-response  signature  and  the  intrinsic-subtype  model  (7)  (Table  3.5).  These 
findings  are  consistent  with  previously  reported  study  that  distinct  gene  predictors, 
although with little overlap in terms of gene identity, may have high rates of concordance 
in  prediction  results  for  individual  samples  (31).  Taken  together,  our  distinct  gene 
signature  outperformed  other  known  predictors  while  being  concordant  in  outcome 
prediction of individual samples.  
   52 
There  is established  precedence for  clinical  use  of  molecular  markers  to  help 
decide customized therapy for individuals with breast cancer. For example, ER and PR, 
and  ERBB2  have  been  used  to  assess  potential  response  to  hormonal  therapy  and 
Herceptin, respectively. However, a single marker such as ER has been found insufficient 
to fully stratify patient into different diagnostic/prognostic subtypes. In this study, we 
aimed to identify a transcriptional fingerprint of estrogen, which reflects the downstream 
activity of estrogen signaling pathway, and thus may be a more efficient predictor of 
breast cancer recurrence.  
 
Unlike  most  previously  reported  breast  cancer  signatures  that  were  developed 
using  supervised  analysis  based  on  patient  diagnosis/prognosis  status  (5-10),  our 
signature  was  discovered  by  specifically  selecting  estrogen-regulated  genes,  thus 
representing the activities of estrogen signaling, a key biological characteristic of breast 
cancer tumors. We profiled gene expression of three breast cancer cell lines during early 
time-points following estrogen treatment. We observed that over 80% of our estrogen-
regulated genes were already activated within  1-2 hr following  estrogen treatment  in 
MCF7 breast cancer cell line. Genome-wide location analysis confirmed that a significant 
portion of these genes are directly occupied by ER, suggesting an enrichment of direct 
ER target genes in our signature. In addition, our gene signature distinguishes ER+ and 
ER- patients, as well as separates patients who did well with hormonal therapy from 
those who did not, indicating its specificity in monitoring estrogen activity.  
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In developing the 73-gene outcome signature we focused on in vitro estrogen-
regulated genes and further selected a subset that is associated with patient outcome in 
vivo  in  human  breast  tumors.  These  genes  are  unique  as  they  represent  a  subset  of 
downstream targets of estrogen signaling that are predictive of breast cancer outcome.  
The  73-gene  signature  predicts  breast  cancer  outcome  in  10  out  of  11  datasets  we 
analyzed. Besides correctly assigning most ER- tumors in each dataset into high-risk 
group,  this  signature  is  able  to  stratify  the  ER+  samples  into  prognostic  subtypes, 
suggesting that it may better reflect tumor aggressiveness than ER status alone. Most 
importantly, our signature provides additional prognostic information beyond standard 
clinical factors and yields overall best performance against previously reported breast 
cancer outcome predictors. 
 
Further validation and refinement of our signature using additional datasets with 
larger cohorts of breast cancer patients will help to strengthen its clinical value. This 
study lays the ground for future characterization of individual signature genes to facilitate 
in the understanding of breast cancer progression as well as help select genes with critical 
roles in estrogen response for breast cancer therapy. Furthermore, as RT-PCR assays of 
paraffin-embedded tissues have recently been developed (6), it is technically feasible to 
develop an RT-PCR assay of our 73-gene signature for future validation and, potentially 
later on, for clinical usage. Our signature may be useful in selection of high-risk patients 
for  adjuvant  therapy  as  well  as  in  sparing  some  hormone-sensitive  patients  from 
aggressive therapy.  
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Methods and Materials 
Cell  culture:  Breast  cancer  cell  lines  (MCF-7,  T47-D,  BT-474)  were  maintained  as 
previously described (32). For defined estrogen culture experiments, cells were rinsed in 
PBS,  grown  in  steroid-depleted  media  (phenol  red-free  IMEM  (Improved  Minimal 
Essential Media) supplemented with 10% charcoal stripped calf bovine serum for 2 days, 
and  treated  with  10-9  M  17β-estradiol  for  1,  2,  4,  8,  12  or  24  hours  as  described 
previously (13). 
 
RNA extraction and microarray experiments: RNA was isolated, labeled and hybridized 
according  to  the  Affymetrix  protocol  (Affymetrix  GeneChip  Expression  Analysis 
Technical Manual, Rev. 3) by the University of Michigan Comprehensive Cancer Center 
Affymetrix  and  cDNA  Microarray  Core  Facility  as  described  previously  (13).  All 
primary  array  data  have  been  deposited  in  the  Gene  Expression  Omnibus  (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) with series number GSE3834.  
 
Affymetrix microarray data analysis: Data from microarray experiments were calculated, 
normalized and log2-transformed using RMAExpress (33). As described previously (13), 
the MCF-7 profiles were generated on the Affymetrix U133A platform, and the other 
profiles  were  generated  on  the  Affymetrix  U133  Plus  2.0  platform;  we  thus  only 
considered  22,283  probe  sets  that  were  common  in  both  platforms  for  subsequent 
analysis. Expression values within each cell line were first z-transformed to zero mean 
and unit variance. Time-course experiments were analyzed using EDGE (12) to identify 
genes  differentially  expressed  in  estrogen-treated  relative  to  estrogen-starved  cells.   55 
Multiple hypothesis testing was adjusted by False Discovery Rate (FDR). 1,314 probe 
sets were identified differentially expressed over time with FDR less than 0.01. These 
genes  were  then subjected  to  hierarchical  clustering,  which  resulted in  one  estrogen-
induced gene cluster containing 532 probe sets  and the other estrogen-inhibited gene 
cluster containing 782 probe sets. For subsequent analyses, only genes in the estrogen-
induced cluster were used as we are more interested in estrogen-activated events during 
tumor progression. 
 
Analysis of primary breast tumor data using the estrogen-regulated gene set: All primary 
breast tumor sets used in this study were collected by ONCOMINE (23) from previous 
publications  or  from  the  NCBI  GEO  database.  Genes  within  each  dataset  were 
normalized to zero mean and unit variance. The largest Affymetrix U133A breast cancer 
dataset (10), containing 286 primary breast carcinomas, was used as the training set to 
conduct cross-validation and to develop an optimal gene set as previously described (34). 
All other datasets were used as independent test sets for validation purpose. The basic 
cross-validation procedure is as follows: (1) fit Cox regression model and calculate the 
Cox score for each gene in the Wang et al training set; (2) choose a set J of possible 
values of Cox scores S from step (1), and let pmin=1, emin=1. (3) For each S in J, do the 
following: (4) perform  k-means clustering (k=2) using only  genes with absolute Cox 
scores greater than S. (5) perform a log-rank test to test whether the two clusters have 
different survival rates. Name the p-value of this test as p. (6) If p > pmin, then return to 
step 3. (7) perform 10-fold cross-validation by nearest centroid classification based on the 
class memberships defined by the clusters obtained in step 3. Name the misclassification   56 
error as e. (8) If e ≤ emin, then let Sopt = S, pmin= p, and emin= e, and return to step 3. 
Otherwise return to step 3 without changing the value of Sopt. The optimal value of S is 
the value of Sopt when cycle of this procedure terminates, and the optimal gene signature 
is designated as genes with absolute Cox scores greater than Sopt. The two clusters from 
k-means clustering based on these optimal genes are designated accordingly as either 
“high-risk” or “low-risk” by Kaplan-Meier (KM) survival analysis. Individual samples in 
the  test  data  sets  are  then  predicted  as  “high-risk”  or  “low-risk”  by  nearest  centroid 
classification. When both the training and the test  datasets used the same affymetrix 
platform,  probe  set  IDs  were  used  to  cross-refer  the  two  datasets.  Otherwise,  gene 
symbols were used to map genes from the training set to the test sets. When multiple 
report  identifiers  were  found  for  one  gene  on  a  given  platform,  expressions  of  such 
reporter IDs were averaged per gene.     
 
Survival  Analysis:  KM  survival  plots  were  compared  by  log-rank  test  in  R  (the  R 
Foundation, http://www.r-project.org) for individual datasets. The end point of interest 
for survival analysis is recurrence-free survival unless the dataset only provides overall 
survival  information.  Multivariate  Cox  proportional-hazards  regression  analysis  was 
conducted  on  van  de  Vijver  et  al.  dataset  in  R.  Concordance  of  sample  prediction 
memberships by different signatures was tested in SPSS 11.5 for windows (SPSS Inc., 
Chicago, IL, USA). 
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Table 3.1. Description of the 73 Genes in the outcome signature 
 
Affy_U133A 
Probe Set  Gene Symbol  Affy_U133A 
Probe Set 
Gene 
Symbol 
202148_s_at  PYCR1  220038_at  SGK3 
203564_at  FANCG  204498_s_at  ADCY9 
209773_s_at  RRM2  208922_s_at  STX5 
202954_at  UBE2C  218620_s_at  HEMK1 
202095_s_at  BIRC5  208688_x_at  EIF3S9 
202870_s_at  CDC20  212022_s_at  MKI67 
221436_s_at  CDCA3  206364_at  KIF14 
214096_s_at  SHMT2  218663_at  HCAP-G 
218336_at  PFDN2  206976_s_at  HSPH1 
221520_s_at  CDCA8  218270_at  MRPL24 
214095_at  SHMT2  218009_s_at  PRC1 
203145_at  SPAG5  209408_at  KIF2C 
204092_s_at  AURKA  204817_at  ESPL1 
218726_at  DKFZp762E1312  38158_at  ESPL1 
211881_x_at  IGL@  204962_s_at  CENPA 
206472_s_at  TLE3  203755_at  BUB1B 
202107_s_at  MCM2  222039_at  LOC146909 
216913_s_at  KIAA0690  204441_s_at  POLA2 
219215_s_at  SLC39A4  212949_at  BRRN1 
201710_at  MYBL2  219502_at  NEIL3 
201584_s_at  DDX39  210466_s_at  SERBP1 
204252_at  CDK2  204633_s_at  RPS6KA5 
219910_at  HYPE  203710_at  ITPR1 
201421_s_at  WDR77  215193_x_at  HLA-DRB1 
213906_at  MYBL1  212473_s_at  MICAL2 
211576_s_at  COL18A1  213933_at  PTGER3 
218984_at  PUS7  202464_s_at  PFKFB3 
205284_at  KIAA0133  220266_s_at  KLF4 
220177_s_at  TMPRSS3  212848_s_at  C9orf3 
204489_s_at  CD44  202417_at  KEAP1 
204490_s_at  CD44  204792_s_at  IFT140 
209835_x_at  CD44  200706_s_at  LITAF 
205322_s_at  MTF1  215273_s_at  TADA3L 
218481_at  EXOSC5  221261_x_at  MAGED4 
220029_at  ELOVL2  214736_s_at  ADD1 
208305_at  PGR  220935_s_at  CDK5RAP2 
209273_s_at  HBLD2       58 
Table  3.2.  Multivariate  Cox  proportional  hazards  analysis  of  the  73-gene  outcome 
signature in the Van de vijver et al. ER+ data set. The total number of samples is 225. 
 
   Relapse-Free Survival  Overall Survival 
Variable  Hazard Ratio 
(95% CI)  p-value  Hazard Ratio 
(95% CI)  p-value 
Our estrogen-regulated signature  2.24 (1.35-3.70)  0.002  3.27 (1.62-6.62)  0.001 
The Oh et al. Estrogen-SAM 
genesignature (IIE vs. IE)  2.32 (1.31-4.11)  0.004  2.24 (0.95-5.28)  0.066 
Age  0.94 (0.89-0.98)  0.004  0.94 (0.89-1.00)  0.069 
Size (diameter >2cm vs. <2cm)  1.49 (0.93-2.37)  0.095  1.41 (0.76-2.61)  0.280 
Tumor Grade         
    (intermediate vs. well diff.)  1.40 (0.72-2.72)  0.320  2.02 (0.65-6.28)  0.230 
    (poorly vs. well diff.)  1.30 (0.64-2.63)  0.460  2.86 (0.91-9.02)  0.070 
Node status         
    (1-3 vs. 0 positive nodes)  1.82 (0.93-3.57)  0.082  1.65 (0.66-4.18)  0.290 
    (>3 vs. 0 positive nodes)  2.87 (1.23-6.74)  0.015  2.22 (0.69-7.11)  0.180 
Hormonal or chemotherapy vs. 
no adjuvant therapy  0.33 (0.16-0.66)  0.002  0.43 (0.17-1.13)  0.086 
   59 
Table  3.3.  Multivariate  Cox  proportional  hazards  analysis  of  the  73-gene  outcome 
signature with two known predictors in the Van de vijver et al ER+ data set. Samples 
used for Van't veer et al. training model were excluded, leading to 181 samples in total. 
 
   Relapse-Free Survival  Overall Survival 
Variable  Hazard Ratio 
(95% CI)  p-value  Hazard Ratio 
(95% CI)  p-value 
Our estrogen-regulated signature  2.01 (1.09-3.72)  0.026  3.63 (1.40-9.42)  0.008 
70-gene Signature (poor vs. 
good)  2.42 (1.14-5.14)  0.021  2.37 (0.72-7.85)  0.160 
The Oh et al. Estrogen-SAM 
gene signature (IIE vs. IE)  1.83 (0.95-3.52)  0.070  1.71 (0.62-4.75)  0.300 
Age  0.97 (0.92-1.03)  0.340  1.00 (0.92-1.07)  0.900 
Size (diameter >2cm vs. <2cm)  1.18 (0.68-2.04)  0.560  1.29 (0.60-2.77)  0.510 
Tumor Grade         
    (intermediate vs. well diff.)  0.97 (0.47-2.00)  0.930  1.33 (0.39-4.49)  0.650 
    (poorly vs. well diff.)  0.67 (0.29-1.54)  0.350  1.63 (0.46-5.75)  0.450 
Node status         
    (1-3 vs. 0 positive nodes)  1.86 (0.90-3.88)  0.096  1.76 (0.63-4.92)  0.280 
    (>3 vs. 0 positive nodes)  3.56 (1.39-9.14)  0.008  2.84 (0.77-10.5)  0.120 
Hormonal or chemotherapy vs. 
no adjuvant therapy  0.33 (0.16-0.68)  0.003  0.38 (0.14-1.03)  0.056 
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Table 3.4. Performance comparisons of the estrogen-regulated signature with previously reported breast cancer signatures. Individual 
gene signatures were extracted from the original literature. Except for Oncotype DX and estrogen-regulated predictors were trained in 
Wang et al. breast dataset, the other signatures were trained in each respective dataset. Each signature was used to perform k-mean 
clustering and patients were separated into high-risk and low-risk groups, which were used as a training model to predict samples in 
other datasets by nearest centroid classification. The best signature for each dataset was highlighted in bold. 
 
Signature Source
Log-rank
P-value*
Hazard Ratio 
(95% CI)
C-Index (95% 
CI)**
Log-rank
P-value
Hazard Ratio 
(95% CI)
C-Index (95% 
CI)
Log-rank
P-value
Hazard Ratio 
(95% CI)
C-Index (95% CI)
Number of Genes
Wang_Breast 1.03E-06 2.60 (1.75, 3.86) 0.63 (0.58, 0.67) 0.0007 1.90 (1.30, 2.78) 0.58 (0.54, 0.63) 0.09 1.39 (0.95, 2.04) 0.55 (0.50, 0.59)
Pawitan_Breast 1.20E-07 8.60 (3.3, 22.41) 0.73 (0.66, 0.80) 0.0002 3.65 (1.77, 7.53) 0.65 (0.57, 0.74) ######## 10.3 (3.13, 34.0) 0.71 (0.65, 0.78)
Miller_Breast 0.0004 2.59 (1.50, 4.46) 0.62 (0.56, 0.69) 0.0001 2.71 (1.60, 4.61) 0.63 (0.56, 0.69) 0.001 2.51 (1.43, 4.41) 0.61 (0.55, 0.68)
Vantveer_Breast 0.0003 2.90 (1.58, 5.33) 0.64 (0.57, 0.71) 0.03 1.87 (1.04, 3.36) 0.58 (0.51, 0.65) 0.04 1.91 (1.03, 3.56) 0.58 (0.51, 0.65)
Sotirious_Breast 9.09E-06 2.98 (1.80, 4.93) 0.66 (0.60, 0.72) 0.0005 2.30 (1.42, 3.74) 0.64 (0.58, 0.70) 0.0007 2.41 (1.42, 4.08) 0.64 (0.58, 0.69)
Bild_Breast 0.0001 3.10 (1.69, 5.68) 0.64 (0.58, 0.71) 0.005 2.17 (1.24, 3.81) 0.60 (0.52, 0.67) 0.33 1.34 (0.75, 2.40) 0.55 (0.47, 0.62)
Oh_Breast 0.01 2.71 (1.23, 5.95) 0.62 (0.53, 0.71) 0.009 2.59 (1.23, 5.42) 0.61 (0.52, 0.71) 0.04 2.21 (1.01, 4.86) 0.60 (0.51, 0.69)
Sorlie_Breast 0.003 2.44 (1.32, 4.48) 0.62 (0.54, 0.69) 0.12 1.58 (0.88, 2.84) 0.57 (0.49, 0.64) 0.19 1.49 (0.82, 2.72) 0.57 (0.49, 0.64)
Vandevijver_Breast 1.76E-06 2.76 (1.79, 4.25) 0.64 (0.59, 0.69) 0.001 1.99 (1.31, 3.03) 0.59 (0.54, 0.65) ######## 2.73 (1.73, 4.31) 0.63 (0.58, 0.68)
Signature Source
Log-rank
P-value
Hazard Ratio 
(95% CI)
C-Index (95% 
CI)
Log-rank
P-value
Hazard Ratio 
(95% CI)
C-Index (95% 
CI)
Log-rank
P-value
Hazard Ratio 
(95% CI)
C-Index (95% CI)
Number of Genes
Wang_Breast 0.62 1.12 (0.73, 1.72) 0.52 (0.48, 0.57) 0.0002 2.05 (1.39, 3.01) 0.60 (0.55, 0.65) 0.001 1.86 (1.26, 2.74) 0.59 (0.54, 0.63)
Pawitan_Breast 0.07 1.94 (0.93, 4.06) 0.57 (0.49, 0.65) ######## 8.67 (3.03, 24.8) 0.71 (0.65, 0.78) ######## 4.73 (2.11, 10.6) 0.68 (0.60, 0.76)
Miller_Breast 0.008 2.04 (1.19, 3.48) 0.59 (0.53, 0.66) 0.0002 2.66 (1.54, 4.59) 0.64 (0.57, 0.70) 0.008 2.03 (1.19, 3.46) 0.59 (0.53, 0.66)
Vantveer_Breast 0.002 2.53 (1.37, 4.67) 0.59 (0.53, 0.66) ######## 6.81 (3.35, 13.9) 0.71 (0.65, 0.78) 0.0003 2.98 (1.61, 5.50) 0.64 (0.57, 0.71)
Sotirious_Breast 0.33 1.30 (0.77, 2.19) 0.55 (0.49, 0.61) ######## 2.93 (1.77, 4.87) 0.66 (0.60, 0.72) 0.0009 2.23 (1.37, 3.64) 0.65 (0.59, 0.70)
Bild_Breast 0.0006 2.67 (1.49, 4.79) 0.62 (0.54, 0.69) 0.04 1.78 (1.01, 3.13) 0.60 (0.54, 0.67) 0.04 1.80 (1.03, 3.16) 0.59 (0.52, 0.66)
Oh_Breast 0.12 1.80 (0.86, 3.77) 0.57 (0.47, 0.67) 0.001 3.59 (1.59, 8.12) 0.66 (0.57, 0.75) 0.0003 4.91 (1.87, 12.9) 0.66 (0.58, 0.74)
Sorlie_Breast 0.001 2.61 (1.41, 4.81) 0.61 (0.54, 0.67) 0.01 2.17 (1.18, 3.99) 0.60 (0.53, 0.68) 0.0002 3.10 (1.64, 5.83) 0.64 (0.57, 0.72)
Vandevijver_Breast 0.0006 2.15 (1.37, 3.36) 0.58 (0.53, 0.63) ######## 3.31 (2.10, 5.22) 0.66 (0.61, 0.70) ######## 3.40 (2.18, 5.32) 0.67 (0.62, 0.71)
32 70
14 76 64
Miller et al. Van't veer et al. Oncotype Dx 
16
Our Signature Wang et al. Pawitan et al.
*This result is not adjusted for established clinical parameters such as stage, grade, and receptor status 
**C-index: concordance index (area under the curve) for censored data calculated using Hmisc package in R.  61 
Table 3.5. Two-way contigency table analysis measuring the association association 
among different breast cancer outcome signatures in the van de vijver et al. data set 
 
A. Two-way contigency table on Van de 
vijver et al. Data Set (n=295)   
B. Two-way contigency table on Van de 
vijver et al. Data Set (n=295) 
Our Estrogen-
regulated Signature 
70-gene signature (# 
of patients)   
Our Estrogen-
regulated Signature 
Wound-response 
signature (# of 
patients) 
Good  Poor    Activated  Quiescent 
           Low-Risk  106  53               Low-Risk  98  61 
           High-Risk  9  127               High-Risk  130  6 
             
Statistics for two-way table analysis    Statistics for two-way table analysis 
          p-value  <0.0001                p-value  <0.0001   
          Cramer's V  0.617                 Cramer's V  0.404    
             
C. Two-way contigency table on Van de 
vijver et al. Data Set (n=295)   
D. Two-way contigency table on Van de 
vijver et al. ER+ tumors (n=225) 
Intrinsic Subtype 
Our Estrogen-
regulated Signature (# 
of patients)   
Our Estrogen-
regulated Signature 
Estrogen-SAM 
signature (# of 
patients) 
Low-Risk  High-Risk    Group IE  Group IIE 
Basal-like  3  50               Low-Risk  90  58 
Luminal A  108  15               High-Risk  12  65 
Luminal B  13  42         
HER2+ and ER-  9  26    Statistics for two-way table analysis 
Normal-like  26  3              p-value  <0.0001   
                  Cramer's V  0.431    
Statistics for two-way table analysis         
          p-value  <0.0001           
          Cramer's V  0.720            
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Figure 3.1. Identification and molecular concept map analysis of estrogen-induced genes. 
a.  Heatmap  representation  of  532  in  vitro  estrogen-induced  genes  across  three  ER+, 
estrogen sensitive breast cancer cell lines (MCF-7, T47-D, and BT-474) following 17β-
estradiol treatment. Each row represents a gene, and each column represents a sample 
treated  with  estrogen  for  different  time  periods  (0,  1,  2,  4,  8,  12  or  24  hours  with 
replicates). b-d. Molecular concept map analysis (MCM) of the estrogen-induced genes 
(yellow node with black frame) showing enrichment networks of (b) previously reported 
estrogen-regulated  molecular  concepts  both  in  vitro  and  in  vivo,  (c)  gene  ontology 
concepts, and (d) breast cancer progression and prognosis concepts. Each node represents 
a molecular concept. The node size is proportional to the number of genes in the concept. 
Each edge represents a statistically significant enrichment. Concepts  of “up-regulated 
genes by estrogen treatment” are indicated by light green nodes. Blue, holly green and 
purple nodes represent genes up-regulated in ER+ cancer, high-grade breast cancer, and 
patients with poor outcome, respectively. Enriched gene ontology terms are represented 
by orange nodes.   63 
 
 
 
Figure 3.2. Estrogen-regulated genes stratified breast cancer samples into two groups 
with significantly different prognoses. a. Representation of step-wise cross-validation on 
the Wang et al. training set. The left panel presents the number of misclassified samples 
by cross-validation, and the right panel presents survival difference of the resulted two 
clusters when a particular set of genes were used. The X-axis represents the number of 
top genes, ordered by their corresponding survival significance. The dashed line indicates 
the  threshold  used  to  select  the  optimal  gene  signature.  b.  K-mean  clustering 
representation  of  the  73  estrogen-regulated  genes  in  the  training cohort  (left)  and  its 
Kaplan-Meier  survival  plot  (right).  The  73  genes  were  selected  based  on  minimal 
misclassification error by 10-fold cross validation in the space of the initial identified 532 
genes (Panel a.)   64 
 
 
Figure 3.3. The 73-gene outcome signature predicts clinical outcome of breast cancer. 
The  low-risk  and  high-risk  groups  in  each  study  were  predicted  on  the  basis  of  the 
expression patterns of the 73 signature genes as described in the Method. KM analysis 
was used to evaluate the significance of outcome difference between the two groups. P 
values were calculated by the log-rank test.   65 
 
 
Figure  3.4.  The  73-gene  outcome  signature  predicts  clinical  outcome  of  ER+  breast 
cancer. The ER+ breast cancer samples were extracted from their respective datasets and 
the significance of outcome difference between the low-risk and high-risk groups were 
estimated by KM survival analysis. P values were calculated by the log-rank test. The Ma 
et al. data set is not included in this analysis since nearly all of its samples are ER+ and 
thus have been presented in Figure 3.3. 
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Figure  3.5.  The  73-gene  outcome  signature  predicts  clinical  outcome  in  tamoxifen-
treated breast cancer subcohorts (a-c), gliomas (d-f), and lung adenocarcinoma (g). The 
low-risk  and  high-risk  groups  were  predicted  by  the  73-gene  signature  with  nearest 
centroid classification. KM analysis was used to evaluate the significance of outcome 
difference between the two groups. P values were calculated by the log-rank test.   67 
REFERENCES 
 
1.  Clemons, M, and Goss, P (2001). Estrogen and the risk of breast cancer. N Engl J 
Med 344, 276-285. 
2.  Jordan, VC (2003). Tamoxifen: a most unlikely pioneering medicine.  Nat Rev 
Drug Discov 2, 205-213. 
3.  (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-
1717. 
4.  Brenner, H (2002). Long-term survival rates of cancer patients achieved by the 
end of the 20th century: a period analysis. Lancet 360, 1131-1135. 
5.  Miller, LD, Smeds, J, George, J, et al. (2005). An expression signature for p53 
status in human breast cancer predicts mutation status, transcriptional effects, and patient 
survival. Proc Natl Acad Sci U S A 102, 13550-13555. 
6.  Paik, S, Shak, S, Tang, G, et al. (2004). A multigene assay to predict recurrence 
of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351, 2817-2826. 
7.  Perou, CM, Sorlie, T, Eisen, MB, et al.  (2000). Molecular portraits of human 
breast tumours. Nature 406, 747-752. 
8.  van  de  Vijver,  MJ,  He,  YD,  van't  Veer,  LJ,  et  al.  (2002).  A  gene-expression 
signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009. 
9.  van 't Veer, LJ, Dai, H, van de Vijver, MJ, et al. (2002). Gene expression profiling 
predicts clinical outcome of breast cancer. Nature 415, 530-536. 
10.  Wang, Y, Klijn, JG, Zhang, Y, et al. (2005). Gene-expression profiles to predict 
distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679. 
11.  Pujol,  P,  Daures,  JP,  Thezenas,  S,  et  al.  (1998).  Changing  estrogen  and 
progesterone  receptor  patterns  in  breast  carcinoma  during  the  menstrual  cycle  and 
menopause. Cancer 83, 698-705. 
12.  Leek, JT, Monsen, E, Dabney, AR, and Storey, JD (2006). EDGE: extraction and 
analysis of differential gene expression. Bioinformatics 22, 507-508. 
13.  Creighton,  CJ,  Cordero,  KE,  Larios,  JM,  et  al.  (2006).  Genes  regulated  by 
estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts 
and human breast tumors. Genome Biol 7, R28. 
14.  Oh, DS, Troester, MA, Usary, J, et al. (2006). Estrogen-regulated genes predict 
survival in hormone receptor-positive breast cancers. J Clin Oncol 24, 1656-1664. 
15.  Frasor, J, Danes, JM, Komm, B, et al. (2003). Profiling of estrogen up- and down-
regulated gene expression in human breast cancer cells: insights into gene networks and 
pathways  underlying  estrogenic  control  of  proliferation  and  cell  phenotype. 
Endocrinology 144, 4562-4574. 
16.  Tomlins, SA, Mehra, R, Rhodes, DR, et al. (2007). Integrative molecular concept 
modeling of prostate cancer progression. Nat Genet 39, 41-51. 
17.  Buterin, T, Koch, C, and Naegeli, H (2006). Convergent transcriptional profiles 
induced  by  endogenous  estrogen  and  distinct  xenoestrogens  in  breast  cancer  cells. 
Carcinogenesis 27, 1567-1578. 
18.  Frasor,  J,  Stossi,  F,  Danes,  JM,  et  al.  (2004).  Selective  estrogen  receptor 
modulators: discrimination of agonistic versus antagonistic activities by gene expression 
profiling in breast cancer cells. Cancer Res 64, 1522-1533.   68 
19.  Stossi,  F,  Barnett,  DH,  Frasor,  J,  et  al.  (2004).  Transcriptional  profiling  of 
estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human 
osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 
145, 3473-3486. 
20.  Sotiriou, C, Wirapati, P, Loi, S, et al. (2006). Gene expression profiling in breast 
cancer: understanding the molecular basis of histologic grade to improve prognosis. J 
Natl Cancer Inst 98, 262-272. 
21.  Carroll, JS, Meyer, CA, Song, J, et al. (2006). Genome-wide analysis of estrogen 
receptor binding sites. Nat Genet 38, 1289-1297. 
22.  Lin, CY, Strom, A, Vega, VB, et al. (2004). Discovery of estrogen receptor alpha 
target genes and response elements in breast tumor cells. Genome Biol 5, R66. 
23.  Rhodes, DR, Yu, J, Shanker, K, et al. (2004). ONCOMINE: a cancer microarray 
database and integrated data-mining platform. Neoplasia 6, 1-6. 
24.  Sribnick,  EA,  Ray,  SK,  and  Banik,  NL  (2006).  Estrogen  prevents  glutamate-
induced apoptosis in C6 glioma cells by a receptor-mediated mechanism. Neuroscience 
137, 197-209. 
25.  Marquez-Garban, DC, Chen, HW, Fishbein, MC, Goodglick, L, and Pietras, RJ 
(2007).  Estrogen  receptor  signaling  pathways  in  human  non-small  cell  lung  cancer. 
Steroids 72, 135-143. 
26.  Stabile, LP, and Siegfried, JM (2004). Estrogen receptor pathways in lung cancer. 
Curr Oncol Rep 6, 259-267. 
27.  Freije, WA, Castro-Vargas, FE, Fang, Z, et al. (2004). Gene expression profiling 
of gliomas strongly predicts survival. Cancer Res 64, 6503-6510. 
28.  Phillips, HS, Kharbanda, S, Chen, R, et al. (2006). Molecular subclasses of high-
grade glioma predict prognosis, delineate a pattern of disease progression, and resemble 
stages in neurogenesis. Cancer Cell 9, 157-173. 
29.  Nutt,  CL,  Mani,  DR,  Betensky,  RA,  et  al.  (2003).  Gene  expression-based 
classification  of  malignant  gliomas  correlates  better  with  survival  than  histological 
classification. Cancer Res 63, 1602-1607. 
30.  Bhattacharjee,  A,  Richards,  WG,  Staunton,  J,  et  al.  (2001).  Classification  of 
human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma 
subclasses. Proc Natl Acad Sci U S A 98, 13790-13795. 
31.  Fan, C, Oh, DS, Wessels, L, et al. (2006). Concordance among gene-expression-
based predictors for breast cancer. N Engl J Med 355, 560-569. 
32.  Rae, JM, Johnson, MD, Scheys, JO, et al. (2005). GREB 1 is a critical regulator 
of hormone dependent breast cancer growth. Breast Cancer Res Treat 92, 141-149. 
33.  Bolstad, BM, Irizarry, RA, Astrand, M, and Speed, TP (2003). A comparison of 
normalization methods for high density oligonucleotide array data based on variance and 
bias. Bioinformatics 19, 185-193. 
34.  Bair, E, and Tibshirani, R (2004). Semi-supervised methods to predict patient 
survival from gene expression data. PLoS Biol 2, E108. 
   69 
 
 
 
 
CHAPTER 4 
 
Molecular Classification of Cancer using Genetic Programming 
 
Despite  important  advances  in  microarray-based  molecular  classification  of 
tumors, its application in clinical settings remains formidable. This is in part due to the 
limitation of current analysis programs in discovering robust biomarkers and developing 
classifiers with a practical set of genes. Genetic Programming (GP) is a type of machine 
learning technique that uses evolutionary algorithm to simulate natural selection as well 
as population dynamics, hence leading to simple and comprehensible classifiers. Here we 
applied GP to cancer gene expression profiling data to select feature genes and build 
molecular classifiers by mathematical integration of these genes. Analysis of thousands 
of GP classifiers generated for a prostate cancer dataset revealed repetitive use of a small 
set of highly discriminative feature genes, many of which are known disease-associated. 
GP classifiers often comprise five or less genes and successfully predict cancer types and 
subtypes. Importantly, GP classifiers generated in one study is able to predict samples 
from  an  independent  study,  which  may  have  used  different  microarray  platforms.  In 
addition,  GP  yielded  better  or  similar  classification  accuracy  as  conventional 
classification methods. Further, the mathematical-expression of GP classifiers provides 
insights  into  relationships  between  classifier  genes.  Taken  together,  this  study  has 
demonstrated that GP may be valuable for generating effective classifiers containing a 
practical set of genes for diagnostic/prognostic cancer classification.    70 
 
The  development  of  high-throughput  microarray-based  technology  will 
potentially  revolutionize  cancer  research  in  a  number  of  areas  including  cancer 
classification, diagnosis and treatment. Expression profiling at the mRNA level can be 
used in the molecular characterization of cancer by simultaneous assessment of a large 
number  of  genes  (1-5).  This  approach  can  be  used  to  determine  gene  expression 
alterations between different tissue types such as those obtained from healthy controls 
and cancer patients. Analysis of such large-scale gene expression profiles of cancer will 
facilitate  the  identification  of  a  subset  of  genes  that  could  function  as  diagnostic  or 
prognostic biomarkers. The development of molecular classifiers that allow segregation 
of  tumors  into  clinically  relevant  molecular  subtypes  beyond  those  possible  by 
pathological  classification  may  subsequently  serve  to  classify  tumors  with  unknown 
origin into different cancer types or subtypes. However, due to the large number of genes 
and the relatively small number of patient cases available from such studies, it remains a 
challenge to find a robust gene signature for reliable prediction. 
   
As discussed in Chapter 2, a number of computational and statistical models 
have been developed for molecular classification of tumors. However, many of methods 
are often developed using parametric statistical techniques and thus have difficulty in 
finding non-linear relationships between genes. Alternatively, complex models such as 
neural networks often deliver “black box” solutions for classification and do not give 
insight into relationships between genes. In this study, we present a machine learning 
approach called Genetic Programming (GP) for molecular classification of cancer. GP   71 
belongs to a class of evolutionary algorithms and was first introduced by Koza (6) in 
1992.  Recently,  GP  has  been  shown  to  be  a  promising  approach  for  discovering 
comprehensible rule-based classifiers from medical data (7,8) as well as gene expression 
profiling data (9-14). However, the potential of GP in cancer classification has not been 
fully explored. For example, GP classifiers identified from one dataset have not been 
validated in independent datasets. Here, we applied GP algorithm to cancer expression 
profiling data to identify potentially informative feature genes, build molecular classifiers 
and classify tumor samples. A basic flowchart of GP has been described in Figure 4.1 
and typical parameters used in GP have been detailed in Table 4.1. We tested GP in one 
Small Round Blue Cell Tumors (SRBCTs), one lung adenocarcinoma and five prostate 
cancer datasets (Table 4.2), and evaluated the generality of GP classifiers within and 
across  datasets.  In  addition,  we  compared  the  performance  of  GP  with  that  of  other 
common classification techniques, such as linear discriminant analysis and support vector 
machines, for prediction accuracy. 
 
To investigate the ability of GP to robustly select feature genes, we examined 
gene occurrences across classifiers generated from our GP system. Our results revealed 
that a small set of genes was frequently selected. For example, an analysis of feature 
genes in a set of 1000 best classifiers from GP to distinguish primary prostate cancer 
from metastatic samples on LaTulippe et al. (Memorial Sloan-Kettering Cancer Center, 
MSKCC) prostate dataset (15) indicated a high tendency of GP in selecting certain genes 
across classifiers (Figure 4.2). Figure 4.2A presents the normalized z score (16) of the 
frequency  of  each  gene  in  the  1000  classifiers  that  contains  a  total  of  2000  gene   72 
occurrence, with the X-axis representing Gene Index. As shown in the figure, only 261 
out of the total 3547 genes used for this study occurred at least once. Interestingly, 46 of 
them occurred at least twelve times (z score >=15, p<0.0001, Table 4.3). The fact that 
this small set of genes has dominated the generated classifiers implies that such genes 
may be truly important for prostate cancer metastasis, and may serve as discriminative 
biomarkers for cancer progression. As GP is stochastic and may give different solutions 
in  each  run,  it  is  interesting  to  examine  the  reproducibility  of  gene  selection  across 
independent runs. Thus, we created another independent set of 1000 classifiers using 
identical GP parameters on the same training set. A total of 264 genes occurred at least 
once in this set of GP classifiers. Notably, 206 of them were common in both sets and a 
highly positive correlation of z scores of these gene between the two sets was observed 
(R2 = 0.94, P < 1x10-5, Figure 4.2B). 
  Next we examined the 46 most frequently occurring feature genes in the above 
analysis (Table 4.3). Strikingly, the top 3 probes represented the same gene, MYH11, 
which  has  been  reported  to  be  down-regulated  in  multiple  metastatic  cancers  (17). 
Another top-listed gene  was EZH2, encoding  a polycomb group protein  that  we and 
others have previously characterized as over-expressed in aggressive epithelial tumors 
(18,19). We therefore hypothesized that the top frequently occurring genes might serve as 
a  multiplex  signature  to  distinguish  metastatic  prostate  cancer  from  primary  prostate 
cancer. To test this, hierarchical clustering was performed to group cancer samples based 
on the expression patterns of these genes. As shown in Figure 4.3A, these top 46 genes 
clustered  tumor  samples  into  their  corresponding  diagnostic  classes  (metastatic  or 
primary prostate cancer), each with a unique expression signature. Interestingly, the same   73 
set of genes also successfully classified the independent Yu et al. (Pittsburgh) prostate 
cancer dataset. Similar results were observed when samples of the SRBCT dataset were 
clustered based upon the top 54 frequent feature genes (z score >=14) derived from the 
training samples of this dataset (Figure 4.3B). In addition, we also selected the top 26 
feature genes (z score >=40) from the 2000 classifiers developed from the Lapointe et al. 
(Stanford)  prostate  cancer  training  dataset.  Hierarchical  clustering  based  on  the 
expression pattern of these genes grouped tumors of four independent prostate cancer 
datasets with high classification accuracy (Figure 4.3C-F).  
To further investigate whether such feature genes can be used to predict class 
memberships of validation samples, we carried out class prediction of the SRBCT dataset 
by diagonal linear discriminant analysis (DLDA) and k-nearest neighbor analysis (kNN, k 
=3). The top 54 frequent genes selected from the 2000 classifiers generated from the 
training samples of SRBCT data were used as a gene signature to predict the validation 
samples. Both DLDA and kNN analysis predicted all of the 20 validation samples with 
100% accuracy (data not shown), confirming that the frequent genes derived from GP are 
truly discriminative genes and capable of predicting unknown samples.  
 
Next we sought to examine the performance of GP classifiers comprising only a 
handful  feature  genes.  We  first  evaluated  the  ability  of  GP  classifiers  to  accurately 
classify four diagnostic classes of cancers (NB, RMS, EWS and BL) within the SRBCT 
dataset (20). A set of 63 training samples was used by GP to generate distinguishing 
classifiers  through  cross-validation.  Classification  was  performed  in  a  binary  mode 
(target versus non-target class). For each target class, the top 10 best classifiers were   74 
selected and employed to predict a validation set of 20 samples. Most of the classifiers 
achieved 100% sensitivity and specificity on the training set. Similar prediction accuracy 
was observed when these classifiers were applied to the 20 blinded validation samples. 
The best classifiers (Table 4.4) perfectly predicted all of the validation samples. The 
average prediction accuracy of the top 10 classifiers for each target class was 98.5% for 
BL (95% confidence interval [CI] = 0.97-1.00), 92.5% for EWS (95% CI = 0.89-0.96), 
95.5% for NB (95% CI = 0.91-1.00), 95.5% for RMS (95% CI = 0.92-0.99). Overall, GP 
classifiers achieved comparable classification and prediction performance as the method 
described  in  the  original  study,  while  using  much  less  genes.  This  high  prediction 
accuracy, however, might be partially due to the fact that the 4 cancer types here are 
much more heterogeneous than the subtypes of any single cancer.  
 
Thus,  we  next  examined  GP  in  classifying  subtypes  of  lung  adenocarcinoma, 
wherein  samples  were  designated  as  “high-risk”  or  “low-risk”  based  on  the  original 
publication information  (21). One hundred classifiers were generated by GP from 66 
training samples and the top five were found to have the highest training accuracy of 
98.5%. When these 5 classifiers were applied to the 20 test samples, we found a maximal 
prediction accuracy of 98.5% and an average prediction rate of 84.0% (95% CI, 0.70-
0.99), being comparable with that of other classification methods as described in the later 
session.  
 
A more challenging work is to validate classifiers across independent datasets. 
We thus investigated whether GP could distinguish molecular subtypes of a single cancer   75 
class from independent datasets. Two prostate cancer datasets (Pittsburgh, and MSKCC 
sets) were used to evaluate GP in classifying primary or metastatic prostate cancer. Genes 
within each dataset were standardized to have zero mean and unit variance, given that 
similar proportion of metastatic samples was observed in both datasets. The MSKCC 
samples were used as a training set to generate GP classifiers. The 20 classifiers that 
perfectly  classified  primary  from  metastatic  prostate  cancer  in  the  training  set  were 
selected for prediction. When these classifiers were applied to predict the independent 
Pittsburgh prostate cancer samples, the best classifiers (Table 4.4) correctly predicted all 
metastatic prostate cancers, and 58 out of 62 clinically localized prostate cancers. This 
led to 100% sensitivity and 93.5% specificity. The average prediction accuracy of all of 
the 20 classifiers was 95.2% sensitivity (95% CI = 0.87-1.00) and 82.1% specificity (95% 
CI = 0.65-0.99).  
   
The  above  two  prostate  cancer  datasets  were  hybridized  using  the  same 
Affymetrix  HG-U95Av2  platform  and  shared  similar  proportion  ratios  of  target/non-
target samples. Next, we examined whether classifiers generated by GP could predict 
samples from independent studies that have used different microarray platforms. Three 
prostate cancer datasets (2,22,23) (UM, Stanford, and Pittsburgh datasets) were used to 
test  GP  classifiers  in  predicting  benign  prostate  and  primary  prostate  cancer  (PCA) 
samples. Among them, the Stanford and UM datasets used spot cDNA microarrays while 
the Pittsburgh data used affymetrix HG-U95Av2 oligonucleotide arrays. Two-thirds of 
the Stanford samples were used as a training set to generate GP classifiers, whereas the 
other  one-third,  the  UM  and  Pittsburgh  samples  were  all  considered  as  validation   76 
samples. We used GP to generate 2000 classifiers and selected the  top 26 frequently 
occurring genes (z-score >=40) as potential feature genes. To examine whether these 
genes are present in all three microarray platforms we cross-referenced them to the UM 
and Pittsburgh datasets using gene symbols. Out of these 26 genes, 12 are present in all 
three datasets. We thus entered these 12 genes into the GP system to start a new round of 
5-fold cross-validation on the Stanford training set. Five perfect classifiers were achieved 
and applied to the validation set. Prediction accuracy in the Stanford validation samples 
ranged  from  84.4%  to  90%.  However,  the  classifiers  performed  poorly  on  UM  and 
Pittsburgh  datasets.  We  suspected  that  this  might  be  due  to  the  discrepancy  in  the 
proportion ratio of PCA/benign samples and/or the probe intensity difference across array 
platforms, which led to divergence in the constant D of a classifier (e.g. GENE[A] / 
GENE[B]  - GENE[C] > D).  However,  we believe that  the relationships between the 
classifier genes, although with varying values of D, may still be predictive across studies, 
given that the classifier genes are putative discriminative genes. For instance, one of the 
classifier, formulated as ‘IF (MYO6 + AMACR) >= -2.6776 THEN PCA’ (see Table 
4.5),  did  not  predict  well  on  the  validation  sets.  However,  the  expression  value  of 
“MYO6  +  AMACR”  might  still  be  predictive.  To  test  this,  we  transformed  the  five 
classifiers individually as described in Methods and calculated a prediction score for each 
validation sample by computing the left-side of each classifier-inequality on a continuous 
scale. The predictive ability of each classifier on each validation set was then assessed 
using  the  Area  under  ROC  Curve  (AUC).  Notably,  all  classifiers  were  strongly 
significant (p-values < 5x10-4, Figure 4.4, Table 4.5) in both the Stanford and Pittsburgh 
validation sets. The lowest AUC was 0.91 (95% CI = 0.80-1.00) and 0.87 (95% CI =   77 
0.79-0.95)  respectively.  For  UM  dataset,  except  for  one  classifier  being  marginally 
significant (AUC=0.64, p-value =0.09), all other classifiers were also strongly significant 
(p-values < 5x10-4).  
  An ensemble “meta-classifier” combining multiple classifiers in general  yields 
better  prediction  performance,  as  it  involves  more  genes  and  multiple  predictive 
signatures. Thus, we composed a “meta-classifier” based on the above 5 classifiers. For 
each sample, the calculated prediction scores of the five classifiers were totaled to an 
overall prediction score which was then defined as the prediction score of the “meta-
classifier” for that sample. As expected, this “meta-classifier” revealed higher AUCs in 
each dataset (0.96, 0.99, 0.99 for the Stanford, UM and Pittsburgh set respectively, p-
values <5x10-4, see Figure 4.4, and Table 4.5) 
  
  Examination of classifier genes have revealed that GP classifiers (Table 4.4 and 
4.5) are much simpler than predictors reported by other approaches (1,3,5,20,21,24-27), 
where more than ten genes are often required to build an effective predictor. GP, by 
contrast,  can  utilize  only  2-5  genes  to  produce  effective classifiers  and  achieve  high 
prediction power. This simplicity may owe to the relatively strict expression constraints 
(Table 4.1) and the use of a non-parametric method in selecting informative genes rather 
than usual parametric statistical techniques. Further, unlike some other non-parametric 
approaches such as neural networks and support vector machines, GP is transparent in 
that the entire procedure for classifier generation and evolution is readily available for 
inspection and adjustment. GP also revealed interesting quantitative relationship between 
within-classifier  genes.  Studying  the  specific  genes  used  by  a  classifier  and  their   78 
relationships may provide valuable information about gene interactions, transcriptional 
regulatory pathways, and clinical diagnosis. 
 
One important criterion to assess a classification approach is how it performs in 
comparison to other commonly used algorithms in the same research area. To evaluate 
the performance of GP, the Burkitt lymphomas (‘BL’) in the SRBCT dataset and the 
high-risk class in the lung adenocarcinoma data were chosen as the target classes and five 
classification  methods  including  Compound  Covariate  Predictor  (CCP),  3-Nearest 
Neighbors  (3NN),  Nearest  Centroid  (NC),  Support  Vector  Machines  (SVM),  and 
Diagonal Linear Discriminant Analysis (DLDA) were selected as comparing counterparts 
of the GP method. To produce a fair comparison, we took into account the small number 
of genes used by GP classifiers and conducted the comparison tests based on either 5- or 
10-gene classifiers.  
   
The  same  training  and  validation  sets  as  described  previously  were  used  to 
evaluate the performance of each classification method. The basic procedure was defined 
by two steps: (1) two-sample student t-test was conducted for each gene in the training 
set, and the 5 or 10 genes with the smallest p-values were selected as test classifiers, (2) 
expression data of the selected 5 or 10 genes across the training samples were used to 
build a training model, which was subsequently applied to the validation samples. Each 
individual validation sample was predicted as either ‘target-class’ or ‘non-target class’. 
Misclassification  rate  was  defined  as  the  percentage  of  validation  samples  that  were 
misclassified by a test classifier. Since GP generates multiple classifiers, the average of   79 
the misclassification rates of the top GP classifiers derived from the training set was used 
to represent the misclassification rate of a typical well-performing GP classifier. For the 
SRBCT data, we used the averaged misclassification rate of the top 10 classifiers because 
there were 10 perfect classifiers generated from the training samples to classify ‘BL’ and 
‘Non-BL’. Similarly, the 5 classifiers having the least classification error in the training 
set were used for the lung adenocarcinoma dataset. As shown in Table 4.6, the error rates 
were comparable across different methods. The GP system ranked the 2nd and the 3rd in 
the SRBCT and the lung adenocarcinoma datasets respectively when 5-gene classifiers 
were evaluated. We believe that this may reflect the general prediction strength of GP 
system when only a small number of genes are chosen. 
 
  An intrinsic advantage of GP is that it automatically selects a small number of 
feature  genes  during  “evolution”  (12).  The  “evolution”  of  classifiers  from  the  initial 
population seamlessly integrates the process of gene selection and classifier construction. 
By  contrast,  gene  selection  must  be  performed  in  a  separate  stage  for  many  other 
classification  algorithms  such  as  kNN,  weighted  voting,  and  DLDA.  Moreover,  it  is 
relatively easier for GP to keep the number of genes used in one classifier small. As GP 
searches  a  larger  space  than  most  traditional  classification  approaches,  there  is  an 
increased  chance  of  GP  in  finding  a  better  performing  classifier.  By  identifying  and 
utilizing a small number of genes and developing transparent and human-comprehensible 
rule-based classifiers, GP stands as a good algorithm of choice.  
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  The  challenge  of  the  field  of  molecular  classification  lies  in  the  tradeoff  of 
prediction power and the number of genes used. We have therefore stringently tested GP 
classifiers, which comprised of 5 or less genes, in achieving high prediction accuracy in 
datasets with varying levels of classification complexity. Unlike other studies  (13,28) 
validating their classifiers using  cross-validation  within  a dataset,  our  result not  only 
demonstrated  that  the  top  GP  classifiers  easily  classified  and  predicted  the  SRBCT 
dataset, which contained 4 classes of physiologically heterogeneous cancers, with 100% 
accuracy, but also showed optimal performance in classifying and predicting subtypes of 
prostate cancer, for samples either of the same study or of a different study that used the 
same microarray platform.  In addition, GP-selected feature genes stay discriminative 
even  for  cancer  samples  examined  in  different  studies  that  used  greatly  different 
microarray platforms. Due to this robustness and stability of GP feature genes, we expect 
GP classifier to be highly applicable to clinical diagnosis.  
 
  A major issue in GP as well as other machine learning systems is data over-fitting 
due to a large number of variables and a small number of cases in microarray profiling. 
This occurs when the classifier is strongly biased towards the training set and generates 
poor prediction generality in validation samples. To address this, our study restricted the 
complexity of classifiers and adopted an n-fold cross-validation strategy. By limiting the 
size and complexity of classifiers using the minimum description length principle of risk 
minimization (29), the system was forced to generate the most salient features likely to be 
the most general solutions (30). By re-sampling using n-fold cross-validation, classifiers 
derived from the training samples were re-examined in the test-fold samples to test how   81 
well the learning algorithm could be generalized. If the fitness on the training data in one 
fold is significantly better than the fitness on the test data, it may indicate that there is an 
issue of over-fitting in the data. Therefore, a careful examination of the samples may be 
necessary.  
 
  Another issue for GP is that it is computationally intensive. The estimated running 
time increases along with the complexity of the problem, and the number of variables. 
This can be partially resolved by using parallel processing which segments the problem 
into parts running on different processors simultaneously and then synchronizes among 
them. In addition, variable pre-filtering may also reduce the running time. As described in 
the result section, GP typically selects those inherently discriminative genes and usually a 
small set of genes dominates the selection. Thus, a pre-filtering such as excluding genes 
with  small  variances  may  significantly  reduce  the  running  time  yet  not  affect  the 
performance of classifiers. 
 
  Taken together, in this study we systematically evaluated the feasibility of GP in 
feature selection and cancer classification. By examining the feature genes used by GP 
classifiers  we  have  demonstrated  that  GP  is  able  to  robustly  select  a  set  of  highly 
discriminative genes. In addition, the mathematical expression of GP classifiers reveals 
interesting quantitative relationships between genes. By testing GP classifiers generated 
from training sets in validation sets, we have shown that GP classifiers can successfully 
predict tumor classes and outperform most of other classification methods when only a 
limited number of genes are allowed to build a classifier. Our work suggests that GP may   82 
be useful for feature selection and molecular classification of cancer using a practical set 
of genes. 
 
MATERIALS AND METHODS 
Datasets.  All  datasets  were  obtained  from  ONCOMINE  (31)  or  requested  from  the 
original authors. The Small Round Blue Cell Tumor (SRBCT) data (20) contained 88 
samples  from  four  types  of  cancer  cells:  neuroblastoma  (NB),  rhabdomyosarcoma 
(RMS), the Ewing family of tumors (EWS), and Burkitt lymphomas (BL). The entire 
dataset, excluding five non-SRBCT samples, was divided into a training set (63 samples) 
and  a  validation  set  (20  samples)  as  described  in  the  original  study.  The  lung 
adenocarcinoma dataset (21) contains 86 lung cancer samples. The samples were then 
subdivided into a high- or low-risk group as requested from the authors. Twenty eight 
high-risk and 38 low-risk samples were included in the training set while the remaining 
20 samples were considered as the validation set.  
   
Three  prostate  cancer  datasets  (2,22,23)  from  the  University  of  Michigan 
(Dhanasekaran  et  al,  UM),  Stanford  University  (Lapointe  et  al.,  Stanford)  and  the 
University of Pittsburgh (Yu et al, Pittsburgh) respectively were used to classify primary 
prostate cancer (PCA) from benign prostate samples (BENIGN). A total of 56 samples 
were randomly selected from Stanford dataset as the training set. The rest of the Stanford 
samples, UM and Pittsburgh sets were treated as validation sets. Two prostate cancer 
datasets including the Pittsburgh and MSKCC datasets  (15,23) were also retrieved to 
distinguish metastatic prostate cancer (MET) and PCA. Detailed study information is 
shown in Table 4.2.   83 
 
Genetic Programming for classification: In this study, we used genetic programming to 
discover classifiers that are capable of classifying samples into different cancer types 
based on gene expression patterns. Genetic programming (GP)  (6) is an evolutionary 
algorithm  that  simulates  natural  selection  and  population  dynamics  to  search  for 
intelligible relationships amongst the constituents in a system (classifiers in this study). A 
generic  GP  classifier-based  prediction  is  shown  as:  IF  ‘(GENE[A]  /  GENE[B]  - 
GENE[C]) > D’ THEN ‘TARGET CLASS’, where the IF clause is generated by GP, 
“TARGET CLASS” is pre-defined in the initial configuration file, D is a constant, and 
GENE[A], GENE[B] and GENE[C] represent the expression levels of gene A, B, and C 
respectively. 
 
A basic flowchart for the GP system is given in Figure 4.1A. Briefly, the system 
randomly selects inputs such as gene identifiers and constant values, which are used to 
represent the expression values of corresponding genes. Such selected inputs are then 
combined with the function operators such as arithmetic or Boolean operators to compose 
tree-based GP classifiers, an example of which is given in Figure 4.1B. Such classifiers 
are  eventually accumulated to form an initial  population,  where a small subgroup of 
classifiers is then selected to create a  ‘mating group’. Each classifier in this  ‘mating 
group’ is assessed by a fitness function defined as the area under the receiver-operator 
characteristic  curve  (ROC-AUC),  which  is  used  widely  to  assess  the  accuracy  of  a 
diagnostic test that yields continuous test results in clinical research areas. The two fittest 
classifiers are then selected as ‘mating’ parents by a tournament selection scheme and   84 
‘mated’  to  produce  ‘offspring’  via  selective  genetic  operators  such  as  crossover,  or 
mutation. The crossover operator exchanges a subtree of one parent with the other to 
generate offspring (Figure 4.1C), while the mutation operator probabilistically chooses a 
node in a subtree and replace it with a new created subtree randomly. The generated 
offspring  then  replaces  the  least-fit  parent  classifiers  in  the  population.  Once  new 
offspring fully replaces parent classifiers in the entire population, a new generation that in 
general contains better classifiers is created. This process of mating pool selection, fitness 
assessment, mating and replacement is repeated over generations, progressively creating 
better classifiers until a termination criterion is met (e.g., a perfect classifier with a fitness 
score of 1 or the maximum number of ‘generations’ is reached).  
 
Table  4.1  shows  an  example  of  primary  GP  parameters  used  to  analyze  the 
prostate cancer dataset from LaTulippe et al. (MSKCC) study. Given the limited sample 
size  of  each  dataset  we  employed  n-fold  cross-validation  procedure  to  estimate  the 
generalization of classifiers in predicting samples with unknown class membership. For 
example, when a dataset is selected as the training set, it is randomly subdivided into n 
parts (or folds), wherein classifiers are developed as described in the above GP process 
using samples in n-1 folds. These classifiers are then tested on samples in the left-out fold 
to assess their potential generalization capability since such samples are not involved in 
the development of the classifiers. A good classifier is expected to classify well in the 
training samples as well as the samples in the left-out fold. This process is repeated n 
times with each fold taking turns as the testing fold and the best classifiers are then 
selected based upon overall performance on the training folds and the test fold.   85 
 
We  implemented  parallel  genetic  programming  algorithm  in  C  (patented  by 
Genetics Squared, Inc., Ann Arbor, MI 48104; http://www.genetics2.com). The analyses 
were performed on a parallel computer cluster (7 Dell 1850 1U racks with 2x3.2GHz 
Xeon processor and 1 Dell 1750 1U rack with 1x3.06GHz Xeon processor) running the 
Debian Linux operating system. The running times for different datasets varied from a 
few  minutes  to  a  few  days,  depending  on  a  large  number  of  parameters  like  the 
complexity  of  the  problem,  size  of  population  used  in  the  evolution,  number  of 
generations, cost of fitness calculation, number of classifiers, and size of the data set, etc. 
For the LaTulippe et al. prostate cancer dataset with the parameters listed in Table 4.1, it 
took approximately three and a half hours to complete a set of 1000 classifiers.   86 
Table 4.1 Settings for primary GP parameters used to analyze the Latulippe et al.prostate 
cancer data 
 
Parameter  Setting  Description* 
Terminal Set  All  inputs  including  gene 
expression  values,  and 
constant values. 
A  set  where  all  end  (leaf)  nodes in  the  parse  trees 
representing the programs must be drawn. A terminal 
could be a variable, a constant or a function with no 
arguments 
Function Set  Boolean  and  floating  point 
operators: <, >, <=, =>, *, /, 
+, - 
A set of operators, e.g. +, -, *, ÷ . These act as the 
branch points in the parse tree, linking other functions 
or terminals 
Selection   Generational,  tournament  
size 5 
An evolution is called “generational” when the entire 
existing population of classifiers is replaced by a new 
created  population  at  every  generation.  Tournament 
selection is a mechanism for choosing classifiers from 
a  population.  A  group  of  classifiers  are  selected  at 
random  from  the  population  and  the  best  one(s)  is 
chosen 
Initial population  Each  tree  was  created  by 
ramped half-and-half 
Ramped half and half operates by creating an equal 
number  of  trees  with  each  depth  between  a  pre-
determined minimum and maximum. 
Population size  20000  The number of candidate classifiers in a population 
Number of demes  12  A deme is a separately evolving subset of the whole 
population. The subsets may be evolved on different 
computers.  Emigration  between  subset  may  occur 
every generation. 
Crossover probability  0.2  The  probability  of  creating  a  new  individual  from 
parts of its parents 
Mutation probability  0.2  The  probability  of  a  subtree  replaced  by  another, 
some or all of which is created at random 
Termination criteria  Fitness  score  reaches  1  or 
max generations (50) 
A  statement  or  condition  to  stop  the  genetic 
programming cycle. 
Initial tree depth  3  The initial distance of any leaf from the root of a tree 
Initial node count  3  The initial number of nodes in a tree. 
Maximum tree depth  7  The maximum distance of any leaf from the root of a 
tree 
Maximum  node 
count 
8  The maximum number of nodes in a tree. 
Number of folds  4  The number of parts a training set will be subdivided 
into. 
Deme  migration 
frequency 
Every generation  The frequency of moving classifiers between isolated 
demes 
Deme  migration 
percentage 
5% of individuals  The  percentage  of  classifiers  moving  between  two 
demes. 
Fitness  the  area  under  the  receiver-
operator characteristic curve 
A process which evaluates a member of a population 
and gives it a score or fitness. 
*Source of some term descriptions: Langdom, WB. (1998). Genetic Programming and Data Structures: 
Genetic Programming + Data Structures = Automatic Programming! Amsterdam: Kluwer.   87 
Table 4.2 Gene expression datasets applied to GP system 
 
Class description  Authors  Journal  Array type  # of Genes 
Four  classes:  neuroblastoma 
(NB),  rhabdomyosarcoma 
(RMS),  Burkitt  lymphoma 
(BL), Ewing sarcoma (EWS) 
Khan, J., et al.  Nature Medicine, 7:673   cDNA  2308 
Two  classes:  high-risk  group 
and low-risk group.  Beer, DG et al.   Nature Medicine, 30:41  Affymetrix 
Hu6800  7070 
Two classes: primary prostate 
cancer  (PCA)  and  metastatic 
prostate cancer (MET) 
Latulippe, E., et al.  Cancer Research. 62:4499  Affymetrix 
HG_U95A  3547 
Yu, YP., et al.  J Clin Oncol. 22:2790  Affymetrix 
HG_U95A  3547 
Two  classes:  Benign/normal 
prostate  (BENIGN)  and 
primary  prostate  cancer 
(PCA) 
Lapointe, J. et al.  PNAS. 101:811  cDNA  4168 
Dhanasekaran, SM.  
et al.  Nature. 412(6849):822  cDNA  16965 
Yu, YP., et al.  J Clin Oncol. 22:2790  Affymetrix 
HG_U95A  12558 
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Table 4.3 Frequency of gene occurrences in the 1000 GP classifiers for Latulippe et al 
prostate cancer study 
 
Probe Set  Gene Symbol  Gene Title  Counta  Z-Score 
37407_s_at  MYH11  myosin, heavy polypeptide 11, smooth muscle  112  147.59 
32582_at  MYH11  myosin, heavy polypeptide 11, smooth muscle  101  133.02 
767_at  MYH11  myosin, heavy polypeptide 11, smooth muscle  96  126.40 
1197_at  ACTG2  actin, gamma 2, smooth muscle, enteric  93  122.42 
36931_at  TAGLN  Transgelin  77  101.23 
32755_at  ACTA2  actin, alpha 2, smooth muscle, aorta  65  85.34 
37576_at  PCP4  Purkinje cell protein 4  62  81.36 
774_g_at  MYH11  myosin, heavy polypeptide 11, smooth muscle  61  80.04 
34203_at  CNN1  calponin 1, basic, smooth muscle  31  40.30 
36834_at  MOXD1  monooxygenase, DBH-like 1  28  36.33 
39333_at  COL4A1  collagen, type IV, alpha 1  27  35.01 
773_at  MYH11  myosin, heavy polypeptide 11, smooth muscle  24  31.03 
38834_at  TOPBP1  topoisomerase (DNA) II binding protein 1  23  29.71 
685_f_at  LOC112714  similar to alpha tubulin  23  29.71 
34878_at  SMC4L1  SMC4 structural maintenance of chromosomes 4-
like 1  22  28.38 
35970_g_at  MPHOSPH9  M-phase phosphoprotein 9  22  28.38 
41137_at  PPP1R12B  protein phosphatase 1, regulatory (inhibitor) subunit 
12B  21  27.06 
1884_s_at  PCNA  proliferating cell nuclear antigen  20  25.73 
40407_at  KPNA2  karyopherin alpha 2 (RAG cohort 1, importin alpha 
1)  20  25.73 
32662_at  MDC1  Mediator of DNA damage checkpoint 1  19  24.41 
34376_at  PKIG  protein kinase (cAMP-dependent, catalytic) 
inhibitor gamma  19  24.41 
35742_at  C16orf45  chromosome 16 open reading frame 45  19  24.41 
36987_at  LMNB2  lamin B2  19  24.41 
39145_at  MYL9  myosin, light polypeptide 9, regulatory  18  23.09 
38430_at  FABP4  fatty acid binding protein 4, adipocyte  17  21.76 
1599_at  CDKN3  cyclin-dependent kinase inhibitor 3  16  20.44 
2012_s_at  PRKDC  protein kinase, DNA-activated, catalytic 
polypeptide  16  20.44 
32305_at  COL1A2  collagen, type I, alpha 2  16  20.44 
418_at  MKI67  antigen identified by monoclonal antibody Ki-67  16  20.44 
651_at  RPA3  replication protein A3, 14kDa  16  20.44 
35474_s_at  COL1A1  collagen, type I, alpha 1  15  19.11 
37749_at  MEST  mesoderm specific transcript homolog (mouse)  15  19.11 
38031_at  DDX48  DEAD (Asp-Glu-Ala-Asp) box polypeptide 48  15  19.11 
39990_at  ISL1  ISL1 transcription factor, LIM/homeodomain, 
(islet-1)  15  19.11 
1505_at  TYMS  thymidylate synthetase  14  17.79 
33924_at  RAB6IP1  RAB6 interacting protein 1  14  17.79 
35694_at  MAP4K4  mitogen-activated protein kinase kinase kinase 
kinase 4  14  17.79 
32306_g_at  COL1A2  collagen, type I, alpha 2  13  16.46 
32847_at  MYLK  myosin, light polypeptide kinase  13  16.46   89 
37305_at  EZH2  enhancer of zeste homolog 2 (Drosophila)  13  16.46 
41081_at  BUB1  BUB1 budding uninhibited by benzimidazoles 1 
homolog  13  16.46 
32272_at  K-ALPHA-1  tubulin, alpha, ubiquitous  12  15.14 
36627_at  SPARCL1  SPARC-like 1 (mast9, hevin)  12  15.14 
37347_at  CKS1B  CDC28 protein kinase regulatory subunit 1B  12  15.14 
39519_at  KIAA0692  KIAA0692 protein  12  15.14 
40845_at  ILF3  interleukin enhancer binding factor 3, 90kDa  12  15.14 
  a Count is the number of occurrences of each gene in 1000 rules.   90 
Table 4.4 GP classifiers that distinguish different cancer classes of SRBCT or subtypes 
of prostate cancera 
 
Analysis  Classifier  Training Errors  Test Set Errors 
FNb  FP  FN  FP 
Small ,Round Blue-
Cell Tumor 
IF (HCLS1 – GSTA4 > XPO6) THEN BL  0  0  0  0 
IF (PTPN13 / COX8A > CDK6) THEN EWS  0  0  0  0 
IF (SATB1 > CSDA^2) THEN NB  0  0  0  0 
IF (CDH17/FGFR4 <= MYL4) THEN RMS  0  0  0  0 
Primary Prostate 
Cancer vs. 
Metastatic Prostat 
Cancer 
IF (ARL6IP> MYH11) THEN MET  0  0  0  4 
IF (MYH11 < MYH11) THEN MET  0  0  0  4 
Lung Cancer 
(High-risk vs. Low-
risk) 
IF (LTBP2 - IARS) <= (ADM + CCT2 * FCGR2A) 
THEN High-Risk  0  1  1  0 
IF (GYPB - MN1) < (ADM + (MCFD2 + CKS2)) 
THEN High-Risk  1  0  3  0 
a Only one or two classifiers per class per analysis are listed in the table.  
b FN: the number of false negatives; FP: the number of false positives   91 
Table 4.5 GP classifiers that classify benign prostate and primary prostate cancer 
 
Classifier 
The Area Under the ROC Curve (AUC) and Its 95% 
Confidence Interval 
Lapointe et al. 
Validation Set 
(Stanford) 
Dhanasekaran et 
al. (UM) 
Yu et al. 
(Pittsburgh) 
IF (ENC1 + GJB1) >= -0.8902 THEN PCA  0.95 (0.87 - 1.00)  0.95 (0.90 - 1.00)  0.92 (0.85 - 1.00) 
IF (MYO6 + AMACR) >= -2.6776 THEN 
PCA  0.95 (0.88 - 1.00)  0.99 (0.97 - 1.00)  0.95 (0.90 - 1.00) 
IF (TSPAN13 + PRKCBP1 >= -0.4172 
THEN PCA  0.94 (0.85 - 1.00)  0.88 (0.78 - 0.98)  0.94 (0.90 - 0.99) 
IF (C20ORF74 + DAPK1) >= -0.7765 
THEN PCA  0.91 (0.80 - 1.00)  0.64 (0.49 - 0.80)  0.87 (0.79 - 0.95) 
IF (IMAGE:396839 + ENC1) >= -0.5513 
THEN PCA  0.97 (0.91 - 1.00)  0.82 (0.70 - 0.94)  0.89 (0.81 - 0.98) 
Meta-classifier  0.96 (0.87 - 1.00)  0.99 (0.96 - 1.00)  0.99 (0.98 - 1.00) 
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Table  4.6  The  misclassification  error  rates  of  genetic  programming  (GP)  and  other 
common classification models 
 
                                Error Rate (%) 
Algorithm  SRBCT (BL vs. NON-BL)  Lung Cancer (High-Risk 
vs. Low-Risk) 
  5 Genes  10 Genes  5 Genes  10 Genes 
Genetic Programming  1.5  N/A  16  N/A 
Compound Covariate Predictor  5  5  20  25 
3-Nearest Neighbors  5  5  15  30 
Nearest Centroid  5  5  20  25 
Support Vector Machines  0  5  20  25 
Diagonal Linear Discriminant 
Analysis  5  5  10  20   93 
   
 
Figure  4.1.  A  flowchart  of  the  genetic  programming  (GP)  process.  A.  Briefly,  a 
population of tree-based classifiers is first created by randomly choosing gene expression 
data or constant values and combining with arithmetic or Boolean operators. An example 
of  tree-based  classifiers  is  represented  in  B.  A  small  subgroup  of  classifiers  is  then 
selected as a “mating group” and each classifier in this “mating group” is assessed by a   94 
fitness function, which is defined as the area under the receiver-operator characteristic 
curve (ROC-AUC) in this study. The two fittest classifiers are then selected as ‘mating’ 
parents and ‘mated’ to produce ‘offspring’ by genetic operators (crossover, or mutation). 
The generated offspring then replace the least-fit parent classifiers within the population. 
A new generation of population is generated once the offspring fully replaced ‘parent’ 
classifiers in the population. This process of mating pool selection, fitness assessment, 
mating  and  replacement  is  repeated  over  generations,  progressively  creating  better 
classifiers until a completion criterion is met. After the best classifiers are outputted, 
post-GP analyses are carried out to compute gene occurrence in the classifiers as well as 
to predict on new unknown samples. B. The representation of a genetic programming 
(GP) tree structure for an exemplified classifier, Gene[A] / Gene[B] >3. In general, a GP 
classifier  is  represented  as  a  tree-based  structure  composed  of  the  terminal  set  and 
function set. The terminal set, in tree terminology, are leaves (nodes without branches) 
and may represent as genes or constants. The function set is a set of operators such as 
arithmetic operators (+, −, ￗ, ÷) or Boolean operators (AND, OR, NOT), acting as the 
branch points in the tree, linking other functions or terminals. C. The representation of a 
crossover operator of GP tree.   95 
 
 
Figure 4.2. Feature selection in genetic programming. A. The statistical z-score of each 
of  the  3547  genes  occurring  in  the  1000  classifiers  generated  from  LaTulippe  et  al. 
prostate cancer study by GP based on the parameters listed in Table 2. Let Z=[Xi-E(Xi)]/σ, 
where Xi is the frequency times gene i is selected, E(Xi) is the expectation of frequency 
times gene i is selected, σ is the standard deviation of this binomial model. Let, n=1000, 
p, the probability of gene i being selected randomly, is approximately equal to the total 
counts of frequency in 1000 classifiers divided by the number of classifiers (1000), then 
divided  by  the  total  number  of  genes  (3547),  then  E(Xi)=np, and  σ  = √[np(1-p)].  B. 
Correlation between commonly occurring genes on two independent sets of classifiers. 
Each set contains 1000 classifiers.    96 
 
 
Figure 4.3. Top feature genes derived from GP separate tumors into their corresponding 
diagnostic  classes.  A.  Hierarchical  clustering  using  the  top  46  most  frequent  genes 
derived from the 1000 classifiers generated for LaTulippe et al. (MSKCC) dataset. Genes 
were ranked by the frequency of their occurrences in the classifiers. The top 46 frequent 
genes (z score >=15, see Figure 4.2) were selected for hierarchical clustering. The left 
panel is the clustering of metastatic samples and primary prostate cancer samples for the 
MSKCC data, and the right panel is for the Yu et al. (Pittsburgh) validation dataset. Rows 
represent  genes  and  columns  represent  samples.  The  green  lines  in  the  dendrogram 
indicate primary prostate cancer and the red lines represent metastatic prostate cancer 
samples. B. Hierarchical clustering of the entire SRBCT dataset using the top 54 feature 
genes obtained from the training set. C-F. The top 26 most frequent genes from the 2000 
classifiers generated from Lapointe et al. (Stanford) training set was used to separate 
benign/control prostate samples from primary prostate cancer samples in the Stanford 
training set (C), Stanford validation set (D), Yu et al. (Pittsburgh) validation set (E), and 
Dhanasekaran  et  al.  (UM)  validation  set  (F)  respectively.  The  green  lines  in  the 
dendrogram  indicate  benign/control  prostate  samples  and  the  black  lines  represent 
primary prostate cancer samples.   97 
 
 
Figure 4.4. The receiver-operator characteristic curves (ROCs) of five classifiers and one 
meta-classifier for three prostate cancer validation sets. The classifiers were generated 
from  the  Lapointe  et  al.  (Stanford)  training  set  to  distinguish  benign  prostate  from 
primary prostate cancer. The ROCs are based on continuous prediction scores computed 
from the left side of the classifier inequality (see Methods). The scores of the meta-
classifier are the mean values of prediction scores from each individual classifier. A., B., 
C. represents the ROC curve for Lapointe et al. (Stanford), Dhanasekaran et al. (UM), 
and Yu et al. (Pittsburgh) validation set respectively.   98 
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PART 3: NON-INVASIVE TESTS FOR PROSTATE CANCER DIAGNOSIS 
 
 
CHAPTER 5 
 
Autoantibody Signatures in Prostate Cancer 
 
New  biomarkers,  such  as  autoantibody  signatures,  may  improve  the  early 
detection of prostate cancer. With a phage-display library derived from prostate-cancer 
tissue, we developed a phage protein microarray platform to analyze serum samples from 
119 patients with prostate cancer and 138 controls, with the samples equally divided into 
training and validation sets. A 22-phage-peptide detector that was constructed from the 
training set was evaluated on an independent validation set of 128 serum samples (60 
from patients with prostate cancer and 68 from controls). This phage-peptide detector 
resulted in 88.2% specificity (95% Confidence Interval [CI], 0.78 to 0.95) and 81.6% 
sensitivity  (95%  CI,  0.70  to  0.90)  in  discriminating  between  the  group  with  prostate 
cancer and the control group in the validation set. This panel of peptides also performed 
better than did prostate-specific antigen (PSA) in term of classification accuracy (area 
under the ROC-curve for the autoantibody signature, 0.93; 95% CI, 0.88 to 0.97; area 
under  the  curve  for  PSA,  0.80;  95%  CI,  0.71  to  0.88).  Logistic-regression  analysis 
revealed that the phage-peptide panel provided additional discriminative power over PSA 
(P<0.001). Taken together, this study demonstrated that autoantibodies against peptides   101 
derived from prostate-cancer tissue could be used as the basis for a screening test for 
prostate cancer.  
 
Limitations of the prostate-specific antigen (PSA) test for the early detection of 
prostate cancer (1) indicate the need for other means of screening for this neoplasm. The 
finding that patients with cancer produce autoantibodies against antigens in their tumors 
(2-7)  suggests  that  such  autoantibodies  could  have  diagnostic  and  prognostic  value 
(2,6,8-10). For example, mutant forms of the p53 protein elicit anti-p53 antibodies in 30 
to 40% of patients with various types of cancers (11). Recently, we found that patients 
with prostate cancer produce antibodies against alpha-methylacyl-coenzyme A racemase 
(12),  an  overexpressed  protein  in  epithelial  cells  of  prostate  cancer  (13-15).  This 
autoantibody had 72% specificity and 62% sensitivity in detecting prostate cancer (12), 
indicating that the use of additional prostate-cancer antigens could improve the sensitivity 
and specificity of an autoantibody-based screening test for prostate cancer.  
 
Here we report the use of phage-display microarrays to identify and characterize 
new  autoantibody-binding  peptides  derived  from  prostate-cancer  tissue.  A  similar 
approach has been used to identify selected antigens for the diagnosis of breast cancer 
(16). To develop a phage-display library of prostate-cancer peptides, we isolated mRNAs 
of prostate cancer tissues and inserted the synthesized cDNA fragments into the T7 phage 
system. Peptides that were encoded by the prostate cancer cDNAs were expressed and 
displayed on the surface of the phage fused to the C-terminal of the capsid 10B protein of 
the phage. This surface complex functioned as bait to capture autoantibodies in serum. To   102 
enrich the library for peptides that bind specifically to autoantibodies in patients with 
prostate cancer, we carried out successive rounds of selection and purification, termed 
biopanning (Figure 5.1). Phage clones, each bearing a single fusion peptide derived from 
the prostate-cancer cDNA library, were then selected randomly from the purified library 
to generate protein microarrays on coated glass slides with the use of a robotic spotter. 
Once in a microarray format, the enriched phage clones were used to test serum for 
autoantibodies against prostate cancer peptides.  
 
Initially, we constructed a high-density phage-display microarray containing 2304 
individual phage clones. Five empty clones were also included as negative controls. To 
decrease the complexity of subsequent validation studies, we sought to develop a focused 
array on the basis of the initial high-density arrays. We randomly selected 20 serum 
samples from cancer patients and 11 control samples from the University of Michigan 
collections. After normalization of all values obtained by the scanner, we selected 186 
phage-peptide clones that yielded a ratio of Cy5 to Cy3 greater than 1.2 in at least one of 
the  serum  samples  from  prostate  cancer  patients.  These  clones,  along  with  negative-
control phage clones, were used to construct a smaller, focused protein microarray for 
subsequent screening of serum samples.  
 
Figure 5.2 shows the training and validation phases of this study. A total of 257 
serum  samples  from  119  patients  with  clinically  localized  prostate  cancer  and  138 
controls,  were  tested  on  the  186-element  focused  arrays  (Table  5.1).  In  the  training 
phase, we analyzed 59 samples from patients with prostate cancer and 70 control samples   103 
(Figure 5.2). To identify a best subset of clones for detection of prostate cancer, we used 
a  nonparametric-pattern-recognition  approach  that  consisted  of  a  genetic  algorithm 
combined with k-nearest neighbour to select a subgroup of "informative" phage peptides 
from  the  training  set  based  on  leave-one-out  cross-validation  (17).  Unlike  individual 
feature ranking methods, this approach allows us to find a group of clones that serve 
together to maximize the classification performance even though individual clones may 
not  be  highly  correlated  with  the  diagnostic  status  of  prostate  cancer.  Using  this 
approach, we identified a panel of 22 phage-peptide clones that best distinguished cancer 
patients  from  control  subjects,  with  97.1%  specificity  and  88.1%  sensitivity  in  the 
training set. Figure 5.3A shows a heatmap of the results with the 22 phage-peptide clones 
in the training set.  
  
We next sought to apply this panel of 22 phage peptide clones into an independent 
validation set. By using a weighted voting scheme, we applied these peptides as a class 
detector to classify samples in  the independent validation set  (128 patients) as either 
prostate cancer or control (see Methods). Notably, only 8 of 68 serum samples from 
controls and 11 of 60 samples from patients with prostate cancer were misclassified in 
this validation set (Figure 5.3B), resulting in a specificity of 88.2% (95% CI, 78% to 
95%)  and  a  sensitivity  of  81.6%  (95%  CI,  70%  to  90%).  We  also  observed  similar 
performance when using different prediction methods and resampled datasets.  
 
To examine whether if the 22-phage-peptide detector performs better than the 
conventional PSA test, we next calculated receiver-operating-characteristic (ROC) curves   104 
for  both  of  them  in  the  validation  set.  For  the  22-phage-peptide  detector,  different 
threshold values of weighted voting scores were used as cutoff points to plot the true 
positive rate against the false positive rate. For the entire validation set, the ability of the 
panel of 22 phage peptides to discriminate between prostate-cancer samples and control 
samples was significant (P<0.001), with an area under the curve equal to 0.93 (95% CI, 
0.88 to 0.97) (Figure 5.3C). The area under the curve for PSA was 0.80 (P<0.001; 95% 
CI, 0.71 to 0.88),  which  was expected as these patients  were identified primarily by 
elevated PSA levels. Among patients with PSA levels of 4 to 10 ng per milliliter in the 
validation  set,  the  phage-peptide  detector  remained  significant  discriminatory  power 
(P<0.001) as compared with PSA (P=0.50) in distinguishing serum samples from patients 
with prostate cancer from those of controls. The area under the curve was 0.93 (95% CI, 
0.86 to 1.00) for the phage-display method and 0.56 (95% CI, 0.38 to 0.74) for PSA 
(Figure 5.3D). When the lower limit of PSA was decreased to 2.5 ng per milliliter, the 
discriminatory power of the phage-peptide profile was maintained (P<0.001), with an 
area under the curve of 0.94 (95% CI, 0.88 to 1.00), whereas that for PSA decreased 
slightly to 0.50 (95% CI, 0.33 to 0.66) (Figure 5.3E).  
 
To compare the ROCs for the 22 phage-peptide predictor and PSA, a permutation 
test was performed based on the difference between the AUCs for the two diagnostic 
techniques accounting for the fact that the same samples were used for both assays.  For 
the entire validation set, the difference in AUCs was significant (p < 0.001).  In addition, 
the difference was also significant for the subjects with PSA level between 4-10 ng/ml (p 
= 0.004) and with PSA level between 2.5-10 ng/ml (p < 0.001).    105 
 
To evaluate whether the 22 phage-peptides predictor is a useful supplement to 
PSA,  we  performed  logistic  regression  on  the  validation  set.  We  first  used  cancer 
diagnostic status (cancer/non-cancer) as the response and carried out univariate logistic 
regression for the standardized weighted voting scores and PSA respectively. We found 
that both tests are statistically significant (odds ratio [OR] for the voting scores = 74.22, 
95% CI = 16.17-340.67, p<0.001; OR for PSA = 4.17, 95% CI = 2.05-8.47, p<0.001). 
Next, we performed multivariate logistic regression with disease as the response and fit 
both the voting scores and PSA as covariates. We found that the effect of voting scores 
was strongly significant (OR = 47.69; 95% CI = 9.47-240.21; p<0.001) after adjusting for 
the effect of PSA (OR = 2.91; 95% CI = 1.29-6.56; p=0.01), indicating that the 22 phage-
peptide predictor provides additional predictive value over preoperative PSA level. 
 
We next sequenced the panel of 22 phage-peptide clones. Of these, four were in-
frame  and  within  known  expressed  transcripts,  including  bromodomain-containing 
protein 2 (BRD2), eukaryotic translation initiation factor 4 gamma 1 (eIF4G1), ribosomal 
protein L22 (RPL22), and ribosomal protein L13a (RPL13a). The others were not present 
in  peptide  stretches  in  known  proteins.  These  clones  may  be  weakly  homologous  to 
known proteins or may have no distinct homology to the primary sequences of known 
proteins  and  thus  may  be  "mimotopes"  (i.e.,  stretches  of  amino  acids  that  mimic  an 
antigen but are not homologous at the sequence level). To examine whether the four in-
frame  phage-peptide  clones  (Figure  5.4A)  are  deregulated  in  prostate  cancer  at  the 
transcript level and protein level, we performed a meta-analysis of publicly available   106 
gene expression datasets in prostate cancer (18-24) as well as a preliminary immunoblot 
analysis.  These  analyses  suggested  that  the  four  in-frame  phage  epitopes  are 
overexpressed in prostate cancer (Figure 5.4B and Figure 5.4C).  
 
The use of PSA-based screening for prostate cancer has risen dramatically since 
its introduction in the late 1980s (25,26). However, reliance on PSA for the detection of 
early prostate cancer is still unsatisfactory, especially because of a high rate of false 
positive results (27) — as high as 80% (28,29). This rate results in many unnecessary 
prostate biopsies (30). To circumvent this and other problems of screening for prostate 
cancer, we have begun to evaluate the use of autoantibody signatures to detect prostate 
cancer. 
 
In this study, we used protein microarrays to identify autoantibodies against tumor 
antigens  in  patients  with  prostate  cancer.  Specifically,  we  constructed  phage-protein 
microarrays  in  which  peptides  derived  from  a  prostate-cancer  cDNA  library  were 
expressed as a prostate-cancer – phage fusion protein. The phage-protein microarrays 
were screened to identify phage-peptide clones that bind autoantibodies in serum samples 
from patients with prostate cancer but not in those from controls.  By relying on multiple 
immunogenic  prostate-cancer  peptides,  this  approach  may  improve  the  accuracy  of 
prostate cancer diagnosis over a single biomarker such as PSA.  
 
Our results were consistent across a range of clinical and pathological features, 
including  PSA  level,  Gleason  grade,  stage,  and  presence  or  absence  of  PSA,  with   107 
sensitivities and specificities ranging from 80 to 90% in discriminating between patients 
with  prostate  cancer  and  controls.  In  addition,  this  diagnostic  performance  was 
maintained in the intermediate ranges of PSA (either 4 to 10 ng per milliliter or 2.5 to 10 
ng  per  milliliter).  In  addition,  our  data  revealed  that  the  22-phage-peptide  detector 
significantly increased the diagnostic power of PSA alone (P<0.001), suggesting that our 
autoantibody  signature  may  be  useful  in  combination  with  initial  PSA  screening  to 
improve decision making in biopsy of the prostate.  
 
We have not tested the phage-microarray system for screening for prostate cancer; 
this  requires  extension  and  confirmation  in  community-based  screening  cohorts. 
Furthermore, it will be important to evaluate the autoantibody signatures associated with 
prostate cancer in patients with prostatitis, autoimmune conditions, and other diseases. 
Although  the  technique  is  promising,  how  it  will  perform  in  prospective  and  multi-
institutional studies remains to be determined.  
 
Methods 
Populations and Samples. This study, which was approved by the institutional review 
board of the University of Michigan Medical School, started in March 2003 and ended in 
December 2004. It had discovery, training, and validation phases. All serum samples, 
unless otherwise indicated, were obtained from patients in the University of Michigan 
Health System. Written informed consent was obtained from all patients.  
   108 
In the discovery phase (biopanning and 2304-element microarrays), 39 prostate-
cancer samples and 21 control samples were used. The training phase involved the use of 
59  prostate-cancer  samples  and  70  control  samples.  To  evaluate  the  phage-peptide 
detectors that we developed in the discovery and training phases, we used an independent 
validation set of 60 prostate-cancer samples (48 from the University of Michigan and 12 
from  the  Dana-Farber Cancer  Institute)  and  68  control  samples.  In  the  257  prostate-
cancer samples and control  samples (which included the  training and validation sets, 
Table 5.1), the median levels of PSA were 6.3 ng per milliliter (range, 0.1 to 46.3) and 
1.7 ng per milliliter (range, 0.1 to 24.5), respectively.  
 
Autoantibody Profiling. By iterative biopanning of a phage-display library derived from 
prostate-cancer  tissues,  we  developed  phage  protein  microarrays  and  used  them  to 
develop an autoantibody signature to distinguish samples with prostate cancer from those 
of controls. Details concerning the construction of phage-display libraries and preparation 
of the phage-protein microarrays are shown in Figure 5.1.  
 
Normalization and Analysis of the Microarray Data. Slides were scanned and quantified 
using GenePix 4000B scanner (Axon Laboratories). The Cy5/Cy3 ratios were calculated 
for  each  phage  spot,  and  values  for  duplicate  spots  were  averaged.  The  difference 
between duplicates was <5% for 98% of the spots. Analyses of repeated experiments 
using same serum samples revealed that the results were very consistent with correlation 
coefficient greater than 0.9. According to the experimental design, Cy5/Cy3 was utilized 
so as to control the small variations in the amount of phage particles being spotted. The   109 
ratio of Cy5/Cy3 for each spot was subtracted by median of Cy5/Cy3 of the negative T7 
empty spots with the observation that the signal for the T7 empty phage on each chip 
highly correlated with the signal intensity for the whole array. A Z-transformation was 
applied to data such that the mean of each clone was zero across arrays and the variance 
was 1.0. Normalized data was then subjected to two-way clustering analysis with use of 
Cluster and TreeView. 
 
Development  of  Phage-Peptide  Predictor.  By  employing  186-element  phage-peptide 
microarray platform, 257 sera samples  were tested. These samples  were divided into 
training and validation set. Training set was used to build a class prediction model by a 
leave-one-out-cross-validation  (LOOCV)  strategy  in  Genetic  Algorithm/K-Nearest 
Neighbor (GA/KNN) (k=3 in this study) method (17). The raw data was normalized as 
described above. The normalized array data was then applied to GA for selection of the 
clones and assessment of their relative predictive importance by ranking them based on 
their frequency of occurrence in GA solutions with the top-most clone assigned a rank of 
1. Different numbers of the top-most clones were used to build different KNN prediction 
models.  Misclassification  error  rates  were  calculated  using  LOOCV  to  evaluate  the 
performance of the models. As few as 10 phage clones performed with similar accuracy, 
but  to  maintain  a  diversity  of  clones  for  validation,  we  used  the  22  phage-peptide 
predictor,  which  yielded  the  minimal  misclassification  error  ratessensitivity  during 
LOOCV. For the validation sample set, a weighted voting scheme was adopted, similar to 
that described previously (31). Briefly, let class 0 and class 1 represent non-cancer and 
cancer samples, respectively. Each informative phage clone, derived from the training   110 
set, casts a weighted vote for a class 0 or 1: vx = Tx (ex - bx) where ex is the signal value of 
phage peptide x for each individual validation sample on array images, Tx is the t-statistic 
for comparing the two class means of phage x in the training set, and bx is (µ 0 +µ 1)/2, 
where µ 0, and µ 1 denote the means of phage x for class 0 or 1 in the training set. A 
negative vx indicates a vote for class 0 and a positive value indicates a vote for class 1. 
The total vote V0 for class 0 is obtained by summing the absolute values of the negative 
votes over the informative phage-peptides, while the total vote V1 for class 1 is obtained 
by summing the absolute values of the positive votes. The final voting score Vs is V1-V0 
and the final vote for class 0 or 1 is sign (Vs) and the confidence in the prediction of the 
winning class is |V1-V0| / (V0+V1), where Vi is the vote for class i. 
 
Sequence Analysis of 22 Phage Clones. The top 22 phage clones were amplified by PCR 
using T7 capsid forward and reverse primers (Novagen). Briefly, 2 µl of fresh phage 
lysate with titer of ~ 1010 pfu was incubated with 100 µl of 10 mM EDTA, pH 8.0 at 
60° C for 10 min. After centrifuging at 14,000 g for 3 min, 2 µl of denatured phage was 
used for PCR in 100 µl volume of reaction under standard condition. PCR products were 
confirmed  on  1%  agarose  gel  containing  ethidium  bromide.  After  purifying  with 
MultiScreen-FB filter plate (Millipore) following manufacturer's protocol, PCR products 
were sequenced using T7 capsid forward primer to determine the cDNA inserts. DNA 
sequence and translated protein sequence were aligned using NCBI BLAST. 
 
Meta-Analysis of Gene Expression. The gene expression level of four genes, namely 
BRD2, eIF4G1, RPL13a and RPL22, were studied using ONCOMINE (22). Briefly, each   111 
gene was searched on the database, and the results were filtered by selecting prostate 
cancer. The data from study classes of benign prostate, prostate cancer and / or metastatic 
prostate cancer with p<0.05 were used to plot the box plots with SPSS11.5. P values for 
each group were calculated using student t-test. 
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Table 5.1 Clinical and pathology information for the training and validation samples. 
 
Variable  Training set  Validation set  
Clinically localized prostate cancer patients 
No. of patients  59  60 
Mean age (yr)  SD  58.3  7.7  60.81  9.0 
Mean gland weight (g)  SD  49.55  17.17  51.78  19.57 
Dim. Of max tumor (cm)  SD  1.44  0.75  1.62  0.97 
PSA level (ng/ml)     
Mean  SD  6.19  4.58  10.45  9.52 
0 - 2.4 (%)  17.2  7.7 
2.5 -10 (%)  67.2  53.8 
4 - 10 (%)  50  42.3 
> 10 (%)  15.5  38.5 
Gleason grade (%)     
<= 6  35.7  37.3 
>= 7  64.3  62.7 
Primary tumor identification 
(%) 
   
T2a  29.8  43.7 
T2b  59.6  41.7 
T3a  3.5  2.1 
T3b  7  12.5 
Control subjects with no known history of cancer 
No. of patients  70  68 
Mean age (yr)  SD  62.8  8.6  63.6  9.3 
PSA level (ng/ml)     
Mean  SD  2.88  2.57  3.01  2.68 
0 - 2.4 (%)  61.4  59.7 
2.5 -10 (%)  38.6  34.3 
4 - 10 (%)  32.9  29.9 
> 10 (%)  0  5.9   113 
 
 
Figure 5.1. Schematic representation of the development of phage-protein microarrays to 
characterize autoantibody signatures in prostate cancer. A cDNA library was constructed 
from  a  pool  of  total  mRNA  isolated  from  prostate-cancer  tissue  obtained  from  six 
patients. After digestion, the cDNA library was inserted into the T7 phage vector. The T7 
fusion vectors were then packaged into T7 phages to generate a prostate-cancer cDNA T7 
phage-display library. To enrich the library with clones of peptides reacting with human 
serum from patients with clinically localized prostate cancer and not with serum from 
controls, several cycles of affinity selections (biopanning) were performed. Briefly, the 
phage  libraries  were  preadsorbed  onto  purified  IgGs  from  the  control  pool  of  serum   114 
samples (from 10 patients) to remove nonspecific clones. Next,  the precleared phage 
libraries  were  enriched  for  cancer-specific  peptides  with  the  use  of  a  pool  of  IgGs 
purified from the serum of 19 patients with prostate cancer. The bound phages  were 
eluted  and  propagated  by  infecting  bacterial  cells.  After  five  rounds  of  biopanning, 
enriched prostate-cancer–specific peptide clones were cultured onto LB agar plates. A 
total of 2304 single colonies, including T7 empty phage clones as negative spots and 
antihuman IgG as positive spots,  were randomly  picked and propagated into 96-well 
plates. Phage-clone lysates were then printed onto coated glass slides with the use of a 
robotic spotter to create a phage-protein microarray. Cy5 (red fluorescent dye)–labeled 
antihuman antibody was used to detect IgGs in human serum that were reactive to peptide 
clones, and a Cy3 (green fluorescent dye)–labeled antibody was used to detect the phage 
capsid protein in order to normalize for spotting. Thus, if a phage clone carries a peptide 
that is reactive to human IgG, after scanning, this spot will be yellow in color; otherwise, 
the spot will remain green, representing an unreactive clone. A total of 31 samples (20 
from patients with cancers and 11 from controls) were tested on the 2304 phage-peptide 
microarray. Analysis of these 31 samples identified 186 phage peptides with the highest 
level of differentiation between cancers and controls, which were then used to develop 
focused microarrays for analyses in the subsequent training and validation phases.   115 
 
 
Figure  5.2.  Overview  of  the  strategy  used  for  the  development  and  validation  of 
autoantibody signatures to identify prostate cancer.   116 
 
 
Figure 5.3. Supervised analyses and validation of autoantibody signatures in prostate 
cancer.  A.  Heatmap  representation  of  the  22  phage-peptides  analyzed  for  immuno-
reactivity  across  129  training  samples.  B.  Heatmap  representation  of  the  22  phage-
peptides for 128 independent validation set of sera from prostate cancer patients and 
controls. Individual peptide clones were represented in rows while serum samples were 
represented in columns. Intensities of yellow color represent positive immunoreactivity 
while intensities of black and blue represent no immunoreactivity. C, Performance of the 
22  phage-peptide  predictor  as  compared  with  PSA  in  the  validation  set.  Receiver 
operating characteristic (ROC) curves are based on multiplex analysis of the 22 phage-
peptide biomarkers and serum PSA (n=128; 60 prostate cancer patients and 68 control 
subjects).  The  red  line  represents  the  22  phage-peptide  predictor,  and  the  green  line 
represents the PSA test. D, Performance of the 22 phage-peptide predictor in patients 
with PSA levels between 4-10 ng/ml.  The patients were from 128 validation samples 
with  total  number  of  42  (22  cancers  and  20  controls).  See  C  for  color  label.  E. 
Performance of the 22 phage-peptide predictor in patients with PSA levels between 2.5 
and 10 ng/ml. Same as D, the samples were a subset of 128 validation group (n=51, 28 
cancers and 23 controls). Color labels are same as C.   117 
 
 
Figure 5.4. Gene expression meta-analysis of humoral immune response candidates.  A, 
Heatmap representation of the immunoreactivity for four in-frame phage-peptide clones 
assessed across 257 serum samples (Figure 5.2).  See Figure 5.3B for color scheme.  B, 
Relative gene expression levels of in frame phage-peptide clones assessed using publicly 
available  DNA  microarray  data  housed  in  ONCOMINE  (www.oncomine.org).    First 
author of each DNA microarray study is provided. P values for each comparison made is 
provided (e.g., benign vs localized prostate cancer (PCA); PCA vs. metastatic prostate   118 
cancer (MET)).  C, Immunoblot validation of the overexpression of humoral response 
candidates at the protein level in prostate cancer. D. Expression of the humoral response 
candidate eIF4G1 in prostate cancer by immunofluorescence staining. Panel 1 displays 
clinically localized prostate cancer (left) adjacent to a benign gland (right).  Panel 2 
display  magnifications of a single prostate cancer gland. Stains for eIF4G1 (red), E-
cadherin  (green)  and  nuclei  (blue)  were  employed.  Scale  bar  represents  5  µm.  E. 
Histogram of staining intensity from immunohistochemistry. Open box represents benign 
tissue cores, while black box represent tumor cores. X-axis is the stain intensity, and y-
axis is the percentage of tissue cores.   119 
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CHAPTER 6 
 
Multiplexed Urine Test for the Early Detection of Prostate Cancer 
 
Prostate specific antigen (PSA) serum level is currently the standard of care for 
prostate cancer screening in  the United States. The PSA test  lacks specificity due to 
elevated  levels  in  benign  conditions  such  as  benign  prostatic  hyperplasia  (BPH)  or 
prostatitis. Thus, additional biomarkers are needed to supplement or potentially replace 
the serum PSA test. Emerging evidence suggests that monitoring the non-coding RNA 
transcript  PCA3  in  urine  may  be  useful  in  detecting  prostate  cancer  in  patients  with 
elevated  PSA.  Here  we  provide  evidence  that  a  multiplex  panel  of  urine  transcripts 
outperforms PCA3 transcript alone for the detection of prostate cancer. We measured the 
expression of 7 putative prostate cancer biomarkers, including PCA3, in sedimented urine 
using  quantitative  PCR  on  a  cohort  of  234  patients  presenting  for  biopsy  or  radical 
prostatectomy. By univariate analysis, we found that increased GOLPH2, SPINK1 and 
PCA3 transcript expression, and TMPRSS2:ERG fusion status were significant predictors 
of  prostate  cancer.  Multivariate  regression  analysis  demonstrated  that  a  multiplexed 
model including these biomarkers outperformed serum PSA or PCA3 alone in detecting 
prostate cancer. The area under the receiver-operating characteristic curve was 0.758 for 
the  multiplexed  model  versus  0.662  for  PCA3  alone,  p  =  0.003.  The  sensitivity  and 
specificity  for  the  multiplexed  model  were  65.9%  and  76.0%,  respectively,  and  the 
positive  and  negative  predictive  values  were  79.8%  and  60.8%,  respectively.  Taken   122 
together, these results provide the framework for the development of highly optimized, 
multiplex urine biomarker tests for the early detection of prostate cancer. 
 
Prostate cancer is one of the leading causes of cancer-related death in American 
men. Prostate specific antigen (PSA) has been used extensively to screen for prostate 
cancer in the United States, based on early studies showing that PSA levels greater than 4 
ng/ml have predictive value for detecting prostate cancer (1,2). While PSA testing has led 
to a dramatic increase in the detection of prostate cancer (3), PSA as a cancer biomarker 
has substantial drawbacks. For example, PSA is often elevated in benign conditions such 
as  benign  prostatic  hyperlasia  (BPH)  and  prostatitis,  likely  accounting  for  the  poor 
specificity of the PSA test, which has been reported to be only 20% at a sensitivity of 
80%  (4).  Further,  a  study  investigating  men  in  the  Prostate  Cancer  Prevention  Trial 
showed that even in patients with PSA levels lower than 4ng/ml, over 15% had biopsy-
detectable prostate cancer (5). Taken together, this supports the value of identification 
and characterization of prostate cancer biomarkers that could supplement PSA. 
 
Numerous genes have been identified as promising prostate cancer biomarkers, 
including genes specific for prostate cancer, such as  AMACR (6) and PCA3 (7),  and 
markers based on recurrent fusions involving TMPRSS2 and ETS family members (such 
as  TMPRSS2:ERG)  (8).  As  prostate  cells  can  be  detected  in  the  urine  of  men  with 
prostate cancer, urine based diagnostic tests have the advantage of being non-invasive. 
While urine-based testing for PCA3 expression has already been documented in large 
screening programs (9), the feasibility of testing based on other markers has not been   123 
rigorously evaluated.  Importantly, single marker tests, such as  those based on  PCA3, 
ignore the heterogeneity of cancer development, and may only capture a proportion of 
cancer cases. To overcome this limitation, multiplexing, or combining, biomarkers for 
cancer  detection  can  improve  testing  characteristics  (10,11).  Thus,  in  this  study,  we 
sought  to  explore  a  multiplexed  urine-based  diagnostic  test  for  prostate  cancer.  We 
reported  a  new  outlier  gene  in  prostate  cancer  which  represents  a  subset  of  prostate 
cancer and then develop a multiplexed model for urinary dection of prostate cancer by 
combining  this  new  outlier  gene  with  known  prostate  cancer  biomarkers  and  fusion 
genes.  
 
  Recently,  our  lab  developed  a  bioinformatics  approach  termed  COPA  (cancer 
outlier profile analysis) to nominate candidate oncogenes from transcriptomic data based 
on high expression in a subset of cases (8). When applied to the Oncomine compendium 
of tumor profiling studies (www.oncomine.org) (12), COPA successfully identified the 
ETS family members ERG and ETV1 as high-ranking outliers in multiple prostate cancer 
profiling  studies,  leading  to  the  discovery  of  recurrent  gene  fusions involving  the  5’ 
untranslated region of the androgen regulated gene TMPRSS2 with ERG, ETV1, or ETV4 
in prostate cancer cases that over-expressed the respective ETS family member1 (13).  
 
ETS gene fusions occur in 40-80% of prostate specific antigen (PSA)-screened 
prostate cancers, leaving 20-60% of prostate cancers in which the key genetic aberration 
cannot be ascribed to ETS gene fusions. In order to detect new candidate oncogenes in 
ETS negative prostate cancers, our lab performed a COPA-based meta-analysis on 7   124 
prostate cancer profiling studies (14-20).  Eleven genes were nominated as outliers in at 
least 4 of the 7 datasets (Figure 6.1A). Consistent with the previous application of COPA 
filtered by causal cancer genes (8), both ERG and ETV1 were high ranking meta-outliers; 
ERG  ranked  as  the  1st  meta-outlier  (7  studies)  and  ETV1  as  the  5th  meta-outlier  (4 
studies).  
   
Interestingly,  this  analysis  also  identified  SPINK1  (serine  peptidase  inhibitor, 
Kazal type 1), the 2nd ranked meta-outlier, as showing over-expression in prostate cancer 
compared to benign prostate tissue and mutually exclusive over-expression with ERG and 
ETV1 across multiple studies. The profile of SPINK1 expression and scatter plots with 
ERG and ETV1 for two studies (15,20) where SPINK1 was identified as a top-100 outlier 
are shown in Figure 6.1B. We further evaluated the expression of SPINK1 protein in 
prostate cancers. By immunohistochemical (IHC) analysis on tissue microarrays (TMAs), 
we evaluated SPINK1 expression in two independent cohorts, (University of Michigan 
(UM)  and  Swedish  Watchful  Waiting  (SWW))  representing  a  total  of  392  cases  of 
clinically localized prostate cancers that had been previously evaluated for TMRPSS2-
ERG fusion status by fluorescence in situ hybridization (FISH)  (21,22). As shown in 
Figure 6.2A-B, in the UM cohort, 10 and 36 of 75 cases were positive for SPINK1 
expression (13.3%) and TMRPSS2-ERG fusions (48%), respectively, with all SPINK1 
positive cases being TMRPSS2-ERG negative (one sided Fisher’s exact test, p = 0.0008). 
In the SWW cohort, 23 and 57 of 312 cases were positive for SPINK1 expression (7.4%) 
and TMRPSS2-ERG fusions (18.3%), respectively, again with all SPINK1 positive cases 
being TMRPSS2-ERG negative (one sided Fisher’s exact test, p = 0.008).   125 
 
We  also  examined  if  SPINK1  outlier  status  was  associated  with  biochemical 
recurrence after surgical resection. In the Glinsky et al. (15) gene expression dataset, 
which contained tumors from 79 patients (with 37 recurrences), 10 of which showed 
outlier  mRNA  transcript  expression  of  SPINK1  (>0.5  normalized  expression  units). 
These patients had a significantly higher risk of recurrence than patients without outlier 
SPINK1 expression (hazard ratio: 2.65, 95% CI: 1.16-6.07, log rank p = 0.02) by Kaplan-
Meier analysis (Figure 6.2C). A similar analysis was also conducted on the UM cohort 
(75  cases,  28  recurrences)  evaluated  for  SPINK1  status  by  IHC.  By  Kaplan-Meier 
analysis,  SPINK1  positive  staining  was  significantly  associated  with  biochemical 
recurrence (hazard ratio: 2.49, 95% CI: 1.01-6.18, p = 0.04, Figure 6.2D). As a final 
validation,  we  performed  IHC  for  SPINK1  status  on  an  independent  cohort  of  817 
evaluable prostate cancers (200 recurrences) from the Memorial Sloan Kettering Cancer 
Center  (MSKCC).  In  this MSKCC  cohort,  we  defined  SPINK1  positive  cases  in  the 
MSKCC  cohort  as  those  with  at  least  one  core  showing  greater  than  80%  of  cells 
showing positive SPINK1 immunoreactivity, resulting in 75 SPINK positive cases (9%), 
consistent with the other analyses. By Kaplan-Meier analysis, SPINK1 positive cases in 
the MSKCC cohort showed significantly shorter time to biochemical recurrence (hazard 
ratio: 2.32, 95% CI: 1.59-3.39, P = 6.96E-06, Figure 6.2E). While the above survival 
analyses  were  based  on  univariate  analysis,  we  also  performed  multivariate  Cox 
proportional-hazards regression analyses on the above three datasets and confirmed that 
SPINK1 status predicted recurrence independently of other clinical parameters such as 
Gleason score, lymph node status, surgical margin status and pre-operative PSA.   126 
 
In the above section, we have demonstrated by analyzing 971 cancers from three 
cohorts  that  SPINK1  outlier  status  identifies  an  aggressive  subset  of  ETS-negative 
prostate cancers. In the next section, we sought to determine whether such outlier genes 
as ERG and SPINK1, combining with known prostate cancer biomarkers can improve the 
diagnosis of prostate cancer. 
 
We set out to assess expressions of seven putative prostate cancer biomarkers 
using qRT-PCR technique. These biomarkers included those generally over-expressed in 
prostate  cancer,  such  as  PCA3,  AMACR  and  GOLPH2  (6,7),  as  well  as  those  over-
expressed in subsets of prostate cancers, such as ERG and TMPRSS2:ERG, TFF3, and 
SPINK1 (8,23,24). To develop a multiplexed qPCR based test for prostate cancer, we 
profiled a cohort of 138 patients with prostate cancer (86 positive needle biopsy and 52 
radical prostatectomy patients) and 96 patients with negative needle biopsies from the 
University of Michigan.  
   
All genes were first tested by univariate analysis, with GOLPH2 (P = 0.0002), 
SPINK1 (P = 0.0002), PCA3 (P = 0.001) and TMPRSS2:ERG fusion (P = 0.034) showing 
significant association for discriminating patients with prostate cancer from patients with 
negative needle biopsies (Figure 6.3 and Table 6.1). Both AMACR, which has previously 
been shown to be a sensitive and specific biomarker for prostate cancer in tissues (6) and 
TFF3,  which shows high expression in  a subset  of prostate cancers(23,24),  were not 
statistically significant predictors of prostate cancer using urine samples (P = 0.450 and   127 
0.189, respectively). The lack of specificity of AMACR and TFF3 in urine may be due to 
expression of these transcripts in urothelial or kidney derived cellular material which can 
also be shed in the urine. While TMPRSS2:ERG fusion was significantly associated with 
the presence of prostate cancer (Figure 6.3 and Table 6.1), ERG overexpression was not 
associated with cancer presence on univariate analysis (P = 0.166), suggesting that cells 
from other tissues may be contributing ERG transcripts to the urine. Additionally, serum 
PSA  levels  prior  to  biopsy  or  prostatectomy  were  also  not  associated  with  cancer 
presence in this cohort (P = 0.376). When tested as individual variables for the ability to 
detect  prostate  cancer  based  on  the  receiver-operating-characteristic  curves  (ROC), 
GOLPH2 (area under the curve (AUC) = 0.664, P = 2.01E-5), PCA3 (AUC = 0.661, P = 
2.84E-5),  and  SPINK1  (AUC  =  0.642,  P  =  0.0002)  outperformed  serum  PSA 
(AUC=0.508, p=0.837) (Figure 6.3). Thus, in this analysis we have identified a number 
of novel biomarkers for the non-invasive detection of prostate cancer using patient urine 
instead of biopsy samples. Of the seven markers utilized in this study, only PCA3 was 
previously reported as urinary diagnostic biomarker (9). 
 
To determine if a multiplex model could improve on the performance of these 
single  biomarkers,  the  analyzed  prostate  cancer  biomarkers  were  next  tested  in  a 
multivariate  regression  analysis  using  Akaike  Information  Criterion  (AIC)-based 
backward  selection  (25)  to  drop  insignificant  terms  from  the  model.  This  analysis 
resulted  in  a  final  model  that  included  SPINK1  (P  =  7.41E-5),  PCA3  (P  =  0.003), 
GOLPH2  (P =  0.004)  and  TMPRSS2:ERG  (P =  0.006)  (Table  6.1).  To  evaluate  the 
performance  of  this  model  for  diagnosing  prostate  cancer,  we  then  performed  ROC   128 
analysis based on the predicted probabilities derived from the final model. For our cohort, 
we compared the ROC curves from the multiplexed model and PCA3 alone, as urine 
based detection of PCA3 has previously been evaluated in similar cohorts as a single 
biomarker using alternative detection technologies (9,26-29). For example, Van gils et al. 
demonstrated that in a cohort of 534 men presenting for prostate biopsy with serum PSA 
between 3-15 ng/mL, urinary PCA3 detection expression had an area under the ROC 
curve (AUC) of 0.66 compared to 0.57 for serum PSA (9). As shown in Figure 6.4A, in 
our cohort, the AUC for the multiplexed model (0.758, P = 1.91E-11) was significantly 
improved (P=0.003 (30)) compared to the AUC for PCA3 alone (0.662, P = 2.58E-5). At 
the  point  on  the  multiplex  model  ROC  with  the  maximum  sum  of  sensitivity  and 
specificity (65.9% and 76.0%, respectively), the positive predictive value was 79.8% and 
the negative predictive value was 60.8% (Figure 6.4A). As we and previous studies used 
different methodologies to detect PCA3 transcripts in patient urine, directly comparing 
AUCs  is  inappropriate;  however,  we  demonstrate  that  PCA3  shows  improved  AUC 
compared  to  serum  PSA,  consistent  with  previous  reports  (9,26-29).  Importantly,  we 
demonstrate that a multiplex model including PCA3 significantly improves the predictive 
ability of PCA3 alone, suggesting the ability to improve  PCA3 and other single-gene 
based diagnostic tests. The rationale for the multiplex approach is consistent with tests 
offered to breast cancer patients to identify patients at high risk for disease recurrence 
(10,31).  
   
As all samples were used to  select the best subset  of variables for regression 
analysis, there is a potential to over-optimize the reported AUC. Thus, we used a leave-  129 
one-out-cross validation (LOOCV) strategy to generate an unbiased AUC. As shown in 
Figure 6.4B, the AUC for the LOOCV multiplex model (0.736) is again significantly 
better (P = 0.006) than that for LOOCV PCA3 alone (0.645). At the point on the LOOCV 
multiplex model ROC with the maximum sum of sensitivity and specificity (62.3% and 
75.0%, respectively), the positive predictive value was 78.2% and the negative predictive 
value was 58.1% (Figure 6.4B).  
 
Lastly, we tested the ability of these genetic markers to predict clinical risk groups 
based on patient parameters. Clinical risk groups were determined by clinical patient data 
that direct the decision to pursue biopsy, to determine treatment, or to stratify patients for 
surveillance regimens (see Methods). We observed only limited associations between 
these prostate cancer biomarkers and clinical risk groups, with GOLPH2, SPINK1 and 
TMPRSS2:ERG  status  showing  marginal  correlates  with  clinical  stage,  and  major 
gleason.  As  the  biomarkers  in  this  study  were  chosen  based  on  their  ability  to 
differentiate benign prostate tissue and prostate cancer, it is not surprising that they did 
not show strong association with risk stratification measures, such as Kattan nomogram 
prediction of recurrence or organ confined status. Thus, the ideal marker panel would be 
designed  to  enable  risk  stratification  based  on  pre-biopsy  urine  samples  while 
incorporating  markers  designed  to  predict  cancer  presence.  Similar  to  the  previously 
described PCR based test for breast cancer recurrence risk, a prostate cancer risk test 
could drive high risk patients to therapies more suited for their disease course (10).  
   130 
In  summary,  we  demonstrate  that  a  multiplexed  qRT-PCR  based  assay  on 
sedimented urine collected from patients presenting for prostate biopsy or prostatectomy 
exhibits  superior  performance  relative  to  serum  PSA  or  PCA3  alone.  Of  note,  the 
multiplex urine test that we present here, which is a combination of PCA3, SPINK1, 
GOLPH2  and  TMPRSS2:ERG  gene  fusion  status  achieves  a  specificity  and  positive 
predictive value of >75%, making it a potentially useful test to complement serum PSA, 
which has poor specificity in detecting prostate cancer. This study establishes a basic 
framework  for  the  development  of  a  urine  multiplex  test  for  the  early  detection  and 
prognosis  of  prostate  cancer.  Future  studies  will  be  directed  at  improving  the 
performance of this first generation urine multiplex test by evaluating additional markers 
for inclusion as well as allow for improved risk stratification and patient counseling prior 
to treatment decision making. 
 
Methods 
Cancer Outlier Profile Analysis (COPA). COPA analysis was performed on 7 prostate 
cancer gene expression data sets (14-20) in Oncomine (www.oncomine.org) as described 
(8). Briefly, for each data set, gene expression values are median-centered, setting each 
gene’s median expression value to zero. Second, the median absolute deviation (MAD) is 
calculated and scaled to 1 by dividing each gene expression value by its MAD. Of note, 
median and MAD are used for transformation as opposed to mean and standard deviation 
so that outlier expression values do not unduly influence the distribution estimates, and 
are thus preserved post-normalization. In each dataset, genes are rank-ordered by their 
COPA scores at three percentile cutoffs: 75th, 90th and 95th. For each dataset, we defined   131 
outlier genes as those that ranked in the top 100 COPA scores at any one of the percentile 
the cutoffs. To identify meta-outlier genes, we ranked genes by the number of studies 
where the gene was identified as a top 100 outlier. Genes identified as outliers in the 
same number of studies were further ranked by their average outlier rank across those 
studies.  
 
Immunohistochemsitry (IHC) and fluorescence in situ hybridization (FISH). IHC for the 
University  of  Michigan  (UM)  and  Swedish  Watchful  Waiting  (SWW)  cohorts  was 
performed  using  a  mouse  monoclonal  antibody  against  SPINK1  (H00006690-M01, 
Abnova, Taipei City, Taiwan) on tissue microarrays (TMA) containing cores from 75 
(UM) and 312 (SWW) evaluable cases of localized prostate cancer. Staining in greater 
than 1% of cancerous epithelial cells was deemed positive. Previously, we have evaluated 
cases on these tissue microarrays for TMRPSS2-ERG fusion status by FISH using break 
apart ERG assays as previously described (21,22). A one-sided Fisher’s exact test was 
used to evaluate the relationship between SPINK1 and fusion status, as these studies were 
performed  with  the  prior  hypothesis  that  there  was  an  inverse  correlation  between 
SPINK1 expression and fusion status. 
 
MSKCC Immunohistochemistry. IHC for the MSKCC cohort was performed using an in 
house  mouse  monoclonal  antibody  against  SPINK1  on  tissue  microarrays  containing 
triplicate cores from 817 evaluable cases of localized prostate cancer. The percentage of 
positive  tumor  cells  in  each  core  was  estimated  and  assigned  values  of  0%,  5%,  or 
multiples of 10%. The intensity of the expression was assigned a value of 0, 1, 2, or 3.   132 
Triplicate cores from each specimen were scored separately and the presence of tumorous 
tissue in at least two interpretable cores was required to include a case for analysis. We 
considered cases as SPINK1 positive if any of the three cores showed >80% of cancerous 
cells showing positive SPINK1 immunoreactivity (intensity 1-3). 
 
Urine Collection, RNA isolation, amplification and quantitative PCR. This study was 
approved by the Institutional Review Board (IRB) of the University of Michigan Medical 
School and samples were obtained from 276 patients with informed consent following a 
digital rectal exam before either needle biopsy (n=216) or radical prostatectomy (n=60) at 
the  University  of  Michigan  Health  System  (UMHS).  Urine  was  voided  into  urine 
collection  cups  containing  DNA/RNA  preservative  (Sierra  Diagnostics  LLC,  Sonora, 
CA). Isolation of RNA from urine and whole transcriptome amplification (WTA) were as 
described in (32). Quantitative PCR (qPCR) was used to detect seven prostate cancer 
biomarkers  (AMACR,  ERG,  GOLPH2,  PCA3,  SPINK1,  TFF3,  and  TMPRSS2:ERG 
fusions)  and  the  control  transcripts  PSA  and  GAPDH  from  WTA  amplified  cDNA 
essentially as described(32,33). The primer sequences for ERG (exon5_6)(8), GAPDH, 
(34) AMACR (35) and PSA(36) were previously described and for other biomarkers were 
as follows: 
GOLPH2-f: CTGGTGGCCTGCATCATCGTCTTG, 
GOLPH2-r: GCTGCTCCCGCTGCTTCTCCA, 
PCA3-f: CATGGTGGGAAGGACCTGATGATAC, 
PCA3-r: GATGTGTGGCCTCAGATGGTAAAGTC, 
SPINK1-f: CAAAAATCTGGGCCTTGCTGAGAAC,   133 
SPINK1-r: AGGCCTCGCGGTGACCTGAT, 
TFF3-f: AACCGGGGCTGCTGCTTTGACTC, 
TFF3-r: TCCTGCAGGGGCTTGAAACACCA. 
TMPRSS2:ERG fusions were detected using Taqman primers/probe, with the following 
sequences: 
TM-ERGa3-f: CTGGAGCGCGGCAGGAA, 
TM-ERGa3 -r: CCGTAGGCACACTCAAACAACGA, 
TM-ERGa3_MGB-probe: 5’-MGB-TTATCAGTTGTGAGTGAGGAC-3’. 
Threshold levels were set during the exponential phase of the qPCR reaction using 
Sequence Detection Software version 1.2.2 (Applied Biosystems, Foster City, CA), with 
the same baseline and threshold set for each plate, to generate threshold cycle (Ct) values 
for all genes for each sample.  
 
Outcome Analysis. For Kaplan-Meier analysis of the Glinsky et al.(15) and UM datasets, 
biochemical recurrence was defined as a 0.2 ng/ml increase in PSA or recurrence of 
disease after prostatectomy, such as development of metastatic cancer, if biochemical 
recurrence information was not available.  For the MSKCC cohort, only biochemical 
recurrence,  defined  as  PSA  >  0.2  ng/ml  after  surgical  resection  with  a  second 
confirmatory  PSA-measurement  >  0.2  ng/ml,  was  considered,  as  all  patients  with  a 
clinical failure had previously had a biochemical recurrence. For outcome analysis from 
the Glinsky et al. dataset, samples positive for outlier expression of SPINK1 were defined 
as those with greater than 0.5 normalized expression units (as shown in Figure 1B). For 
the  IHC  analysis  of  the  UM  and  MSKCC  cohorts,  positive  cases  were  defined  as   134 
described  above.  Kaplan-Meier  analysis  and  multivariate  Cox  proportional-hazards 
regression were then used to examine the association of SPINK1 with biochemical PSA 
recurrence.  
 
Urinary Data Analysis. qPCR was performed on WTA cDNA from urine collected from 
111 biopsy-negative patients and 165 patients with prostate cancer (105 biopsy positive 
patients and 60 prostatectomy patients). Samples that had PSA Ct values greater than 27 
were  excluded  to  ensure  sufficiency  of  the  amount  of  prostate  cells  in  the  samples, 
leading to 105 biopsy-negative and 152 samples from patients with prostate cancer in the 
analysis.  For  qPCR  analysis,  we  used  raw  –ΔCt  (to  stabilize  the  variance  of  testing 
variables)  as  opposed  to  testing  markers  against  control  (2–ΔCt).  TMPRSS2:ERG  was 
dichotomized  as  a  binary  variable  to  reflect  the  fusion  positive  or  negative  status 
observed in tissue samples(8,37), with positive samples defined as those with Ct values 
less than 37. As PCA3 has been reported to be a prostate tissue-specific marker(7), it was 
normalized against urine PSA (CtPSA-CtPCA3). All other testing variables were adjusted 
against  their  mean  urine  PSA  and  GAPDH  values  ((CtPSA+CtGAPDH)  /  2-CtVariable).  We 
excluded 23 samples showing  outlier values, as at least one testing variable in those 
samples showed an adjusted value below 3 standard deviations from its sample mean, 
suggesting qPCR failure. This resulted in a final data set of samples from 138 patients 
with prostate cancer (86 positive needle biopsy and 52 radical prostatectomy patients) 
and 96 biopsy-negative patients. 
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Statistical  Analysis.  Univariate  and  multivariate  logistic  regressions  were  used  to 
examine associations between prostate cancer diagnostic status and testing variables. For 
multivariate logistic regression, the Akaike Information Criterion (AIC)-based backward 
selection was used to drop insignificant terms (25). All testing markers were included in 
the  initial  regression  model  which  was  further  refined  by  the  AIC-based  backward 
selection. After the final model was determined, the predicted probability for each sample 
was used as input to generate the receiver operating characteristic (ROC) curve and the 
area under the curve (AUC) was calculated. As all samples were used for regression 
model generation, the estimated AUC may be over-optimized. To correct this bias, we 
further  performed  a  leave-one-out  cross  validation.  Briefly,  one  sample  was  omitted 
while  the  regression  model  was  trained  on  the  remaining  samples  to  select  optimal 
markers and estimate their coefficients. The prediction probability for the left-out sample 
is then calculated based on the model prediction. This procedure was repeated until every 
sample was left out once and the derived prediction probability values were then used for 
ROC analysis. Similarly, PCA3 alone was fitted in a logistic regression model to generate 
an  AUC.  The  difference  of  AUCs  was  examined  as  described  previously  (30).  All 
analyses were performed in R (http://www.r-project.org) and ROC curves were plotted 
in SPSS 11.5 (SPSS Inc., Chicago, IL, USA).   136 
Table 6.1. Univariate and multivariate logistic regression analyses used to identify urine 
biomarkers for the detection of prostate cancer. For the multivariate analysis,  Akaike 
Information  Criterion  (AIC)-based  backward  selection  was  used  to  drop  insignificant 
terms. 
 
Univariate Logistic Regression Analysis 
Variable  Coefficient  P-value 
GOLPH2  0.4444  0.0002 
SPINK1  0.25  0.0002 
PCA3  0.187  0.001 
TMPRSS2:ERG  0.609  0.034 
ERG  0.043  0.166 
TFF3  0.11  0.189 
PSA (serum)  0.0151  0.376 
AMACR  0.049  0.45 
 
Multivariate Logistic Regression Analysis 
Variable  Coefficient  P-value 
SPINK1  0.308  7.41E-05 
PCA3  0.191  0.003 
GOLPH2  0.372  0.004 
TMPRSS2:ERG  0.924  0.006 
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Figure 6.1. Meta COPA identifies SPINK1 as a mutually exclusive outlier with ERG and 
ETV1  in  prostate  cancer.  Meta-COPA  analysis  of  7  prostate  cancer  gene  expression 
profiling datasets in Oncomine. A. Genes were ranked by the number of studies in which 
they scored in the top 100 outliers (ranked by COPA) at any of the three pre-defined 
percentile cutoffs (75th, 90th, 95th). Genes were further ranked by their average COPA 
rank (Avg. Rank) in studies where they ranked in the top 100. B. The expression of 
SPINK1 and scatter plots of  ERG vs.  SPINK1  and  ETV1 vs.  SPINK1  expression are 
shown  from  two  studies  where  SPINK1  ranked  as  a  top  100  COPA  outlier.  The 
expression of SPINK1, in normalized expression units, for all profiled samples including 
benign  prostate  tissue  (blue),  clinically  localized  prostate  cancer  (PCa,  red)  and 
metastatic PCa (Met PCa, green), as well as Gleason pattern 6, 7, 8 or 9 prostate cancer 
(magenta, orange, light blue and purple, respectively) are shown in the top panels. Scatter 
plots  are shown  for  ERG  vs.  SPINK1  (middle  panels) and  ETV1  vs.  SPINK1  (lower 
panels) for all samples in both studies.   139 
 
 
Figure 6.2.  SPINK1  over-expression identifies an aggressive subset  of ETS negative 
prostate  cancers  and  can  be  detected  non-invasively.  A-B.  SPINK1  expression  was 
evaluated in two cohorts (University of Michigan (UM) and Swedish Watchful Waiting 
(SWW)) using immunohistochemsitry (IHC) on tissue microarrays that have previously 
been evaluated for TMRPSS2-ERG status by fluorescence in situ hybridization (FISH). 
A. Representative SPINK1 positive and negative cores are shown, along with cells from 
the same cores negative and positive for TMRPSS2-ERG rearrangement by FISH. A   140 
TMRPSS2-ERG rearrangement through intrachromosomal deletion is indicated by loss 
of  one  5’  (green)  ERG  signal.  B.  Contingency  tables  for  SPINK1  expression  and 
TMRPSS2-ERG  status  and  p-values  for  Fisher’s  exact  tests  for  both  cohorts  are 
indicated.  C-E.  Relationship  between  SPINK1  outlier  expression  and  biochemical 
recurrence after surgical resection. Kaplan-Meier analyses of outlier SPINK1 expression 
from the (C) Glinsky et al. DNA microarray dataset and SPINK1 IHC from the (D) UM 
and (E) Memorial Sloan Kettering Cancer Center (MSKCC) cohorts and biochemical 
recurrence  after  surgical  resection  are  shown.  F.  Non-invasive  detection  of  SPINK1 
outlier-expression in men with TMRPSS2:ERG negative prostate cancer. Total RNA was 
isolated from the urine of 148 men with prostate cancer and assessed for TMRPSS2:ERG 
and SPINK1 expression by quantitative PCR. Samples above the dashed red line show 
SPINK1  outlier  expression  (See  Methods).  Contingency  table  for  SPINK1  outlier 
expression and TMPRSS2:ERG status and the Fisher’s exact test p-value is shown.   141 
 
Figure 6.3. Characterization of candidate urine-based biomarkers of prostate cancer. A-
C, Quantitative PCR (qPCR) was performed on whole transcriptome amplified (WTA) 
cDNA from urine obtained from patients presenting for needle biopsy or prostatectomy. 
Biomarker expression in patients with negative needle biopsies (green) or patients with 
prostate cancer (positive needle biopsy or prostatectomy, red) are shown. Normalization 
was performed using –ΔCt, with PCA3 normalized to urine PSA expression as performed 
previously(26).  AMACR, ERG, GOLPH2, SPINK1 and TFF3 were normalized to the 
average of urine sediment  PSA and  GAPDH  expression.  TMPRSS2:ERG  gene fusion 
expression was dichotomized as positive or negative. The –ΔCt values of genes that were 
not significant predictors of prostate cancer by univariate analysis (see Table 6.1) are 
shown in A, and the expression of those that were significant predictors are shown in B & 
C. P values from the univariate analysis for the detection of prostate cancer are indicated. 
D,  Receiver  operator  characteristic  (ROC)  curves  for  individual  variables  for  the 
diagnosis of prostate cancer.  The area under the curves (AUC) for GOLPH2, PCA3, 
SPINK1 and serum PSA are 0.664, 0.661, 0.642 and 0.508, respectively.    142 
 
 
Figure  6.4.  A  multiplexed  set  of  urine  biomarkers  outperforms  PCA3  alone  in  the 
detection of prostate cancer. A. Multivariate regression analysis resulted in a multiplexed 
model including SPINK1, PCA3, GOLPH2 and TMPRSS2:ERG as significant predictors 
of  prostate  cancer  (see  Table  6.1).  ROC  analysis  was  then  performed  based  on  the 
predicted  probabilities  derived  from  the  final  model.  The  multiplexed  model  (red) 
showed significantly greater AUC than PCA3 (blue) alone (0.758 vs 0.662, P = 0.003) for 
the detection of prostate cancer. The point on the ROC curve with the maximum sum of 
sensitivity (Sens) and specificity (Spec) is indicated by the dashed line, and the positive 
and negative predictive values (PPV and NPV, respectively) are given. B. As in A, except 
a leave-one-out cross validation (LOOCV) strategy was used to generate unbiased AUCs. 
The AUC for the LOOCV multiplex model is significantly better than LOOCV of PCA3 
alone (0.736 vs. 0.645, P = 0.006).   143 
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PART 4: AN INTEGRATIVE APPRAOCH TO MODEL PROSTATE CANCER 
PROGRESSION 
 
 
CHAPTER 7 
 
Integrative Genomic and Proteomic Analysis of Prostate Cancer Reveals Signatures 
of Metastatic Progression 
 
Molecular profiling of cancer at the transcript level has become routine. Large 
scale  analysis  of  proteomic  alterations  during  cancer  progression  has  been  a  more 
daunting  task.  Here,  we  employed  high-throughput  immunoblotting  in  order  to 
interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that 
were altered in prostate cancer relative to benign prostate and 156 additional proteins that 
were  altered  in  metastatic  disease.  An  integrative  analysis  of  this  compendium  of 
proteomic  alterations  and  transcriptomic  data  was  performed  revealing  only  48-64% 
concordance between protein and transcript levels. Importantly, differential proteomic 
alterations  between  metastatic  and  clinically  localized  prostate  cancer  that  mapped 
concordantly  to  gene  transcripts  served  as  predictors  of  clinical  outcome  in  prostate 
cancer as well as other solid tumors.  
 
Prostate cancer is a highly prevalent disease in older men of the Western world 
(1,2). Unlike other cancers, more men die with prostate cancer than from the disease 
(3,4). Deciphering the molecular networks that distinguish progressive disease from non-  147 
progressive disease will shed light into the biology of aggressive prostate cancer as well 
as lead to the identification of biomarkers that will aid in the selection of patients that 
should be treated (5). To begin to understand prostate cancer progression with a systems 
perspective, we need to characterize and integrate the molecular components involved (6-
9). A number of groups have employed gene expression microarrays to profile prostate 
cancer tissues (10-18) as well as other tumors (19-22) at the transcriptome level but much 
less  work  has  been  done  at  the  protein  level.  Proteins,  as  opposed  to  nucleic  acids, 
represent  the functional effectors of cancer progression and thus serve as therapeutic 
targets as well as markers of disease. 
 
In  the  present  study,  we  utilized  a  high-throughput  immunoblot  approach  to 
characterize proteomic alterations in human prostate cancer progression focusing on the 
transition  from  clinically  localized  prostate  cancer  to  metastatic  disease.  Using  an 
integrative approach we were able analyze proteomic profiles with mRNA transcript data 
from several laboratories. Our analyses also indicated the proteins that were qualitatively 
concordant with gene expression could be used to define a multiplex gene predictor of 
clinical outcome.  
 
In  order  to  derive  a  first  approximation  of  the  prostate  cancer  proteome,  we 
employed high-throughput immunoblot analysis. This method, while not feasible for use 
on many individual samples, allowed us to screen pooled tissue extracts for qualitative 
levels of hundreds of proteins (and post-translational modifications) using commercially 
available antibodies. The basic approach is illustrated in Figure 7.1A. Extracts from five   148 
tissue specimens of benign prostate, clinically localized prostate cancer and metastatic 
prostate cancer from distinct patients were pooled. Each of the 3 pools of tissue extracts 
were  run  on  preparative  SDS-PAGE  gels,  transferred  to  PVDF,  and  incubated  with 
different antibodies using a miniblot apparatus. Figure 7.1B displays representative data 
using  the  high-throughput  immunoblot  approach.  Known  proteomic  alterations  in 
prostate cancer progression such as EZH2 (23) and AMACR (24-26) are highlighted in 
red while novel associations such as GSK-3beta and IRAK1 are highlighted in green. To 
further increase the number of proteins analyzed, we used an analogous high-throughput 
immunoblot methodology provided by commercial services (see Methods). Thus, in total 
we  assessed  1484  antibodies  against  1354  distinct  proteins  or  post-translational 
modifications. Of these antibodies, 521 detected a band of the expected molecular weight 
in at least one of the pooled extracts. Antibodies that did not detect the correct molecular 
weight  protein  product  may  represent  lack  of  antibody  sensitivity  (or  poor  quality 
antibody) or absence of protein expression in prostate tissues. 
 
To validate the proteomic alterations identified by this screen in individual tissue 
extracts (as opposed to pooled extracts), we analyzed 86 proteins and 2 post-translational 
modifications by conventional immunoblot analysis using 4-5 tissue extracts per class. As 
with  most  gene  expression  studies  done  in  prostate,  our  proteomic  screen  employed 
grossly  dissected  tumor  specimens.  Thus,  the  proteomic  alterations  that  we  detected 
could be due to differences in the stromal-eptihelial ratio of the tissues in addition to 
actual alterations in the epithelial cells. In order to evaluate the proteomic alterations in 
situ, we employed high-density tissue microarrays (27). As only a subset of the identified   149 
proteins have antibodies that are compatible with immunohistochemical analysis, a single 
tissue microarray containing 216 specimens from 51 cases was stained using twenty of 
these IHC-compatible antibodies. Representative tissue microarray elements are shown in 
Figure 7.2A. Each tissue microarray element was evaluated by a pathologist and scored 
for staining (scale of 1-4) as per cell type considered (e.g., epithelial, stromal etc…). 
Using an in situ technique such as evaluation by immunohistochemistry allowed us to 
distinguish  stromal  versus  epithelial  expressed  proteins.  In  general,  proteins  that 
demonstrated a decrease in expression in the metastatic tumors most often were stromally 
expressed  proteins.  As  the  amount  of  stroma  per  unit  area  decreases  with  tumor 
progression, metastatic samples demonstrated a parallel significant decrease in protein 
expression of paxillin and ABP-280, among others. In order to visualize and cluster the 
tissue microarray data (28), the qualitative evaluations were normalized (See Methods). 
Similar to gene expression analyses (21,29), unsupervised hierarchical clustering of the 
data revealed that the in situ protein levels could be used to accurately classify prostate 
samples  as  benign,  clinically  localized  prostate  cancer,  or  metastatic  disease  (Figure 
7.2B). 
 
This high-throughput immunoblotting of prostate extracts led to the identification 
of a several known and previously unknown proteomic alterations in prostate cancer. For 
example, previous studies have shown that the anti-apoptosis protein, XIAP (30), the 
racemase AMACR (24-26) and the Polycomb Group protein EZH2 (23) are dysregulated 
in  prostate  cancer  progression.  Novel  associations  (increases  or  decreases  in  protein 
expression)  with  prostate  cancer  progression  identified  by  this screen include the  E2   150 
ubiquitin ligase UBc9, the cytosolic phosphoprotein stathmin, the death receptor DR3, 
and the Aurora A kinase (STK15), among others. 
 
Having  amassed  this  compendium  of  proteomic  alterations  in  prostate  cancer 
progression,  we  next  examined  the  general  concordance  with  the  prostate  cancer 
transcriptome. To this end we developed an integrative model to incorporate qualitative 
proteomic alterations as assessed by high-throughput immunoblotting (but applicable to 
other proteomic technologies), with transcriptomic data derived from 8 prostate cancer 
gene  expression  studies  (Figure  7.3).  As  both  the  genomic  and  proteomic  approach 
involve analysis of grossly dissected tissues, this facilitates molecular comparisons to be 
made. The high-throughput immunoblot analysis of benign prostate, clinically localized 
prostate cancer and metastatic disease yielded 521 proteins of the expected molecular 
weight. Immunoreactive bands in each of the three tissue extracts were assessed and 
comparisons were made between benign tissue and clinically localized prostate cancer 
(Figure 7.3A) and between clinically localized prostate cancer and metastatic disease 
(Figure  7.3B).  Visually  qualified  proteins  that  were  over-expressed  were  coded  red, 
under-expressed proteins were coded blue, and unchanged proteins were coded white. 
Based  on  this  analysis, 64  proteins  were  dysregulated  in  clinically  localized  prostate 
cancer relative to benign prostate tissue, while 156 proteins were dysregulated between 
metastatic disease relative to clinically localized prostate cancer. As might be expected, 
most  of  the  proteins  analyzed  were  unchanged  in  the  context  of  prostate  cancer 
progression (i.e., 87.7% (457/521) of the proteins were unchanged between clinically   151 
localized  prostate  cancer  and  benign  and  70.1%  (365/521)  of  the  proteins  were 
unchanged between clinically localized and metastatic disease). 
 
The set of quantifiable proteins (n=521) was then mapped to the NCBI Locus link 
and  UniGene  databases  to  identify  each  corresponding  gene.  Data  for  mRNA  was 
extracted for these genes using 8 publicly available prostate cancer gene expression data 
sets (See methods). Over 90% of the genes were represented in at least one microarray 
study, allowing for integrative analysis to be performed. All eight of the prostate profiling 
studies made a comparison between clinically localized prostate cancer and benign tissue, 
while only four of these studies made a comparison between clinically localized disease 
and metastatic disease. Genes which could only be found in one-fourth of studies or less 
were excluded, leading to 481 genes involved in the former comparison and 492 involved 
in the latter comparison. Since we assessed over- and under-expressed genes separately, a 
one-sided t test was conducted per each gene per each profiling study (See Methods). As 
with  the  proteomic  approach,  comparisons  between  benign  and  clinically  localized 
prostate cancer (Figure 7.3A) and localized disease and metastatic disease (Figure 7.3B) 
were made. If an mRNA transcript was significantly over-expressed in a particular study 
it was coded red, under-expressed transcripts were coded blue, and white was used for 
unchanged transcripts. 
 
Figure  7.3  presents  an  integrative  analysis  of  proteomic  data  with  gene 
expression meta-data in prostate cancer progression. An mRNA transcript alteration was 
considered  “concordant”  with  a  proteomic  alteration  if  a  majority  of  the  microarray   152 
profiling  studies  (at  least  50%)  showed  the  same  qualitative  differential  (increased, 
decreased, or unchanged) as the high-throughput immunoblot approach. According to 
these criteria, 289 (60.1%) out of 481 mRNA transcripts were concordant with protein 
levels in clinically localized prostate cancer relative to benign prostate tissue. Similarly, 
291  (59.1%)  out  of  492  mRNA  transcripts  were  concordant  with  protein  levels  in 
metastatic  prostate  cancer  relative  to  clinically  localized  disease.  Out  of  the  156 
proteomic alterations identified between metastatic and localized prostate cancer, 50 were 
concordant with mRNA transcript and 90 were discordant with mRNA transcript while 
the remaining alterations did not have mRNA measurements to map to (Figure 7.3B-C). 
Thus, similar to studies done in yeast (31,32), bacteria (33), and cell lines (34), there was 
only weak concordance between protein and mRNA levels in prostate cancer progression. 
 
To further explore the poor concordance we observed between protein and meta-
data  from  transcriptomic  analyses,  we  profiled  the  pooled  samples  as  well  as  the 
individual samples that comprised the pools on Affymetrix HG-U133 plus 2 microarrays. 
The same integrative analysis was carried out to examine the concordant relationship 
between the protein alterations observed in the pooled tissues by immunoblotting and 
transcript alterations observed in the corresponding pooled and individual tissues. The 
individual  samples  were  included  in  order  to  calculate  statistical  significance  for 
transcript alterations. Similar or even lower concordance was observed between protein 
and  transcript  (61.0%  concordance  in  clinically  localized  prostate  cancer  relative  to 
benign  prostate  tissue, and  48.2%  for  metastatic  prostate  cancer  relative  to  clinically 
localized disease, Figure 7.4A).    153 
 
We also investigated the protein and mRNA concordance in individual samples. 
We focused on the 86 proteins identified as outliers in the larger high-throughput screen. 
The  immunoblot  intensities  were  semi-quantitated  and  correlation  coefficients  were 
calculated for each protein (see Methods). We found that a total 55 out of 86 proteins 
were  observed  to  a  have  a  positive  correlation  with  mRNA,  which  led  to  64.0% 
concordance between proteins and transcripts (Figure 7.4B). On sub classification, we 
observed a concordance of 54.7% and 66.3% in case of localized prostate cancer relative 
to benign prostate tissues and the metastatic disease relative to localized prostate cancer 
respectively. 
 
This proteomic screen identified proteins that are altered from benign prostate to 
clinically localized prostate cancer and a distinct set  of alterations between clinically 
localized disease to metastatic disease. Since we are interested in the transition from 
clinically localized to metastatic disease we next focused on this comparison. As the 
metastatic tissues analyzed in this study are androgen-independent (35), and by contrast 
the clinically localized tumors are generally androgen-dependent, we evaluated whether 
there was an enrichment of androgen-regulated proteomic alterations discovered by our 
screening. Androgen regulated genes (ARGs) are essential for the normal development of 
the  prostate  as  well  as  the  pathogenesis  of  prostate  cancer  (36-38).  Pertinent  to  this 
analysis, Velasco et al. developed a meta-analysis of ARGs which represents a cross-
comparison of 4 gene expression (39-42) and 2 SAGE datasets (43,44). ARGs were then 
defined as a union of these 6 datasets, all of which represented functional induction of   154 
mRNA transcript by androgen in vitro. Interestingly, 27 out of the 150 protein alterations 
(exclusive of post-translational modifications) we identified as being differential between 
metastatic and clinically localized disease, were designated as androgen-regulated by the 
Velasco et al (42) ARG compendium. To demonstrate that this finding is statistically 
significant, we selected random sets of 150 genes from the Yu et al. (18) or the Glinsky 
et al. (45) prostate cancer profiling studies and found that the chance of selecting 27 
ARGs was minimal (Ps < 0.001 for both of the Yu et al. and Glinsky et al. data). Thus, 
androgen-regulated  proteins  are  significantly  enriched  in  the  differential  comparison 
between androgen-dependent and independent prostate cancer. 
 
While examining concordant proteomic alterations, interestingly, we found that 
EZH2, a Polycomb group protein that we and others have previously characterized as 
being over-expressed in aggressive prostate and breast cancer (23,46) was one of the 50 
proteins  identified  as  being  concordantly  over-expressed  in  metastatic  tissues  at  the 
mRNA and protein level (Figure 7.3B-C). As EZH2 was a member of this 50 gene 
concordant  signature,  we  hypothesized  that  proteomic  alterations  that  distinguish 
metastatic  prostate  cancer  from  clinically  localized  disease  may  serve  as  a  multiplex 
signature of prostate cancer progression when applied to clinically localized disease (i.e., 
“more  aggressive”  genes  would  be  expressed  in  progressive  prostate  cancer).  While 
antibodies have yet to be developed to test all of these proteomic alterations in situ by 
immunohistochemistry, we postulated that mRNA transcript levels could be used instead 
due to their concordance with protein levels in this signature.  To test this hypothesis we 
selected prostate cancer gene expression datasets that monitored over 85% of the genes in   155 
the  concordant  genomic/proteomic  signature,  included  biochemical  recurrence 
information  (time  to  PSA  recurrence),  as  well  as  reported  on  at  least  50  clinically 
localized specimens. According to Dobbin et al. (47), the number of samples required for 
developing prognostic markers was approximately 51 or above for a general human gene 
expression dataset with the variance of a gene over samples as 0.5, type I error as 0.001, 
and type II error as 0.05. Thus we chose n=50 as our minimal sample size requirement in 
this analysis. 
 
The  prostate  cancer  gene  expression  datasets  that  fulfilled  these  criteria  were 
carried out by Yu et al. (18) and Glinsky et al.(45), both of which represent Affymetrix 
oligonucleotide datasets and each of which measured at least 44 out of the 50 genes in the 
concordant signature. Although the Singh et al. and LaPointe et al. studies reported over 
50 samples in their studies, the number of samples for which we have available follow-up 
information was less than 30 (29 and 20 samples for the LaPointe and Singh dataset, 
respectively). In addition, the average follow-up time for the samples in LaPointe study 
was only 10.7 months. Thus we excluded both datasets in the analysis. We then chose to 
build our prediction models with the Yu et al. data set and test the performance on the 
Glinsky  et  al.  data  set.  Utilizing  an  approach  described  earlier  (48),  unsupervised 
hierarchical clustering in the space of this 44-gene concordant signature resulted in two 
main clusters of individuals in the Yu et al. study (Figure 7.5A). Kaplan-Meier (KM) 
survival  analysis  of  the  clusters  indicated  that  the  two  groups  of  individuals  are 
significantly  different  based  on  time  to  recurrence  status  (P  =  0.035,  Figure  7.5A). 
Notably,  when  we  use  the  90  discordant  genes  (mRNA  transcripts  that  are  not   156 
qualitatively  concordant  with  protein  levels)  we  found  that  these  signatures  did  not 
generate a clinical outcome distinction (P= 0.238). Moreover, by permutation test, we 
also observed that random sets of 44 genes did not generate such prognostic distinctions 
(See Methods), indicating that our concordant signature was not likely due to chance. To 
assess the validity of this concordant signature, we utilized the Glinsky et al. study as an 
independent test set (Figure  7.5B). Each of the samples in  the Glinsky  dataset  were 
classified as high- or low-risk based on a k-nearest neighbor (k-NN) model developed 
using the Yu et al. study as a training set (k=3). Based on the class predictions derived 
from the concordant signature, KM survival analysis revealed a significant difference in 
survival based on the risk stratification (P = 0.001, Figure 7.5B). As expected, this was 
not the case with the discordant signature when applied to the Glinsky et al. sample set 
(P= 0.556). A similar result was observed when a predictive model built on the Glinsky et 
al. data was applied to the Yu et al. data (P < 0.001 and P = 0.02 for the Glinsky et al. 
and Yu et al. data, respectively). We then carried out  multivariate Cox proportional-
hazards regression analysis of the risk of recurrence on the Glinsky et al. validation set. 
Table 7.1 shows that the concordant signature predicted recurrence independently of the 
other clinical parameters such as surgical margin status, Gleason sum, and pre-operative 
PSA. With an overall hazard ratio of 3.66 (95% CI: 1.36-7.02, P<0.001), it was by far the 
strongest predictor of prostate cancer recurrence in the model. 
 
Next, we sought to refine the concordant signature of prostate cancer progression 
by reducing the number of genes required. By using the Yu et al. study as a training set, 
the 44 concordant genes were ranked by a univariate cox model. The same clustering   157 
procedure  was  employed  to  identify  two  clusters  based  on  the  top  number  of  genes 
ranging from a minimum of 5 to a maximum of 44. Based on this iterative analysis, we 
identified 9 genes that demarcated two main clusters that differed most significantly by 
KM survival analysis (Figure 7.5A, Methods). The Glinsky et al. study was again used 
as  an  independent  validation  set  confirming  that  the  9-gene  concordant  signature 
identified  two  groups  of  individuals  which  differed significantly  based  on  recurrence 
(Figure 7.5B). Together, this integrative analysis suggests that mRNA transcripts that 
correlate with protein levels in metastatic prostate cancer can be used as gene predictors 
of progression in clinically localized disease. 
 
Next, we sought to explore the generality of the concordant progression signature 
in other solid tumors. We identified four tumor profiling datasets from the Oncomine 
compendium  (49)  that  fulfilled  the same  criteria  that  we  used  in  the  prostate cancer 
analyses (see above). In 95 primary breast adenocarcinomas (50), tumors bearing the 50-
gene concordant progression signature were more likely to progress to metastasis than 
those lacking this signature (P = 0.0025). We observed a similar result in 80 primary 
breast infiltrating ductal carcinomas (51) (P = 0.002, Figure 7.5C). Moreover, this result 
was also observed in a series of 84 primary lung adenocarcinomas (52) ( P = 0.03; Fig 
5C) and 56 gliomas (53) (P =0.01; Figure 7.5C). Furthermore, we used two common 
gene expression prediction models (diagonal linear discriminant analysis and k-nearest 
neighbor  analysis)  and  conducted  direct  comparisons  of  the  performances  of  the 
progression signature and the “study-specific” signature in each individual study where 
such a specific signature was available (see  Table 7.2). The result indicated that the   158 
progression  signature  was  able  to  retrieve  similar  or  even  superior  prediction 
performance in most of the studies, especially when employing the k-nearest neighbor 
prediction  model.  This  is  remarkable  as  this  signature  was  derived  exclusively  from 
prostate samples but had utility not only in prostate cancer datasets but also in breast 
cancer, lung cancer, and glioma datasets. Again, this suggests that there is likely biology 
inherent in the integrated predictor. Of note, we found that the smaller 9-gene model was 
only  effective  in  discriminating  prognostic  classes  in  the  Freije  et  al  glioma  study 
(P=0.016) but not in the other solid tumor data sets. This suggests that the 9-gene model 
may be relatively specific for prostate cancer while the 50-gene model has more universal 
applicability.  Taken  together,  our  observations  suggest  that  the  progression 
proteomic/genomic signature identified by the integrative analysis of metastatic prostate 
cancer  may  have  utility  in  the  prognostication  of  clinically  localized solid  tumors  in 
general. Biologically, this suggests that aggressive tumors of different tissue origin begin 
to share the molecular machinery of a de-differentiated state. 
 
While these proteomic alterations have potential to serve as a multiplex biomarker 
of  cancer  aggressiveness,  they  may  also  shed  light  into  the  biology  of  neoplastic 
progression. As proteins, rather than RNA transcripts, are the primary effectors of the 
cell,  they play the central  and most  distal  role in  the functional  pathways to  cancer. 
Interestingly, EZH2, which we previously have shown to have a role in prostate cancer 
progression  (23),  is  a  member  of  this  concordant  genomic/proteomic  signature, 
suggesting that other members of this signature may have utility as biomarkers as well as 
could  have  a  role  in  the  biology  of  progression.  For  example,  this  screen  identified   159 
Aurora-A kinase (STK15) as being overexpessed in metastatic prostate cancer as well as 
being a member of the 50-gene concordant signature. This serine-threonine kinase has 
been shown to be amplified in a number of human cancers (54,55), play a key role in 
G2/M cell cycle progression (56), and inhibit p53 (57), among other functions. Another 
candidate cancer regulatory molecule in the 50-gene concordant signature was KRIP1 
(KAP-1),  which  is  known  to  repress  transcription  via  binding  the  methyltransferase 
SETDB1 (58). 
 
In  this  study,  we  initially  used a  pooling  strategy  to  perform  high-throughput 
immunoblot  analysis.  While  it  would  be  more  ideal  to  involve  replicate  protein 
measurements across multiple prostate tissues and then make comparisons to mRNA, the 
difficulty in monitoring thousands of antibodies on many individual samples and the cost 
of  running  multiple  samples  across  thousands  of  antibodies  required  us  to  adopt  the 
pooling approach. Further, analyses of concordance with mRNA expression on individual 
samples that comprised the pool confirmed the general feasibility of this strategy. We 
also noticed that there were recognized problems with annotations for microarrays. A 
recent study (59) reported that up to 50% Affymetrix probes do not have a matching-
sequence in the Reference Sequence database (Refseq), questioning the reliability of such 
probes. As this study represents an initial foray in the area of integrative analyses, we 
used  basic  gene  identifier-based  matching  for  cross-platform  annotations.  Another 
potential limitation in the present study is that some immunoblots exhibit reactivity at 
multiple sizes potentially representing multiple protein isoforms. Thus, measuring the 
protein  intensity  for  one  ‘expected’  band  may  not  be  adequate  for  determining  a   160 
correlation with transcripts. However, most of the reported changes here are the result of 
alterations in the reported or predicted molecular weight isoform. In future studies, we 
will investigate the various isoforms and proteolytically cleaved products. 
 
Taken together we provide a general framework for the integrative analysis of 
proteomic and transcriptomic data from human tumors (Figure 7.6). Proteomic profiling 
of  prostate  cancer  progression  identified  over  one  hundred  altered  proteins  in  the 
transition from clinically localized to metastatic disease (a significant fraction of which 
were androgen regulated). While this approach was useful to integrate high-throughput 
immunoblot  data,  the  general  paradigm  can  also  be  applied  to  mass spectrometry  or 
protein microarray based technologies as they mature in the future. Differential proteins 
were then mapped to mRNA transcript levels to assess mRNA/protein concordance levels 
in a human disease state. Importantly, gene expression alterations that matched protein 
alterations qualitatively  could  be used as predictors of prostate cancer progression in 
clinically  confined  disease.  Together,  this  would  suggest  that  clinically  aggressive 
prostate cancer bears a “signature” set of genes/proteins that is characteristic of metastatic 
disease. The observation that the concordant proteomic/genomic signature can be applied 
to other solid tumors suggests commonalities in the undifferentiated state of advanced 
tumors. 
 
Methods 
High-throughput  Immunoblot  Analysis.  Tissues  utilized  were  from  the  radical 
prostatectomy series at the University of Michigan and from the Rapid Autopsy Program,   161 
which are both part of University of Michigan Prostate Cancer Specialized Program of 
Research Excellence (S.P.O.R.E.) Tissue Core. Institutional Review Board approval was 
obtained to procure and analyze the tissues used in this study. To develop the tissue 
extract pools the following frozen tissue blocks were identified: 5 each of benign prostate 
tissues,  clinically  localized  prostate  cancer,  and  hormone-refractory  metastatic  tissues 
(35). Based on examination of the frozen sections of each tissue block, specimens were 
grossly dissected maintaining at least 90% of the tissue of interest. Total proteins were 
extracted from each tissue by homogenizing samples in boiling lysis buffer. One hundred 
micrograms of protein from each tissue extract pool was boiled in sample buffer and 
subjected to 4-15% preparative SDS-PAGE and transferred to PVDF and probed with 
different antibodies. To supplement the number of proteins analyzed, the same extracts 
were analyzed using two commercial service providers, BD  biosciences and Kinexus. 
Validation immunoblots for selected proteins in different functional classes were carried 
out using 4-15% linear gradient SDS-PAGE for protein separation. The signal intensities 
were semi-quantitated using Scion Image software. 
 
Microarray Analysis. Total RNA from the individual and pooled samples were analyzed 
on  Affymetrix  U133  2.0  Plus  arrays  by  the  University  of  Michigan  Comprehensive 
Cancer Center Affymetrix Core. The amount  and integrity of RNA  was analyzed by 
spectrophotometry  and  the  Agilent  Bioanalyzer  (Agilent  Technologies).  Biotin-labled 
cRNA synthesis, hybridization, washing, staining and scanning were done following the 
manufacturer’s protocols (Affymetrix). All RNA samples and arrays met standard quality 
control metrics.   162 
 
Tissue Microarray Analysis (TMA).  A prostate cancer progression TMA composed of 
benign  prostate  tissue,  clinically  localized  prostate  cancer,  and  hormone  refractory 
metastatic  prostate  cancer  was  developed.  These  cases  came  from  well  fixed  radical 
prostatectomy specimens as described previously (24). A total of 216 tissue samples were 
collected from 51 patients. Protein expression was determined using a validated scoring 
method (10,23,24) where staining was evaluated for intensity and the percentage of cells 
staining  positive.  Benign  epithelial  glands  and  prostate  cancer  cells  were  scored  for 
staining  intensity  on  a  4  tiered  system  ranging  from  negative  to  strong  expression.  
Hierarchical clustering on samples and proteins was carried out after data normalization.  
Measurements  for  duplicated  samples  in  the  same  patient  were  averaged  and  each 
measurement was divided by the global mean of the entire dataset and then base 2 log-
transformed. 
 
Integrative  Molecular  Analysis.  To  map  the  antibodies  and  their  respective  protein 
targets,  we  retrieved  the  official  gene  names  from  the  NCBI  Locuslink  for  our 
antibody/protein lists. To complement protein levels, transcriptome data was assembled 
from 8 publicly available prostate cancer gene expression datasets  (10-14,16-18)  and 
each probe was mapped to Unigene Build #173. Expression values from multiple clones 
or probe sets mapping to the same Unigene Cluster ID were averaged. Each gene in each 
study was normalized across samples so that the mean equaled zero and the standard 
deviation  equaled  to  1.  Missing  data  was  imputed  by  the  k-nearest  neighbors  (k=5) 
imputation approach (60).    163 
 
The  eight  prostate  cancer  profiling  studies  were  included  in  the  analysis  of 
clinically localized prostate cancer relative to benign prostate tissue, while only 4 studies 
were included in the analysis of metastatic prostate cancer vs. localized prostate cancer 
due to the availability of metastatic samples in those studies. Genes that were only found 
in  one-fourth of studies  or less  were excluded, leading  to 483 genes  involved in  the 
former analysis and 494 involved in the latter analysis.  A one-sided permutation t-test 
was conducted per gene per study  using  the multtest  package in R 2.0.  A gene  was 
considered differentially expressed if its p-value was less than 0.05 without adjustment 
for multiple testing.  An mRNA transcript alteration was considered “concordant” with a 
proteomic  alteration  if  a  majority  of  the  microarray  profiling  studies  (at  least  50%) 
showed the same qualitative differential (increased, decreased, or unchanged) as the high-
throughput immunoblot approach.  The gene/proteins were then assigned to concordant 
and discordant groups based on this criterion. 
 
Integrative Genomic and Proteomic Analysis of Individual Prostate Cancer Samples. We 
carried out profiling of mRNA expression analysis in 13 of the 14 individual samples 
used for the individual protein measurements (one was excluded due to an insufficient 
amount of tissue). We examined the concordance between proteins and transcripts for 
individual samples, focusing on the 86 proteins identified as outliers in the larger high-
throughput screen. The immunoblot intensities were semi-quantitated using Scion Image 
software and the Spearman’s rank correlation was calculated for each protein. An mRNA   164 
transcript alteration was considered “concordant” with a proteomic alteration if a positive 
correlation was found. 
 
Clinical Outcomes Analysis. Six different cancer profiling studies  (18,45,50-53) were 
used  for  evaluation  of  prognostic  value  of  these  concordant  genes.  Average  linkage 
hierarchical  clustering  using  an  uncentered  correlation  similarity  metric  was  used  to 
identify two main clusters of clinically localized prostate cancer samples based on the 44 
concordant mRNA transcripts that were qualitatively concordant with protein expression 
in the Yu et al. (18) study (only 44 out of 50 of the concordant signature were assessed 
on these arrays). Kaplan-Meier survival analysis of cluster-defined subgroups was then 
conducted  and  the  log-rank  test  was  used  to  calculate  the  statistical  significance  of 
difference between the two subgroups (SPSS 11.5).  High-/low- risk labels were then 
assigned to each group.  A permutation test was performed to evaluate the significance of 
this “progression” concordant signature.  We selected 1000 random sets of 44 genes from 
the  Yu  et  al.  data  set  and  then  used  these  gene  sets  to  carry  out  1000  independent 
clusterings  of  the  primary  prostate  cancer  samples,  and  subjected  each  grouping  to 
Kaplan-Meier survival analysis. 
 
To validate the prognostic association of the 44-gene concordant signature, an 
independent (clinically localized) prostate cancer gene expression dataset from Glinsky et 
al. (45) was used. The Yu et al. clustering functioned as the “training set” to define high-
/low-risk groups. Each “test” sample of the Glinsky et al. study was classified into one of 
the two groups based on k-nearest neighbor classification (k=3).  Kaplan-Meier survival   165 
curves were plotted for the two groupings. This “progression” signature was then refined 
by reducing the number of genes involved. By using Yu et al. study as a training set, the 
concordant genes were ranked by univariate Cox model. Again, the clustering procedure 
was used to identify two clusters based on the top number of genes (ranging from 5 to 
44).  The Glinsky et al. study was then used as a validation set to verify performance of 
the refined signature by k-nearest neighbors (k=3) prediction analysis. The generality of 
this  “progression”  signature  was  evaluated  by  using  other  solid  tumor  datasets.  The 
signature was applied to two breast cancer (51)-(50), one lung cancer (52) and one glioma 
(53) gene expression study. Hierarchical clustering was used to identify two main clusters 
for patients in each study and Kaplan-Meier survival analysis was conducted to evaluate 
the statistical significance of differences between survival curves. 
 
Multivariable Analysis. We used a Cox proportional-hazards regression model to carry 
out the multivariate analysis. The dichotomized values of the concordant “progression” 
signature,  preoperative  PSA,  Gleason  sum  score  from  prostatectomy  specimens, 
preoperative  clinical  stage,  age,  and  status  of  surgical  margins  were  included  as 
covariates. The calculation was performed with the R 2.0 statistical package.   166 
Table 7.1 Multivariable Cox proportional-hazards analysis of the risk of recurrence as a 
first event on the Glinsky et al. validation set. 
 
Table 7.1. Multivariable proportional-hazards analysis of the risk 
of recurrence as a first event on the Glinsky et. al. validation Set 
Variable  Hazard Ratio 
(95% CI)  P Value 
High-Risk signature (vs.  
    low-risk signature ) 
    3.66 (1.77 – 7.59)  <0.001 
PSA     1.04 (1.00 – 1.09)  0.043 
Gleason Sum Score 
    Score >7 (vs. score <=7) 
 
  1.73 (0.79 – 3.76) 
 
0.17 
Tumor Stage 
    Stage T2 (vs. stage T1) 
 
   0.85 (0.42 – 1.75) 
 
0.67 
Age     1.06 (1.00 – 1.13)  0.06 
Surgical Margins 
    Positive (vs. negative) 
 
    2.18 (0.92 – 5.18) 
 
0.08 
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Table  7.2  Comparisons  of  the  performances  of  the  progression  signature  and  study-
specific signatures in individual study cohort. 
 
Signature 
Cohort 
Glinsky et al. 
(Prostate) 2 
Van’t Veer et al. 
(Breast) 
Huang et al. 
(Breast) 
Freije et al. 
(Glioma) 
# of genes in a signature 1  14  70  164  595 
Diagonal linear discriminant analysis 
Progression signature  73% (19 of 26)  79% (15 of 19)  73% (38 of 52)  NA 
Study-specific signature  73% (19 of 26)  79% (15 of 19)  83% (43 of 52)  NA 
k-nearest neighbor analysis (k=3) 
Progression signature  77% (20 of 26)  79% (15 of 19)  69% (36 of 52)  NA 
Study-specific signature  57% (15 of 26)  68% (13 of 19)  77% (40 of 52)  NA 
Kaplan-Meier survival analysis (log rank test) 3 
Progression signature  NA  NA  NA  P = 3.7x 10-5 
Study-specific signature  NA  NA  NA  P = 2x10-4 
1.  The number of genes in a signature reported in the original study. When the signature was applied 
to other datasets, genes were cross-referenced by UniGene cluster IDs and values of multiple 
reporters mapping to the same gene were averaged. 
2.  For Glinsky et al. study, we randomly assigned two-thirds samples into a training set and used the 
rest of samples as a validation set due to that the entire data was used as a validation set in the 
original publication; For van’t veer et al. and Freije et al studies, we used same validation sets as 
described in the original publications.  For Huang et al. study, we followed the same strategy as 
described in the study and used a leave-one-out cross validation in order to make a fair 
comparison.  All of accuracies reported here were calculated based on the validation sets. 
3.  A log rank test, same as described in the study was used to evaluate the difference of two distinct 
patient groups derived from two main clusters of hierarchical clustering performed on the 
validation set.   168 
 
Figure  7.1  High-throughput  immunoblot  analysis  to  define  proteomic  alterations  in 
prostate cancer progression.  A, A flowchart of the general methodology employed to 
profile proteomic alterations in tissue extracts. Pooled tissue extracts (n=5 each) from 
clinically localized prostate cancer, hormone-refractory metastatic prostate cancer, and 
benign prostate tissues were separated on preparative SDS-PAGE gels and transferred to 
PVDF membranes. The membranes were incubated with commercial antibodies using a 
miniblotter system. PCA, clinically localized prostate cancer. MET, metastatic prostate 
cancer. B, Representative high-throughput immunoblots performed for pooled benign, 
clinically  localized  prostate  cancer  and  metastatic  prostate  cancer  tissues.  Each  lane 
represents analysis of an individual protein. Three representative blots are displayed for 
each  tissue  extract.  Selected  proteins  altered  in  prostate  cancer  progression  are 
highlighted. MW, molecular weight.   169 
 
 
Figure 7.2 Tissue microarray analyses of protein markers deregulated in prostate cancer 
progression.  A.  Selected  images  of  tissue  microarray  elements  representing  immuno-
histochemical analysis of proteins altered in prostate cancer progression. Relative levels 
of  proteins  as  assessed  by  blinded  pathology  analysis  of  tissue  microarrays  (n=216 
specimens) is provided to the right. B, Cluster analysis of twenty proteins dysregulated in 
prostate cancer progression evaluated for in situ protein levels by tissue microarrays. 
Unsupervised hierarchical clustering of protein levels (columns) and samples (rows) was 
performed and a heatmap generated. Red color represents high protein levels while black 
refers to intermediate levels and green represents low or absent protein levels.   170 
 
Figure 7.3 Integrative analysis of proteomic and transcriptomic meta-data in prostate 
cancer progression. A, Color map of integrative analysis relating protein alterations to 
gene expression in clinically localized prostate cancer relative to benign prostate tissue. 
For gene expression meta-analysis (transcript analysis), the first author of each prostate 
cancer  gene  expression  study  is  indicated  in  columns  while  individual  genes  are   171 
represented as rows.  Red color indicates significantly increased expression at the P=0.05 
threshold level for prostate cancer relative to benign tissue, while blue indicates down-
regulation  at  the  same  threshold,  and  white  indicates  unchanged  expression.  Protein 
levels (protein) in pooled clinically localized prostate cancer extracts (as described in 
Figure 7.1), were visually qualified by high-throughput immunoblot analysis as over-
expressed  (red),  under-expressed  (blue),  or  unchanged  (white)  and  mapped  to  the 
corresponding mRNA transcript. Proteins which were not expressed (or corresponding 
antibodies that did not produce an immunoreactive band of the correct molecular weight) 
or the corresponding mRNA transcript level was not present in over one fourth of the 
profiling studies were excluded from the integrative analysis. Proteomic alterations in 
prostate  cancer  that  were  concordant  or  discordant  with  the  meta-analysis  of  gene 
expression were expanded to the right. B, As in A except the integrative analysis was 
carried out  between  metastatic prostate cancer relative to clinically localized prostate 
cancer.  C,  Conventional  immunoblot  validation  of  selected  proteins  differentially 
expressed  between  metastatic  prostate cancer  and  clinically  localized  prostate cancer. 
Individual tissue extracts from 3-4 benign, 5 clinically localized prostate cancer, and 5 
metastatic prostate cancer samples are shown. 
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Figure 7.4 Integrative genomic and proteomic analysis of pooled and individual prostate 
tissue extracts. A. Color maps of integrative analyses relating protein alterations observed 
in pooled tissues by immunoblotting and transcript alterations observed in the pooled and   173 
individual tissues by gene expression analyses. Please refer to  Figure 7.3A for color 
scheme.  B,  Color  maps  depicting  integrative  genomic  and  proteomic  analysis  of 
individual prostate tissue samples. Proteins in each tissue extract were assessed based on 
intensities  derived  from  conventional  immunoblot  analysis.  We  focused  on  the  86 
proteins  identified  as  outliers  in  the  larger  high-throughput  screen.  Transcriptomic 
profiles  from  the  same  samples  were  derived  from  Affymetrix  microarrays.  The 
immunoblot intensities were semi-quantitated and a correlation was calculated for each 
protein. Concordance was defined based on positive correlation between proteins and 
transcripts (See Methods).    174 
 
 
Figure 7.5 Proteomic alterations in metastatic prostate cancer identify gene predictors of 
cancer aggressiveness. A, A concordant 44- (out of 50) gene predictor was developed 
based on proteomic alterations that were concordant with gene expression (Figure 7.3B) 
and subsequently evaluated for prognostic utility on a prostate cancer gene expression 
dataset (Yu et al.). Hierarchical clustering of the tumor samples (columns) and genes 
(rows) is provided (left panel). Red indicates high relative levels of gene expression while 
green represents low relative levels of gene expression. Horizontal bars above the heat   175 
maps indicate the recurrence status of each patient (black box, biochemical or tumor 
recurrence; white box, recurrence-free). Patients were categorized into two major clusters 
defined by the 44-gene signature. The prediction model was further refined to a 9-gene 
signature. Kaplan-Meier survival analysis based on the groups defined by the 44-gene 
concordant cluster (middle panel) and the 9-gene concordant cluster (right panel). B, The 
concordant 44-gene predictor and the refined concordant 9-gene predictor were evaluated 
in an independent prostate cancer profiling dataset. Each sample was assigned to a low-
risk or high-risk group by k-nearest neighbor classification using cluster-defined low-
/high-risk groups of the Yu et al. as a training dataset (left panel; see methods). Kaplan-
Meier plot of the predicted high-/low-risk groups in the space of the concordant 44 genes 
(middle  panel)  or  the  concordant  9  genes  (right  panel).  C,  Same  as  A,  except  the 
concordant  predictor  was  evaluated  in  other  solid  tumors.  Huang  et  al.  (51)  breast 
adenocarcinoma (left panel), Freije et al. glioma (53) (middle panel), and Bhattacharjee 
et al. (52) lung adenocarcinoma (right,).   176 
 
 
Figure 7.6 Integrative molecular analysis of cancer to identify gene predictors of clinical 
outcome. Proteomic profiles comparing metastatic prostate cancer to clinically localized 
prostate cancer were used to identify a composite gene predictor of clinical outcome in 
localized  disease.  This  integrated  proteomic-transcriptomic  signature  represents  a 
prostate cancer progression signature and can be extended to other solid tumors. 
   177 
REFERENCES 
 
1.  Chan,  JM,  Jou,  RM,  and  Carroll,  PR  (2004).  The  relative  impact  and  future 
burden of prostate cancer in the United States. J Urol 172, S13-16; discussion S17. 
2.  Linton, KD, and Hamdy, FC (2003). Early diagnosis and surgical management of 
prostate cancer. Cancer Treat Rev 29, 151-160. 
3.  Johansson, JE, Holmberg, L, Johansson, S, Bergstrom, R, and Adami, HO (1997). 
Fifteen-year  survival  in  prostate  cancer.  A  prospective,  population-based  study  in 
Sweden. Jama 277, 467-471. 
4.  Albertsen, PC, Hanley, JA, Gleason, DF, and Barry, MJ (1998). Competing risk 
analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically 
localized prostate cancer. Jama 280, 975-980. 
5.  Kumar-Sinha,  C,  and  Chinnaiyan,  AM  (2003).  Molecular  markers  to  identify 
patients at risk for recurrence after primary treatment for prostate cancer. Urology 62 
Suppl 1, 19-35. 
6.  Hood, L, Heath, JR, Phelps, ME, and Lin, B (2004). Systems biology and new 
technologies enable predictive and preventative medicine. Science 306, 640-643. 
7.  Grubb, RL, Calvert, VS, Wulkuhle, JD, et al. (2003). Signal pathway profiling of 
prostate cancer using reverse phase protein arrays. Proteomics 3, 2142-2146. 
8.  Petricoin, EF, 3rd, Ornstein, DK, Paweletz, CP, et al. (2002). Serum proteomic 
patterns for detection of prostate cancer. J Natl Cancer Inst 94, 1576-1578. 
9.  Paweletz, CP, Charboneau, L, Bichsel, VE, et al. (2001). Reverse phase protein 
microarrays which capture disease progression show activation of pro-survival pathways 
at the cancer invasion front. Oncogene 20, 1981-1989. 
10.  Dhanasekaran,  SM,  Barrette,  TR,  Ghosh,  D,  et  al.  (2001).  Delineation  of 
prognostic biomarkers in prostate cancer. Nature 412, 822-826. 
11.  Lapointe, J, Li, C, Higgins, JP, et al. (2004). Gene expression profiling identifies 
clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101, 811-816. 
12.  LaTulippe,  E,  Satagopan,  J,  Smith,  A,  et  al.  (2002).  Comprehensive  gene 
expression analysis of prostate cancer reveals distinct transcriptional programs associated 
with metastatic disease. Cancer Res 62, 4499-4506. 
13.  Luo, J, Duggan, DJ, Chen, Y, et al. (2001). Human prostate cancer and benign 
prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61, 
4683-4688. 
14.  Luo, JH, Yu, YP, Cieply, K, et al. (2002). Gene expression analysis of prostate 
cancers. Mol Carcinog 33, 25-35. 
15.  Magee, JA, Araki, T, Patil, S, et al. (2001). Expression profiling reveals hepsin 
overexpression in prostate cancer. Cancer Res 61, 5692-5696. 
16.  Singh, D, Febbo, PG, Ross, K, et al. (2002). Gene expression correlates of clinical 
prostate cancer behavior. Cancer Cell 1, 203-209. 
17.  Welsh, JB,  Sapinoso,  LM,  Su,  AI, et  al.  (2001).  Analysis  of  gene expression 
identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 
61, 5974-5978. 
18.  Yu,  YP,  Landsittel,  D,  Jing,  L,  et  al.  (2004).  Gene  expression  alterations  in 
prostate cancer predicting tumor aggression and preceding development of malignancy. J 
Clin Oncol 22, 2790-2799.   178 
19.  Golub, TR, Slonim, DK, Tamayo, P, et al. (1999). Molecular classification of 
cancer: class discovery and class prediction by gene expression monitoring. Science 286, 
531-537. 
20.  Hedenfalk,  I,  Duggan,  D,  Chen,  Y,  et  al.  (2001).  Gene-expression  profiles  in 
hereditary breast cancer. N Engl J Med 344, 539-548. 
21.  Perou, CM, Sorlie, T, Eisen, MB, et al.  (2000). Molecular portraits of human 
breast tumours. Nature 406, 747-752. 
22.  Alizadeh, AA, Eisen, MB, Davis, RE, et al. (2000). Distinct types of diffuse large 
B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511. 
23.  Varambally, S, Dhanasekaran, SM, Zhou, M, et al. (2002). The polycomb group 
protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629. 
24.  Rubin,  MA,  Zhou,  M,  Dhanasekaran,  SM,  et  al.  (2002).  alpha-Methylacyl 
coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287, 1662-1670. 
25.  Luo, J, Zha, S, Gage, WR, et al. (2002). Alpha-methylacyl-CoA racemase: a new 
molecular marker for prostate cancer. Cancer Res 62, 2220-2226. 
26.  Jiang, Z, Woda, BA, Rock, KL, et al. (2001). P504S: a new molecular marker for 
the detection of prostate carcinoma. Am J Surg Pathol 25, 1397-1404. 
27.  Kononen, J, Bubendorf, L, Kallioniemi, A, et al. (1998). Tissue microarrays for 
high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847. 
28.  Nielsen, TO, Hsu, FD, O'Connell, JX, et al. (2003). Tissue microarray validation 
of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to 
tumors of similar histology. Am J Pathol 163, 1449-1456. 
29.  Eisen, MB, Spellman, PT, Brown, PO, and Botstein, D (1998). Cluster analysis 
and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95, 14863-
14868. 
30.  Krajewska, M, Krajewski, S, Banares, S, et al. (2003). Elevated expression of 
inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 9, 4914-4925. 
31.  Griffin, TJ, Gygi, SP, Ideker, T, et al. (2002). Complementary profiling of gene 
expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol 
Cell Proteomics 1, 323-333. 
32.  Washburn, MP, Koller, A, Oshiro, G, et al. (2003). Protein pathway and complex 
clustering  of  correlated  mRNA  and  protein  expression  analyses  in  Saccharomyces 
cerevisiae. Proc Natl Acad Sci U S A 100, 3107-3112. 
33.  Baliga, NS, Pan, M, Goo, YA, et al.  (2002). Coordinate regulation of energy 
transduction modules in Halobacterium sp. analyzed by a global systems approach. Proc 
Natl Acad Sci U S A 99, 14913-14918. 
34.  Tian,  Q,  Stepaniants,  SB,  Mao,  M,  et  al.  (2004).  Integrated  genomic  and 
proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 3, 960-
969. 
35.  Shah,  RB,  Mehra,  R,  Chinnaiyan,  AM,  et  al.  (2004).  Androgen-independent 
prostate  cancer  is  a  heterogeneous  group  of  diseases:  lessons  from  a  rapid  autopsy 
program. Cancer Res 64, 9209-9216. 
36.  Mooradian, AD, Morley, JE, and Korenman, SG (1987). Biological actions of 
androgens. Endocr Rev 8, 1-28. 
37.  Culig,  Z,  Hobisch,  A,  Hittmair,  A,  et  al.  (1998).  Expression,  structure,  and 
function of androgen receptor in advanced prostatic carcinoma. Prostate 35, 63-70.   179 
38.  Koivisto, P, Kolmer, M, Visakorpi, T, and Kallioniemi, OP (1998).  Androgen 
receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152, 1-9. 
39.  DePrimo,  SE,  Diehn,  M,  Nelson,  JB,  et  al.  (2002).  Transcriptional  programs 
activated  by  exposure  of  human  prostate  cancer  cells  to  androgen.  Genome  Biol  3, 
RESEARCH0032. 
40.  Nelson,  PS,  Clegg,  N,  Arnold,  H,  et  al.  (2002).  The  program  of  androgen-
responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99, 11890-
11895. 
41.  Segawa, T, Nau, ME, Xu, LL, et al.  (2002). Androgen-induced expression of 
endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21, 
8749-8758. 
42.  Velasco, AM, Gillis, KA, Li, Y, et al. (2004). Identification and validation of 
novel androgen-regulated genes in prostate cancer. Endocrinology 145, 3913-3924. 
43.  Waghray, A, Feroze, F, Schober, MS, et al. (2001). Identification of androgen-
regulated  genes  in  the  prostate  cancer  cell  line  LNCaP  by  serial  analysis  of  gene 
expression and proteomic analysis. Proteomics 1, 1327-1338. 
44.  Xu,  LL,  Su,  YP,  Labiche,  R, et  al.  (2001).  Quantitative expression  profile  of 
androgen-regulated genes in prostate cancer cells and identification of prostate-specific 
genes. Int J Cancer 92, 322-328. 
45.  Glinsky,  GV,  Glinskii,  AB,  Stephenson,  AJ,  Hoffman,  RM,  and  Gerald,  WL 
(2004). Gene expression profiling predicts clinical outcome of prostate cancer.  J Clin 
Invest 113, 913-923. 
46.  Kleer, CG, Cao, Q, Varambally, S, et al. (2003). EZH2 is a marker of aggressive 
breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl 
Acad Sci U S A 100, 11606-11611. 
47.  Dobbin,  K,  and  Simon,  R  (2005).  Sample  size  determination  in  microarray 
experiments for class comparison and prognostic classification. Biostatistics 6, 27-38. 
48.  Ramaswamy,  S,  Ross,  KN,  Lander,  ES,  and  Golub,  TR  (2003).  A  molecular 
signature of metastasis in primary solid tumors. Nat Genet 33, 49-54. 
49.  Rhodes, DR, Yu, J, Shanker, K, et al. (2004). ONCOMINE: a cancer microarray 
database and integrated data-mining platform. Neoplasia 6, 1-6. 
50.  van 't Veer, LJ, Dai, H, van de Vijver, MJ, et al. (2002). Gene expression profiling 
predicts clinical outcome of breast cancer. Nature 415, 530-536. 
51.  Huang, E, Cheng, SH, Dressman, H, et al. (2003). Gene expression predictors of 
breast cancer outcomes. Lancet 361, 1590-1596. 
52.  Bhattacharjee,  A,  Richards,  WG,  Staunton,  J,  et  al.  (2001).  Classification  of 
human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma 
subclasses. Proc Natl Acad Sci U S A 98, 13790-13795. 
53.  Freije, WA, Castro-Vargas, FE, Fang, Z, et al. (2004). Gene expression profiling 
of gliomas strongly predicts survival. Cancer Res 64, 6503-6510. 
54.  Jeng,  YM,  Peng,  SY,  Lin,  CY,  and  Hsu,  HC  (2004).  Overexpression  and 
amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10, 2065-2071. 
55.  Neben, K, Korshunov, A, Benner, A, et al. (2004). Microarray-based screening 
for molecular markers in medulloblastoma revealed STK15 as independent predictor for 
survival. Cancer Res 64, 3103-3111.   180 
56.  Hirota, T, Kunitoku, N, Sasayama, T, et al. (2003). Aurora-A and an interacting 
activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. 
Cell 114, 585-598. 
57.  Katayama, H, Sasai, K, Kawai, H, et al. (2004). Phosphorylation by aurora kinase 
A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36, 55-62. 
58.  Schultz,  DC,  Ayyanathan,  K,  Negorev,  D,  Maul,  GG,  and  Rauscher,  FJ,  3rd 
(2002).  SETDB1:  a  novel  KAP-1-associated  histone  H3,  lysine  9-specific 
methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by 
KRAB zinc-finger proteins. Genes Dev 16, 919-932. 
59.  Mecham,  BH,  Klus,  GT,  Strovel,  J,  et  al.  (2004).  Sequence-matched  probes 
produce increased cross-platform consistency and more reproducible biological results in 
microarray-based gene expression measurements. Nucleic Acids Res 32, e74. 
60.  Troyanskaya, O, Cantor, M, Sherlock, G, et al. (2001). Missing value estimation 
methods for DNA microarrays. Bioinformatics 17, 520-525. 
 
   181 
 
 
 
 
PART 5: CONCLUSION 
 
 
CHAPTER 8 
 
Conclusion 
 
Molecular cancer classification, the classification of tissue or other specimens for 
diagnostic, prognostic, and predictive purposes on the basis of multiple gene expression, 
has  been  demonstrated  a  promising  technology  for  optimizing  the  management  of 
patients with cancer. In this dissertation, I have developed (1) an estrogen-regulated gene 
signature that can robustly predict cancer outcome in human breast cancer; (2) efficient 
yet  comprehensible  molecular  classifiers  using  genetic  programming  for  cancer 
classification;  (3)  non-invasive  diagnostic  tools  for  early  detection  of  prostate cancer 
based on either patient serum or patient urine profiling; (4) a system approach to model 
metastatic  progression  in  prostate  cancer.  These  results  support  that  high-throughput 
microarray  profiling  and  resulted  candidate  biomarkers,  if  used  properly  and 
thoughtfully, are capable of developing more accurate diagnostic or prognostic tests for 
human cancer in clinic, supplementary to traditional histopathological methods. 
   
Breast cancer is the most common cancer among women in the US, accounting 
for nearly 1 of every 3 cancers diagnosed. Despite of current advance in breast cancer 
research, accurate prognosis for breast cancer patients has been a more daunting task. In   182 
this thesis work (Chapter 3), we analyzed gene expression profiles of breast cancer cells 
in vitro and in vivo in order to uncover a molecular signature which may serve as a better 
indicator of cancer outcome. We set out to mine estrogen signaling pathway to identify 
estrogen-regulated genes as estrogen plays an essential role in breast cancer progression. 
We focused on in vitro estrogen-regulated genes and further selected a subset that is 
associated  with  patient  outcome  in  vivo  in  human  breast  tumors.  The  final  73-gene 
signature  developed  by  leave-one-out  cross  validation  successfully  predicts  clinical 
outcome in over ten patient cohorts. Besides correctly assigning most ER- tumors in each 
dataset  into  high-risk  group,  this  signature  is  able  to  stratify  the  ER+  samples  into 
prognostic subtypes, suggesting that it may better reflect tumor aggressiveness than ER 
status alone. Most importantly, the signature provides additional prognostic information 
beyond standard clinical factors and yields overall best performance against previously 
reported  breast  cancer  outcome  predictors.  This  signature  may  be  thus  valuable  in 
selection of high-risk patients for adjuvant therapy as well as in sparing some hormone-
sensitive patients from aggressive therapy.  
 
One  important  facet  of  clinical  tests  is  cost-effectiveness,  which  makes  the 
expression profiling of a large number of genes simultaneously less attractive in clinical 
trials. Thus, developing accurate yet simple classifiers using a handful of genes is in high 
demand. In this dissertation, we evaluated the capability of one evolutionary algorithm, 
Genetic Programming  (GP),  in  building  molecular  classifiers  using  a  practical  set  of 
genes (Chapter 4). We tested it on one Small Round Blue Cell Tumors (SRBCTs), one 
lung  adenocarcinoma  and  five  prostate  cancer  datasets.  We  have  found  that  GP   183 
repetitively uses a small set of highly discriminative feature genes to produce classifiers, 
which often comprise five or less  genes and are able to predict samples correctly in 
independent datasets. As GP utilizes the quantitative information among genes to connect 
genes each other, the classifiers generated by GP are usually simple and human-readable. 
In addition, comparing to other conventional classification methods, GP yields better or 
similar  classification  performance.  Thus,  given  these  unique  characteristics  of  GP,  it 
stands out as a good algorithm of choice for application of DNA microarray profiling to 
clinic. 
 
Contrast to breast cancer in women, prostate cancer is the most common form of 
cancer affecting men in the Western world. Current common screening test for prostate 
cancer is to use prostate specific antigen (PSA). While PSA testing has led to a dramatic 
increase  in  the  detection  of  prostate  cancer,  it  has  substantial  false  positive  rate, 
supporting that additional cancer biomarkers or signatures may be required to ameliorate 
the  accuracy  of  prostate  cancer  diagnosis.  As  cancer  patients  produce  autoantibodies 
against antigens in their tumors and prostate cells can be detected in the urine of patients 
with prostate cancer, serum/urine based diagnostic tests have the advantage of being non-
invasive. In Chapter 5, we developed a phase-display protein microarrays to analyze 
serum samples from 119 patients with prostate cancer and 138 controls. By profiling 
global humoral immune response of these samples, we discovered 22 phage peptides 
grouped  as  a  predictor  that  yielded  88.2%  specificity  and  81.6%  sensitivity  in 
discriminating  between  the  group  with  prostate  cancer  and  the  control  group  of  a 
validation set and outperformed PSA testing. This work demonstrates the feasibility of   184 
multiplex humoral immune response as the basis for a screening test for prostate cancer 
although further extension and confirmation in community-based screening cohorts is 
needed. 
 
In Chapter 6, we combine prostate cancer “outlier” genes and known prostate 
cancer  biomarkers  to  develop  a  multiplexed  qPCR  based  urine  test  for  detection  of 
prostate  cancer.  Previously  identified  “outlier”  genes  (ERG,  TMPRSS2:ERG  and 
SPINK1)  by  our  lab  and  known  prostate cancer  biomarkers  such  as  PCA3,  AMACR, 
GOLPH2  are  assessed  in  sedimented  urine  using  qPCR.  We  analyzed  234  patient 
samples and found that a multiplexed model including  PCA3, GOLPH2, SPINK1 and 
TMPRSS2:ERG yielded an area under roc (AUC) of 0.76, significantly outperforming 
serum PSA or PCA3 alone in detecting prostate cancer (AUC 0.57 for serum PSA, and 
0.66  for  PCA3).  While  urine-based  testing  for  PCA3  expression  has  already  been 
documented in large screening programs, we demonstrate that this multiplexed qRT-PCR 
based assay can further improve the diagnostic accuracy of prostate cancer. 
 
Finally,  with  the  explosion  of  gene  expression  data  and  the  advent  of  high-
throughput  proteomic  profiling,  interrogative  efforts  in  both  oncoproteomics  and  the 
cancer transcriptomics ushered in a ‘systems’ era that necessitates integrated approaches 
to analysis. Chapter 7 delineates an integrative model for culling a molecular signature 
of metastatic progression in prostate cancer from proteomic and transcriptomic analyses. 
Proteomic profiling of prostate cancer progression identified over one hundred altered 
proteins in the transition from clinically localized to metastatic disease. These differential   185 
proteins were then mapped to mRNA transcript levels in multiple expression studies to 
assess mRNA/protein concordance levels in prostate cancer, leading to discovery of a 50-
gene signature of prostate cancer progression. While this approach is used to integrate 
high-throughput  immunoblot  data  in  this  thesis  work,  the  general  framework  of 
integrating multiple-source data can be extended to other proteomic platforms such as 
quantitative mass spectrometry, or protein microarray based technologies as they mature 
in the future. More critically, the discovered 50-gene signature not only predicts clinical 
outcome in localized prostate cancer, but also can be extrapolated to other solid tumor 
types including primary tumors of the breast, lung, and gliomas, suggesting common 
molecular machinery in poorly differentiated aggressive neoplasms. This is a powerful 
validation  of  the  integrative  model  showing  clinical  import.  The  marriage  of  such  a 
model with those in early detection has the potential to manifest in overt survival benefit 
for cancer patients.   186 
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Philip Kantoff obtained serum samples and tissue information. 
 
CHAPTER 6   188 
Bharathi Laxman, David Morris, Jianjun Yu, Scott Tomlins and Arul Chinnaiyan 
conceived the experiments and wrote the manuscript. David Morris obtained the urine 
samples and Bharathi Laxman performed qPCR experiments. Jianjun Yu developed the 
multiplex model and performed survival analysis of tissue microarrays. Daniel Rhodes 
performed  outlier  analysis.  Rohit  Mehra,  and  Anders  S.  Bjartell  performed 
immunohistochemical analysis of tissue microarrays. 
 
CHAPTER 7 
Sooryanarayana  Varambally,  Jianjun  Yu  and  Arul  Chinnaiyan  conceived  the 
project and wrote the manuscript. Jianjun Yu performed in silico analyses and developed 
the  integrative  model.  Sooryanarayana  Varambally  and  Bharathi  Laxman  performed 
high-throughput  immunoblot.  Uma  Chandran,  Federico  Monzon,  and  Michael  Becich 
provided a set of gene expression data. John Wei, Rajal Shah, Kenneth Pienta obtained 
tissue samples. Rohit Mehra, and Mark Rubin evaluated immunohistochemistry on tissue 
microarrays.  Daniel  Rhodes  performed  pathway  analysis.  Debashis  Ghosh  provided 
biostatistical support. 
 